Malik, Natasha (2019) *Elucidating the role of mTOR complexes (mTORC1 and mTORC2) in normal haemopoiesis and in Chronic Lymphocytic Leukaemia*. PhD thesis.

[http://theses.gla.ac.uk/74330/](http://theses.gla.ac.uk/74330/)

Copyright and moral rights for this work are retained by the author

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author

The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author

When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given

Enlighten: Theses
[https://theses.gla.ac.uk/](https://theses.gla.ac.uk/)
research-enlighten@glasgow.ac.uk
Elucidating the Role of mTOR Complexes (mTORC1 and mTORC2) in Normal Haemopoiesis and in Chronic Lymphocytic Leukaemia

Natasha Malik, BSc

Thesis submitted for the Doctor of Philosophy at the University of Glasgow

Institute of Cancer Sciences
School of Medicine, Veterinary and Life Sciences

Submitted: August 2019

Word count: 65289

© Natasha Malik
Abstract

Mechanistic target of rapamycin (mTOR) functions within a complex signalling cascade, through its activity in two unique complexes mTORC1 and mTORC2, to promote a multitude of different cellular functions including autophagy, protein synthesis and survival. The exact role of these complexes during leukaemia initiation/maintenance remains to be elucidated. Here, using transgenic knockout (KO) mouse models, we determine the individual roles of mTORC1 (targeting Raptor) and mTORC2 (targeting Rictor) in normal haemopoiesis and in CLL initiation/maintenance.

Our results demonstrate that mice carrying a targeted KO of Raptor at the haemopoietic stem cell (HSC) stage (Vav-Raptor KO) do not survive post birth. This is due to anaemia resulting from a significant decrease in Ter119+ population, a significant decrease in Klf1 and Klf2 gene expression, and a significant increase in the megakaryocyte-erythroid progenitor (MEP) population, suggesting a block at the MEP stage in Vav-Raptor KO foetal liver (FL). While mTORC1 plays a fundamental role in RBC development, we show that mTORC2 plays a potential role in RBC regulation, as Rictor-deficient HSPCs exhibit an increase in RBC colony formation ex vivo. Conditional KO (cKO) of Raptor (Mx1-Raptor cKO) in adult mice results in splenomegaly accompanied by increased spleen organ cellularity. Furthermore, there is a significant decrease in B cell lineage commitment, with a block in B cell development at the Lin-Sca-1-CD117+ (LSK) stage in the BM. mTORC2, on the other hand regulates late B cell maintenance as indicated by a significant decrease in transitional B cells (T1/T2), marginal zone progenitor (MZP), and follicular 1 (fol1) cells in Vav-Rictor KO mice compared to controls.

To address the role of mTORC1 and mTORC2 in CLL initiation/maintenance in vitro, BM-derived haemopoietic progenitor cells (HPCs) isolated from control (cre-), Raptor-deficient (Mx1-Raptor cKO) or Rictor-deficient (Vav-Rictor KO) mice were retrovirally-transduced with a kinase dead PKCa (PKCaKR) construct to induce an aggressive CLL-like disease. Raptor-deficient BM progenitors exhibited reduced proliferation and failed to generate a CLL-like disease, due to
a block in B cell lineage commitment in vitro. However, there was an increase in cell cycling and migration in PKCaKR CLL-like cells with Rictor-deficiency suggesting a role of mTORC2 in disease maintenance.

To determine a role for mTORC1 in disease maintenance in vivo, NSG mice were transplanted with Mx1-Raptor control or Mx1-Raptor cKO PKCaKR transduced BM cells. Once disease was established in vivo, cKO was induced and disease load and progression was monitored. Our data demonstrate a decrease in disease load with Raptor cKO, together with a significant increase in survival. Additionally, host mice transplanted with CD19-Raptor KO PKCaKR cells exhibited a significant increase in survival. However, these mice eventually died of disease due to limitations of the KO model.

Lastly, to test the translational capacity of mTOR inhibitors, efficiency of AZD2014 (dual mTOR inhibitor), ibrutinib and a combination of the two drugs was assessed in reducing PKCaKR CLL-like disease load in host mice. AZD2014 was as efficient at reducing disease load as ibrutinib, however combination therapy of these drugs was not as efficient compared to single agents. Interestingly, we demonstrate that a more aggressive PKCaKR CLL-like disease (in secondary transplants) is more mTORC1 dependent than in primary transplants, as indicated by the superiority of rapamycin (allosteric mTORC1 inhibitor) in markedly decreasing disease load as compared to AZD2014 in host mice.

Taken together, mTORC1 plays an essential role in haemopoiesis, with Raptor-deficiency causing a block in RBC and B cell development at the MEP and LSK stage respectively. In comparison, Rictor-deficiency regulates later B cell lineages and promotes RBC colony formation, potentially through mTORC1 activation. Importantly, CLL-like cells lacking mTORC2 have increased cell cycling and migration whereas mTORC1 deficiency causes a decrease in disease load. Therefore, mTORC1 and mTORC2 play distinct/complementary roles in haemopoietic development and leukaemia initiation/progression. These studies provide a strong foundation for further studies testing novel mTOR inhibitors for CLL in our models.
Declaration

The work presented in this thesis represents the original work carried out by the author and has not been submitted, in any form, to any other university.

Natasha Malik
March 2019
Acknowledgements

I would first and foremost like to thank Dr. Alison Michie for her endless support throughout my PhD. You are kind, generous, funny and a loving person and I am grateful to have you by my side as a friend and as the best mentor I could ever ask for. Thank you for always believing in me and in listening to anything and everything I have to say, no matter the situation. I don’t think I can thank you enough for all that you do.

I would also like to thank Prof. Owen Sansom for all his time and effort throughout my PhD. I am grateful for all the opportunities and skills I have gained by being under your umbrella. Thank you.

A special thank you to Prof. Tessa Holyoake. No matter where you are, you always give us motivation to strive for the best and be the best version of ourselves.

Dr. Anuradha Tarafdar taught me basic laboratory skills when I first was a student and that helped me think as an independent scientist and strengthened my scientific platform. For that I thank you and am very grateful. Thank you, Dr. Emilio, Jennifer, Dr. Jodie, Dr. Ailsa, and Michael for helping me out in the lab and listening to my rants when I needed to vent. You all are wonderful people and have become great friends of mine. Big thank you to Karen Dunn, without you all the in vivo work would be a disaster. Thank you for always being there and helping me even when you have been very busy. A huge thank you to Colin Nixon from the IHC department for helping me with all the IHC and being so accommodating.

The Swedish quote translates: It does not matter how slow you go, just that you don’t stop. The Indian ‘doha’ teaches to fight procrastination and to finish all work as soon as you can. My family and friends have given me constant
reminders of these quotes whenever I needed it. My parents, Narinder and Ipsita have listened to my project and my results over the phone a million times even though they did not fully understand the research. They have always pushed me and helped me whenever I needed it. Thank you. I thank all my sisters Anita, Nidhi and Meenakshi and my brother Vikram for always being there. Thank you Nidhi, for being there for me emotionally and being my rock. Pravish, thank you for being you. You have always been there for me no matter what. I am privileged to have such support and love in my life.

Throughout my PhD, I have made some wonderful friends who have cooked (Chinmay) and baked for me, helped, listened to me. Thank you, Caroline and Cecilia, for everything you do and for telling me when I am being unreasonable. Thank you for caring, being bluntly honest and for making my time during my project all-the-more fun.
# Table of Contents

Abstract .................................................................................................................. i  
Declaration .............................................................................................................. iii  
Acknowledgements ................................................................................................ iv  
Table of Contents ................................................................................................... vi  
  Table of Figures ................................................................................................... x  
  Table of Tables ................................................................................................... xiii  
  List of Abbreviations ........................................................................................... xiv  

## Chapter 1  Introduction ......................................................................................... 1  
  1.1  Early Haemopoiesis: ...................................................................................... 2  
  1.2  Erythropoiesis .............................................................................................. 4  
  1.3  B1 B cells and B2 B cells .............................................................................. 5  
  1.4  B cell development ....................................................................................... 6  
      1.4.1  TFs involved in B cell development ....................................................... 6  
      1.4.2  Developmental stages ........................................................................... 9  
  1.5  mTOR signalling pathway .......................................................................... 12  
      1.5.1  mTOR signalling and its functions ....................................................... 15  
      1.5.2  mTOR in embryogenesis ...................................................................... 17  
      1.5.3  mTORC1 and mTORC2 signalling in HSCs/HSPCs ......................... 18  
      1.5.4  mTORC1 and mTORC2 signalling in Erythrocytes ........................... 20  
      1.5.5  mTORC1 and mTORC2 signalling in Myeloid cells ......................... 21  
      1.5.6  mTORC1 and mTORC2 signalling in B cells ....................................... 22  
      1.5.7  mTORC1 and mTORC2 signalling in T cells ....................................... 24  
      1.5.8  mTOR signalling in leukaemogenesis .................................................. 25  
  1.6  Chronic Lymphocytic Leukaemia ................................................................. 27  
      1.6.1  Mutational status and prognosis .......................................................... 28  
      1.6.2  Role of microenvironment ................................................................... 28  
      1.6.3  Current therapy ..................................................................................... 30  
  1.7  Mouse models commonly used in haemopoiesis ......................................... 33  
      1.7.1  Cre-loxP KO system ............................................................................. 33  
      1.7.2  Limitations of the cre/loxP system ....................................................... 38  
      1.7.3  NSG/NRG mouse models ................................................................. 39  
  1.8  Mouse models in CLL .................................................................................. 40  
      1.8.1  TCL1 mouse model .............................................................................. 40  
      1.8.2  PKCaKR model in vivo ........................................................................ 41  
      1.8.3  PKCaKR model in vitro: OP9 co-culture .............................................. 42  
  1.9  Aims of project .............................................................................................. 42  

## Chapter 2  Materials and Methods ....................................................................... 43
2.1 Mouse models ................................................................. 44
  2.1.1 Cre-loxP System......................................................... 44
  2.1.2 Organ Processing...................................................... 45
  2.1.3 Transplants .............................................................. 46
  2.1.4 OP9-GFP cell line ................................................... 47
  2.1.5 Retroviral packaging lines ........................................ 47
  2.1.6 Retroviral transduction ............................................ 48
  2.1.7 In vitro KO induction ............................................... 49
2.2 K562 cell lines .............................................................. 50
  2.2.1 Hemin treatment induced erythroid differentiation .......... 50
  2.2.2 Galactose supplemented erythroid differentiation .......... 50
  2.2.3 Drug treatment ....................................................... 50
2.3 Flow cytometry ............................................................. 50
  2.3.1 Assessing K562 differentiation ................................... 51
  2.3.2 CLL and lineage phenotyping ..................................... 51
  2.3.3 Fixation and permeabilization ................................... 51
  2.3.4 Assessing intracellular markers ................................ 52
  2.3.5 Assessment of Apoptosis .......................................... 52
  2.3.6 Assessment of Cell Cycle ......................................... 52
  2.3.7 Assessment of proliferation ...................................... 52
2.4 Colony Forming Cell (CFC) Assay .................................... 53
2.5 Migration Assay ............................................................ 53
  2.5.1 Cell Starvation ....................................................... 53
  2.5.2 SDF-1 mediated Migration Set-up ............................... 54
2.6 RNA extraction ............................................................ 54
2.7 cDNA Synthesis: .......................................................... 54
  2.7.1 cDNA synthesis - RT-PCR ........................................ 54
  2.7.2 One-step cDNA synthesis: ........................................ 55
2.8 DNA extraction and Gel electrophoresis ............................ 56
2.9 Western blotting ........................................................... 56
2.10 Immunohistochemistry .................................................. 58
  2.10.1 Antigen retrieval: .................................................. 58
  2.10.2 Antibody staining: ................................................ 58
  2.10.3 Amplification and Visualisation: ............................... 59
  2.10.4 Counterstaining and dehydration: ............................. 59
2.11 Statistics ........................................................................ 59
2.12 Tables and Figures ........................................................ 60

Chapter 3 The Role of mTOR in Erythropoiesis and Myelopoiesis .... 79
3.1 Aims and objectives ........................................................ 80
3.2 Results .................................................................................................................. 81
3.2.1 Mice lacking mTORC1 within the haemopoietic lineage do not survive after birth and Raptor-null adult mice display splenomegaly .......... 81
3.2.2 Raptor-null mice have a disruption in RBC, myeloid, and B cell lineages in vivo .................................................................................. 82
3.2.3 Mice lacking Raptor at the HSC stage have a disruption in early B cell population and a block in RBC development at the MEP stage in vivo ...... 83
3.2.4 Exploiting K562 CML cell line as an in vitro model for erythropoiesis 85
3.2.5 K562 cell line differentiation into RBCs is blocked with mTOR inhibition in vitro ................................................................................. 85
3.2.6 mTORC1 and mTORC2 regulate RBC maintenance ex vivo. ........... 86
3.3 Discussion ............................................................................................................. 87
3.4 Tables and Diagrams ........................................................................................... 96

Chapter 4 Role of mTORC1 and mTORC2 in Lymphopoiesis ..................... 110

4.1 Aims and Objectives ......................................................................................... 111
4.2 Results ............................................................................................................... 112
4.2.1 Mice with induced Raptor deficiency at an adult stage exhibit optimal characteristics of KO when assessed 5 wk post 4 poly(I:C) inoculations. .................................................. 112
4.2.2 mTORC1 plays a role in developmental haemopoiesis in vivo .......... 115
4.2.3 mTORC2 plays a role in later stages of development. ..................... 118
4.3 Discussion ......................................................................................................... 123
4.3.1 Optimisation ............................................................................................... 123
4.3.2 Validation of KO Targets .......................................................................... 124
4.3.3 Splenic Architecture in KO models ......................................................... 126
4.3.4 mTORC1/2 signalling in apoptosis ......................................................... 128
4.3.5 Impact of mTORC1/2 deletion on haemopoietic lineage development 129
4.4 Figures ............................................................................................................. 135

Chapter 5 Role of mTORC1 and mTORC2 in CLL .................................... 161

5.1 Introduction ...................................................................................................... 162
5.2 Results ............................................................................................................... 163
5.2.1 Ablation of mTORC1 blocks CLL initiation in vitro ......................... 163
5.2.2 mTORC2 plays a role in CLL-like phenotype maintenance at later stages in vitro ................................................................. 166
5.2.3 mTORC1 affects CLL maintenance in vivo. ..................................... 167
5.2.4 Using mTOR inhibitors and current clinical drugs to combat CLL in vivo. 170
5.3 Discussion ...................................................................................................... 173
5.3.1 Role of mTORC1 and mTORC2 in leukaemia initiation and/or progression in vitro ................................................................. 174
5.3.2 Role of mTORC1 and mTORC2 in leukaemia progression in vivo ...177
5.4 Figures ........................................................................................................ 183
General Discussion and Conclusions ................................................................. 202
Bibliography ........................................................................................................ 207
Related Publications ........................................................................................... 233
Table of Figures

Figure 1.1 Diagram showing the hierarchy of haemopoietic cell differentiation. ........................................ 3
Figure 1.2 Diagram showing the summary of B cell development.............................................. 8
Figure 1.3 Diagram showing stages of early B cell development in the bone marrow along with table summarizing various stages of early B cell development including phenotype (surface markers) and events in the pre-proB cell, proB cell, preB cell and immature B cell stages......................................................... 10
Figure 1.4 Diagram showing stages of late B cell development in the spleen along with table summarizing various stages of early B cell development including phenotype (surface markers) and events in the transitional (T-3), marginal zone progenitor (MZP)/MZ, follicular 1 (fol1) and fol2 B cell and B1 B cell stages. APC - antigen-presenting cells. ................................................................. 11
Figure 1.5 Diagram of the AKT/mTOR signalling pathway......................................................... 14
Figure 1.6: Gating strategy of early myeloid progenitors in vivo. ........................................ 70
Figure 1.7: K562 cell line and its differentiation into an erythrocyte-like lineage. ........................................ 71
Figure 1.8: Cre–fl/fl mice exhibit splenomegaly in vivo. ......................................................... 72
Figure 1.9: Different colonies formed by Vav-cre Rictor(fl/fl) BM (CD117 enriched cells) using the m3434 and m3334 MethoCult media............................................... 74
Figure 1.10: Flow cytometry representative plot showing the different phases of cell cycle by propidium iodide (PI) staining. .................................................. 76
Figure 1.11: Representative plot showing cell trace violet (CTV) fluorescence over 3 days thereby measuring the proliferation of a population ............... 77
Figure 1.12: Different colonies formed by Vav-cre Rictor(fl/fl) BM (CD117 enriched cells) using the m3434 and m3334 MethoCult media............................................... 78
Figure 1.13: Vav-Raptor KO mice are perinatally lethal and Raptor-null adult mice exhibit splenomegaly in vivo. ......................................................... 79
Figure 1.14: Gating strategy of haemopoietic lineages in Vav-cre Raptor and Mx1-cre Raptor(fl/fl) primary lymphoid organs. ........................................... 80
Figure 1.15: Vav/Mx1-cre+Raptor(fl/fl) mice exhibit a disruption in haemopoiesis in vivo. ......................................................... 81
Figure 1.16: Gating strategy of progenitor cells and early B haemopoietic lineages in Vav- and Mx1-cre Raptor models. ......................................................... 82
Figure 1.17: Mx1- and Vav-cre+Raptor(fl/fl) mice exhibit a block in B cell development at the LSK stage. ......................................................... 83
Figure 1.18: Gating strategy of early myeloid progenitors in Vav- and Mx1-cre Raptor models. ......................................................... 84
Figure 1.19: Vav-Raptor KO mice exhibit a block in RBC development at MEP stage in vivo. ......................................................... 85
Figure 1.20: Mx1-Raptor cKO mice have aberrations at the MEP stage with opposite trends in Vav-Raptor KO mice in vivo. ......................................................... 86
Figure 1.21: K562 cells differentiate into an erythrocyte-like lineage with changes in surface markers and size, which are changed with mTOR inhibitors. ......................................................... 87
Figure 1.22: mTOR inhibitors abrogate RBC differentiation in a human cell model. ......................................................... 88

x
Figure 3.11: Proving the role of mTORC1 in the differentiation of RBCs in K562 cells at the phenotype and molecular level.  .................................................................108
Figure 3.12: Demonstrating a functional block in RBC development in Mx1-Raptor cKO mice, together with an increase in RBC generation in Vav-Rictor KO mice.  .................................................................109
Figure 4.1: Optimization of the Mx1-cre Raptor cKO model.  ..............................................135
Figure 4.2: Optimization of the Mx1-cre Raptor cKO model assessing stem and early B cell progenitors in vivo.  .................................................................136
Figure 4.3: Optimization of the Mx1-cre Raptor cKO model assessing B cell lineages in vivo.  .................................................................137
Figure 4.4: Optimization of the Mx1-cre Raptor cKO model assessing late B cell lineages in vivo.  .................................................................138
Figure 4.5: Control experiment showing no difference between WT mice and mice expressing cre on alleles.  .................................................................139
Figure 4.6: Characterization of lymphoid organs in Raptor KO models.  ..............140
Figure 4.7: Confirmation of Raptor cKO at the protein, gene and at the substrate level for mTOR pathway members in Mx1-Raptor cKO mice.  ..............................................141
Figure 4.8: Gating strategy of haemopoietic lineages in Mx1-cre and CD19-cre Raptor mouse models.  .................................................................142
Figure 4.9: Raptor cKO in adult mice leads to significant aberrations in haemopoietic lineages in vivo.  .................................................................143
Figure 4.10: Raptor-deficiency in B cells leads to a decline in B cell lineage in vivo.  .................................................................144
Figure 4.11: Gating strategy of late B cell lineages in Mx1-cre and CD19-cre Raptor models.  .................................................................145
Figure 4.12: Raptor-deficiency in adult mice leads to aberrations in late B cells in vivo.  .................................................................146
Figure 4.13: Raptor-deficiency in B cells leads to aberrations in late B cells in vivo.  .................................................................147
Figure 4.14: Gating strategy for determining live, early apoptosing and apoptotic cells in Mx1-cre and CD19-cre Raptor models.  .................................................................148
Figure 4.15: Raptor-deficiency in adult mice leads to increased apoptosis in B cells in vivo.  .................................................................149
Figure 4.16: Optimization of the Vav-cre Rictor KO model.  ..............................................150
Figure 4.17: Optimization of the Vav-cre Rictor KO model age for phenotypic analysis of haemopoietic lineages.  .................................................................151
Figure 4.18: Characterization of Rictor KO models.  .................................................................152
Figure 4.19: Confirming Rictor cKO by assessing protein and gene expression of mTOR pathway members.  .................................................................153
Figure 4.20: Gating strategy of haemopoietic lineages in Vav-cre and Mx1-cre Rictor models.  .................................................................154
Figure 4.21: Rictor-deficiency leads to B and T cell aberrations in vivo.  ..............155
Figure 4.22: Gating strategy for determination of cell viability in Vav-cre and Mx1-cre Rictor models.  .................................................................156
Figure 4.23: Rictor-deficiency does not cause apoptosis in vivo.  ..............................................157
Figure 4.24: Gating strategy of early B cell lineages in Vav-cre and Mx1-cre Rictor models.  .................................................................158
Figure 4.25: Gating strategy of late B cell lineages in Vav-cre and Mx1-cre Rictor models.  .................................................................159
Figure 4.26: Rictor-deficiency at the HSC stage, in adult mice, and in B cells leads to aberrations in late B cells in vivo.  .................................................................160
Figure 5.1 BM from adult mice with Raptor-deficiency does not develop into PKCaKR CLL-like cells in vitro.  .................................................................183
Figure 5.2 Raptor-deficiency abrogates B cell lineage commitment and leads to the absence of PKCaKR CLL-like cells in vitro. .................................................. 184
Figure 5.3 Raptor-deficiency in CD19+ cells leads to decreased proliferation, migration and cell cycle arrest of PKCaKR CLL-like cells in vitro. .............. 185
Figure 5.4 The generation of an inducible model of Raptor-deficiency in vitro. .................................................................................................................. 186
Figure 5.5 CLL-like cells with induced Raptor-deficiency exhibit a block in proliferation in vitro. .................................................................................. 187
Figure 5.6 Rictor-deficiency does not abrogate CLL-initiation in vitro. ....... 188
Figure 5.7 CLL-like cells with Rictor-deficiency exhibit a decreasing trend in cell count and percentage at later stages of culture in vitro. .................... 189
Figure 5.8 Rictor-deficiency at the HSC stage and in adult mice plays a role at later stages of CLL in vitro................................................................. 190
Figure 5.9 CLL cells with Rictor-deficiency at the HSC stage exhibit increased migration at later stages of culture. .............................................. 191
Figure 5.10 Raptor-deficiency induced after disease development abrogates CLL-like disease in vivo. ............................................................................. 192
Figure 5.11 Mice with an established CLL-like disease exhibit a decrease in disease load with induced Raptor-deficiency in vivo. ......................... 193
Figure 5.12 Mx1-Raptor cKO model is not completely efficient and causes disease relapse due to increased Raptor expression. ............................... 194
Figure 5.13 Raptor-deficiency solely in CD19+ CLL-like cells does not affect CLL-like disease initiation in vivo. ..................................................... 195
Figure 5.14 Raptor-deficiency solely in CD19+ CLL-like cells increases survival in CLL-like disease in vivo. ............................................................... 196
Figure 5.15 CLL-like disease is reduced with a combination treatment of AZD2014 and ibrutinib in vivo. ................................................................. 197
Figure 5.16 Combination therapy does not reduce CLL-disease load more efficiently than single agents in vivo. ................................................. 198
Figure 5.17 Secondary transplants of CLL-like disease are responsive to rapamycin treatment in vivo. ................................................................. 199
Figure 5.18 Rapamycin is a more potent agent for decreasing CLL-disease load in vivo. ......................................................................................... 200
Figure 5.19 A potentially different mechanism of rapamycin in decreasing CLL-like disease load compared to AZD2014 in vivo. ......................... 201
Table of Tables

Table 1.1 Summary of various promoters used in the cre-loxP system to excise mTORC1 (*Raptor*) or mTORC2 (*Rictor*) in haemopoietic cells and in B lymphocytes. ................................................................. 35
Table 1.2 Summary of promoters used to control cre expression. Table also describes all the organs/cells the cre transgenes will be active. ......................... 36
Table 2.1: List of companies and their addresses from where reagents and materials were purchased. ................................................................. 61
Table 2.2: Antibodies used for flow cytometry. Master mixes (MM) made for phenotypic identification. ................................................................. 62
Table 2.3: Biotinylated antibodies used to delineate early B and myeloid developmental stages and lineages for flow cytometry. .......................... 63
Table 2.4: List of antibodies used for phospho-flow cytometry. All antibodies were purchased from BD Biosciences, unless stated otherwise. .......... 64
Table 2.5: Antibodies used for viability assays on the flow cytometer. ......... 65
Table 2.6: List of primers used for PCR reactions. ........................................ 66
Table 2.7: List of protease inhibitors in the cComplete mini, EDTA-free protease inhibitor cocktail from Roche.................................................. 67
Table 2.8: List of antibodies used for western blotting. ............................... 68
Table 2.9: List and details of antibodies used for IHC. ................................. 69
Table 3.1: *Vav-cre*Raptor*fl/fl* mice do not survive to weaning (4 wk old), exhibiting perinatal lethality. ................................................................. 96
Table 3.2: *Mx1-cre Raptor*fl/fl* mice genotypes at weaning (4 wk). .......... 97
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4EBP1</td>
<td>4E binding protein 1</td>
</tr>
<tr>
<td>AA</td>
<td>amino acids</td>
</tr>
<tr>
<td>ABC</td>
<td>avidin-biotin-complex</td>
</tr>
<tr>
<td>AGM</td>
<td>aorta-gonad-mesonephros</td>
</tr>
<tr>
<td>AML</td>
<td>acute myeloid leukaemia</td>
</tr>
<tr>
<td>AMPK</td>
<td>AMP-protein kinase</td>
</tr>
<tr>
<td>APC</td>
<td>Antigen-presenting cells</td>
</tr>
<tr>
<td>APRIL</td>
<td>a proliferation-inducing ligand</td>
</tr>
<tr>
<td>ATF4</td>
<td>activating transcription factor 4</td>
</tr>
<tr>
<td>BAFF</td>
<td>B cell activating factor</td>
</tr>
<tr>
<td>BCAP</td>
<td>B-cell adaptor for PI3K</td>
</tr>
<tr>
<td>BCR</td>
<td>B-cell receptor</td>
</tr>
<tr>
<td>BCL-2</td>
<td>B cell CLL/lymphoma 2</td>
</tr>
<tr>
<td>BEL-A</td>
<td>Bristol Erythroid Line Adult</td>
</tr>
<tr>
<td>BFU-E</td>
<td>burst forming unit-erythroid</td>
</tr>
<tr>
<td>BLNK</td>
<td>B cell linker protein</td>
</tr>
<tr>
<td>BM</td>
<td>bone marrow</td>
</tr>
<tr>
<td>BMDM</td>
<td>bone marrow derived macrophages</td>
</tr>
<tr>
<td>BMSCs</td>
<td>Bone marrow stromal cells</td>
</tr>
<tr>
<td>BME</td>
<td>B-mercaptoethanol</td>
</tr>
<tr>
<td>BMSCs</td>
<td>BM stromal cells</td>
</tr>
<tr>
<td>bp</td>
<td>base pairs</td>
</tr>
<tr>
<td>BRU</td>
<td>Beatson Research Unit</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>BTK</td>
<td>Bruton’s tyrosine kinase</td>
</tr>
<tr>
<td>CAR-T cells</td>
<td>chimeric antigen receptor T cells</td>
</tr>
<tr>
<td>c-myc</td>
<td>c-myelocytomatosis viral oncogene</td>
</tr>
<tr>
<td>CD19-Raptor</td>
<td>CD19-Raptor control</td>
</tr>
<tr>
<td>KO</td>
<td>CD19-Raptor KO</td>
</tr>
<tr>
<td>CD19-cre-/+</td>
<td>CD19-cre-/+ Raptor&lt;sup&gt;fl/fl&lt;/sup&gt;</td>
</tr>
<tr>
<td>CD19-cre+/-</td>
<td>CD19-cre+/- Raptor&lt;sup&gt;fl/fl&lt;/sup&gt;</td>
</tr>
<tr>
<td>CD19-cre+/-</td>
<td>CD19-cre+/- Raptor&lt;sup&gt;fl/fl&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
**CD19-Rictor control**  
**CD19-cre<sup>−/−</sup>-Rictor<sup>fl/fl</sup>**

**CD19-Rictor KO**  
**CD19-cre<sup>−/−</sup>-Rictor<sup>fl/fl</sup>**

CDK  
cyclin-dependent kinase

CFC  
colony forming cell assay

CFU  
colony forming unit

CFU-E  
colony forming unit-erythroid

CFU-G  
colony forming unit-granulocyte

CFU-GEMM  
colony formation unit-granulocyte-erythroid-megakaryocyte-macrophage

CFU-GM  
colony forming unit-granulocyte macrophage

CFU-M  
colony forming unit-macrophage

CIRS  
Co-morbidity illness Rating scale

cKO  
conditional knockout

CLL  
chronic lymphocytic leukaemia

CLP  
common lymphoid progenitor

CML  
chronic myeloid leukaemia

CMP  
common myeloid progenitor

cre  
causes recombination recombinase

D  
day

DAB  
diaminobenzidine tetrahydrochloride

dH<sub>2</sub>O  
deionised water

DLBL  
diffuse large B-cell lymphoma

DN  
double negative

DNMTs  
DNA methyltransferases

DP  
double positive

DPX  
distyrene, polystyrene, xylene

e-KLF  
erthyroid Krüppel-like factor

E10  
embryonic day 10

EBF1  
early B cell factor 1

eIF-4E  
eukaryotic initiation factor

EF2K  
elongation factor 2 kinase

ERK  
extracelluar regulated mitogen activated protein kinase

EryD  
definitive erythroblasts
ES cells  Embryonic stem cells
ETC  electron transport chain
Exosc8  Exosome complex 8
FACS  fluorescent assorted cell sorting
FBS  foetal bovine serum
FCR  fludarabine, cyclophosphamide and rituximab
FL  foetal liver
FLT3-ITD  internal tandem repeats of FLT3
fol  follicular
FOXO1  Forkhead Box O1
FRB  FKBP-Rapamycin Binding
FSC-A  forward scatter-area
GC  germinal centre
GF  growth factor
GlyA  GlycophorinA
GMP  granulocyte-macrophage progenitor
GSK3  glycogen synthase kinase-3
H&E  haematoxylin and eosin
HBSS  Hank’s balanced salt solution
HPCs  Haemopoietic progenitor cells
HRI  heme-regulated eIF2α kinase
HRP  horseradish-peroxidase
HSC  haemopoietic stem cell
HSCT  haemopoietic stem cell transplant
HSPC  haemopoietic stem progenitor cell
IFNβ  interferon β
IFNγ  interferon γ
Ig  immunoglobulin
IGF  insulin growth factor
IgVH  Immunoglobulin variable heavy chain
IHC  immunohistochemistry
IL2Rγ  interleukin 2 receptor common chain gamma
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMLECs</td>
<td>innate myelo-lymphoblastoid effector cells</td>
</tr>
<tr>
<td>ip</td>
<td>intra peritoneal</td>
</tr>
<tr>
<td>IRS</td>
<td>insulin receptor substrate</td>
</tr>
<tr>
<td>ITAM</td>
<td>immunoreceptor tyrosine-based activation motifs</td>
</tr>
<tr>
<td>KD</td>
<td>knockdown</td>
</tr>
<tr>
<td>KI</td>
<td>knock-in</td>
</tr>
<tr>
<td>KLF</td>
<td>Krüppel-like factor</td>
</tr>
<tr>
<td>KO</td>
<td>knockout</td>
</tr>
<tr>
<td>LCMV</td>
<td>lymphocytic choriomeningitis virus</td>
</tr>
<tr>
<td>LN</td>
<td>lymph node</td>
</tr>
<tr>
<td>loxP</td>
<td>locus of crossover in P1</td>
</tr>
<tr>
<td>LPS</td>
<td>lipopolysaccharide</td>
</tr>
<tr>
<td>LSCs</td>
<td>Leukaemic stem cells</td>
</tr>
<tr>
<td>LSK</td>
<td>Lin-Sca1+cKit+</td>
</tr>
<tr>
<td>LMPP</td>
<td>lymphoid-primed multipotent progenitors</td>
</tr>
<tr>
<td>LT-HSC</td>
<td>long-term haemopoietic stem cell</td>
</tr>
<tr>
<td>M-CSF</td>
<td>macrophage-colony stimulating factor</td>
</tr>
<tr>
<td>MACS</td>
<td>Magnetic assorted cell sorting</td>
</tr>
<tr>
<td>MAM</td>
<td>mitochondria-associated endoplasmic reticulum membranes</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen-activated kinases</td>
</tr>
<tr>
<td>MCL</td>
<td>mantle cell lymphoma</td>
</tr>
<tr>
<td>MCL-1</td>
<td>myeloid cell leukaemia 1</td>
</tr>
<tr>
<td>MEP</td>
<td>megakaryocyte-erythrocyte progenitor</td>
</tr>
<tr>
<td>MFI</td>
<td>mean fluorescent intensity</td>
</tr>
<tr>
<td>MHC</td>
<td>major histocompatibility complex</td>
</tr>
<tr>
<td>miR</td>
<td>microRNA</td>
</tr>
<tr>
<td>MOPS</td>
<td>mM 3-(N-morpholino) propane sulfonic acid</td>
</tr>
<tr>
<td>MPECs</td>
<td>memory precursor effector cells</td>
</tr>
<tr>
<td>MPN</td>
<td>myeloproliferative neoplasm</td>
</tr>
<tr>
<td>MPPs</td>
<td>multipotent progenitor cells</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger RNA</td>
</tr>
<tr>
<td>mTOR</td>
<td>mechanistic target of rapamycin</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>mTORC</td>
<td>mechanistic target of rapamycin complex</td>
</tr>
<tr>
<td>Mx-Raptor cKO</td>
<td><em>Mx1-cre</em>/<em>Raptor</em>^{fl/fl}</td>
</tr>
<tr>
<td>Mx-Raptor control</td>
<td><em>Mx1-cre</em>/<em>Raptor</em>^{fl/fl}</td>
</tr>
<tr>
<td>Mx-Rictor cKO</td>
<td><em>Mx1-cre</em>/<em>Rictor</em>^{fl/fl}</td>
</tr>
<tr>
<td>Mx-Rictor control</td>
<td><em>Mx1-cre</em>/<em>Rictor</em>^{fl/fl}</td>
</tr>
<tr>
<td>MZ</td>
<td>marginal zone</td>
</tr>
<tr>
<td>MZP</td>
<td>marginal zone progenitor</td>
</tr>
<tr>
<td>NBF</td>
<td>neutral buffered formalin</td>
</tr>
<tr>
<td>NEAA</td>
<td>neutral essential amino acids</td>
</tr>
<tr>
<td>NFκB</td>
<td>nuclear factor kappa B</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Heath and Care excellence</td>
</tr>
<tr>
<td>NK cells</td>
<td>natural killer cells</td>
</tr>
<tr>
<td>NLCs</td>
<td>nurse-like cells</td>
</tr>
<tr>
<td>NOD</td>
<td>non-obese-diabetic</td>
</tr>
<tr>
<td>NRG</td>
<td>NOD-Rag-IL2Rγ</td>
</tr>
<tr>
<td>NSG</td>
<td>NOD-SCID-IL2Rγ</td>
</tr>
<tr>
<td>OG</td>
<td>Oral gavage</td>
</tr>
<tr>
<td>OS</td>
<td>Overall survival</td>
</tr>
<tr>
<td>PAMPs</td>
<td>pattern-associated molecular patterns</td>
</tr>
<tr>
<td>PAX5</td>
<td>paired-box-protein-5</td>
</tr>
<tr>
<td>PBMCs</td>
<td>peripheral blood mononuclear cells</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffer saline</td>
</tr>
<tr>
<td>PD-1</td>
<td>programmed death 1</td>
</tr>
<tr>
<td>PDCD4</td>
<td>programmed cell death 4</td>
</tr>
<tr>
<td>PDK1</td>
<td>3-phosphoinositide-dependent kinase 1</td>
</tr>
<tr>
<td>PE</td>
<td>paired end sequencing</td>
</tr>
<tr>
<td>PFS</td>
<td>Progression free survival</td>
</tr>
<tr>
<td>PI</td>
<td>propidium iodide</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>PIP2</td>
<td>phosphatidylinositol-4,5-phosphate</td>
</tr>
<tr>
<td>PIP3</td>
<td>phosphatidylinositol-3,4,5-phosphate</td>
</tr>
<tr>
<td>PKC</td>
<td>protein kinase C</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PKCaKR</td>
<td>Kinase-dead PKCa</td>
</tr>
<tr>
<td>PLC</td>
<td>phospholipase C</td>
</tr>
<tr>
<td>poly(I:C)</td>
<td>polyionosinic:polycytidylic acid</td>
</tr>
<tr>
<td>polybrene</td>
<td>hexadimethrine bromide</td>
</tr>
<tr>
<td>POMC</td>
<td>Proopiomelanocortin</td>
</tr>
<tr>
<td>PP2A</td>
<td>protein phosphatase</td>
</tr>
<tr>
<td>PP2A</td>
<td>protein serine/threonine phosphatase A</td>
</tr>
<tr>
<td>proE</td>
<td>pro-erythroblast</td>
</tr>
<tr>
<td>PTEN</td>
<td>Phosphatase and tensin homolog</td>
</tr>
<tr>
<td>PVDF</td>
<td>polyvinylidene difluoride</td>
</tr>
<tr>
<td>QC</td>
<td>quality check</td>
</tr>
<tr>
<td>Rag</td>
<td>recombination activation genes</td>
</tr>
<tr>
<td>rapa</td>
<td>rapamycin</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>RCN</td>
<td>relative cell number</td>
</tr>
<tr>
<td>RIC</td>
<td>reduced intensity conditioning</td>
</tr>
<tr>
<td>RIN</td>
<td>RNA intergrinty value</td>
</tr>
<tr>
<td>RNAseq</td>
<td>RNA sequencing</td>
</tr>
<tr>
<td>ROR1</td>
<td>receptor tyrosine kinase-like orphan receptor-1</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive oxygen species</td>
</tr>
<tr>
<td>RT</td>
<td>room temperature</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>real time-polymerase chain reaction</td>
</tr>
<tr>
<td>S6K</td>
<td>S6 kinase</td>
</tr>
<tr>
<td>SA</td>
<td>streptavidin</td>
</tr>
<tr>
<td>SCF</td>
<td>stem-cell factor</td>
</tr>
<tr>
<td>SCID</td>
<td>severe combined immunodeficiency</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SDF-1</td>
<td>stromal cell-derived factor 1</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SEM</td>
<td>standard error of mean</td>
</tr>
<tr>
<td>SFK</td>
<td>Src family kinases</td>
</tr>
<tr>
<td>SGK1</td>
<td>serum and glucocorticoid-induced protein kinase 1</td>
</tr>
</tbody>
</table>
SIRPα signal regulatory protein alpha
SLCs surrogate light chains
SLECs short lived effector cells
SSC-A side scatter-area
SYK spleen tyrosine kinase
T1 transitional 1
T2 transitional 2
T3 transitional 3
T-ALL T cell-acute lymphocytic leukaemia
TAE buffer Tris-acetate-EDTA buffer
TAM tumour associated macrophages
TBP TATA-box binding protein
TBS Tris-buffer saline
TBST Tris-buffer saline-Tween
TCL1 T cell leukaemia 1
TCR T cell receptor
TE buffer Tris-EDTA buffer
TECs thymic epithelial cells
TF transcription factor
Th T helper cells
TLR Toll-like receptor
TNF tumour necrosis factor
T-reg T-regulatory
TSC tuberous sclerosis complex
Vav-Raptor control Vav-cre^+/Raptor^fl/fl
Vav-Raptor KO Vav-cre^+/Raptor^fl/fl
Vav-Rictor control Vav-cre^+/Rictor^fl/fl
Vav-Rictor KO Vav-cre^+/Rictor^fl/fl
VEGF vascular endothelial growth factor
VRF Veterinary Research Facility
WT wildtype
YY1 yin-yang1
ZAP-70 70 kDA zeta associated protein
Chapter 1

Introduction
1 Introduction

1.1 Early Haemopoiesis:

Murine haemopoiesis initially occurs in the yolk sac and in two waves, the first of which is known as ‘primitive’ haemopoiesis. At this stage de novo haemangioblasts are generated and produce large quantities of erythrocytes to promote increased oxygenation, accommodating rapid growth. During the second wave of haemopoiesis or ‘definitive’ haemopoiesis, haemopoietic stem cells (HSCs) appear in the aorta-gonad-mesonephros (AGM) region around embryonic day 10 (E10)(1). From E11, HSCs migrate to and colonise the foetal liver (FL) and subsequently the bone marrow (BM) with waves of repopulating HSCs that provide a continuous source of mature haemopoietic lineage cells during the adult life span. The nature of the HSCs differ depending on the microenvironmental niche, with HSCs in the BM being more quiescent than those in the FL(2,3). HSC differentiation into multipotent progenitor (MPP) cells occurs mainly in the FL prior to migration into specific haemopoietic organs, such as the thymus, for further lineage differentiation. Conventionally, MPPs give rise to oligopotent common myeloid or lymphoid progenitors (CMPs or CLPs). CMPs further give rise to megakaryocyte-erythroid progenitors (MEP) and granulocyt-macrophage progenitors (GMP), while CLPs give rise to lymphoid lineage cells(4).

Nevertheless, there exists an alternate hierarchical model of haemopoiesis where MPPs give rise to lymphoid-primed multipotent progenitors (LMPPs) which have also been shown to develop into GMP myeloid progenitors but carry a lymphoid generation bias(5,6). It has previously been demonstrated, that the LinSca1<sup>+</sup>Kit<sup>+</sup> (LSK) HSC compartment of cells express high levels of CD34, Flt3 and IL7, are able to sustain the granulocyte, monocyte, B and T cell lineages. However, they lose megakaryocyte and erythrocyte potential (7,8). It is the further expression of C/EBPα and EBF1 which supports a myeloid and B cell lineage fate respectively (9).

As they get primed towards a lymphoid lineage, they lose the myeloid lineage generation capacity and develop into CLPs (Figure 1.1).
Figure 1.1 Diagram showing the hierarchy of haemopoietic cell differentiation. Haemopoietic stem cells (HSCs) give rise to multipotent progenitors (MPPs) which either develop into common lymphoid progenitors (CLPs) or common myeloid progenitors (CMPs). Literature also alludes to a lymphoid-primed multipotent progenitor (LMPP) population which is lymphoid primed (gives rise to CLPs) but capable of generating megakaryocyte-erythrocyte progenitors (MEPs) and granulocyte-macrophage progenitors (GMPs) giving rise to myeloid and erythroid lineages. CMPs further give rise to MEPs and GMPs whereas CLPs give rise to lymphoid lineages including B, T, and NK cells. Dashed arrows suggest alternative routes of haemopoietic differentiation.
1.2 Erythropoiesis

Erythropoiesis is governed by the complex regulation of key transcription factors (TFs), which enable a balance between erythrocyte progenitors and erythroblasts enabling self-renewal and differentiation. The zinc-finger TFs (4) Gata1 and Gata2 play critical and non-redundant roles during erythroid maturation. Gata2 is expressed in HSCs and early progenitor populations regulating the expression of self-renewal genes, in addition to genes responsible for initiating Gata1 expression. GATA1 plays a vital role in erythroid differentiation, sustaining its own expression and suppressing GATA2 expression, a process known as GATA factor switching (10). Gata1-deficient (Gata1−/−) mice in murine embryos gave rise to lymphoid cells and non-haemopoietic tissues but failed to give rise to a mature erythroid population, resulting from a block at the pro-erythroblast stage due to increased apoptosis. McIver et al., have demonstrated that Foxo3 and Gata1 co-operativity represses exosome complex 8 (Exosc8) expression thereby promoting erythroid maturation. Exosc8 is a vital component of the exosome machinery responsible for epigenetic regulation and RNA surveillance (11).

Recently, IKAROS, a zinc-finger protein has been shown to play a role in foetal and adult erythropoiesis and erythroid lineage commitment as Ikaros gene silencing leads to an irreversible switch to myeloid lineage (12). Pu.1 TF is an established master regulator in haemopoiesis as it is one of the key genes involved in primitive cell fate decisions. Pu.1 expression levels determine myeloid and lymphoid cell fates where higher expression of Pu.1 leads to myeloid cell fate whereas a lower expression to a lymphoid fate (13).

Additionally, a myeloid cell fate is not solely regulated by Pu.1 expression but also the inhibition of Gata1(14) and the expression of Cebpα (15). Cebpα is considered essential for myeloid fate by binding and transcribing genes associated with myelopoiesis at the long-term haemopoietic stem cell stage (LT-HSC) stage (16).

Pu.1 and GATA1 interact to regulate lineage fate where upregulation of Gata1 inhibits Pu.1 transcription and promotes erythroid lineage (17) differentiation whereas expression of Pu.1 inhibits Gata1 expression promoting myeloid lineage fate (18). Gata1 is known to be a very potent TF as it binds to the promoter region of erythroid-Krüppel like factor/ Krüppel like factor 1 (e-Klf/Klf1) (19). Klf1 TF is vital for erythropoiesis as it regulates MEP lineage fate during
erythrocyte development. *Klf1* expression has been shown to promote CD71 surface expression, which leads to the development of the earliest pro-erythroblasts (proE). These cells are nucleated and have oxygen carrying capacity and circulate in the embryo. These cells then develop into definitive erythroblasts (EryD) which is marked by enucleation. CD71, a transferrin receptor, is known to be expressed at all embryonic stem (ES) cells and proE cells(20). Nevertheless, during maturation, proE cells undergo ‘maturational globin switching’ leading to reduced CD71 expression and erythrocyte maturation. TER119, on the other hand is associated with glycophorinA (GlyA) and is correlated with maturing erythrocytes(21). Together, CD71 and TER119 are widely used in flow cytometry to determine the developing stages of erythrocytes: EryA, EryB and EryC stages. TER119<sup>lo</sup>CD71<sup>hi</sup> population is considered as the proE stage. Subsequent populations which express TER119<sup>+</sup>CD71<sup>+</sup>FSC-A<sup>hi</sup> are considered to be in the EryA stage as these populations are larger as they are nucleated. Subsequent enucleation reduces the size and therefore the forward scatter-area (FSC-A) in flow cytometry and EryB populations are CD71<sup>+</sup>TER119<sup>+</sup>. Lastly, maturation of erythrocytes is marked by a reduction in CD71 expression which are considered TER119<sup>+</sup> EryC cells(22).

‘Maturational globin switching’ also involves the ‘globin switching’ from γ- to B-Globin for the maturation of erythrocytes via *Klf1* activity(23). In human haemopoietic development, B-GLOBIN is expressed when erythropoiesis moves to the BM. Initially, the yolk-sac expresses ε-GLOBIN, followed by the expression of γ-GLOBIN in the FL and spleen. Therefore, *Klf1* mediated B-GLOBIN expression is vital for the development of mature erythrocytes(24). Whilst *Klf1* plays a major role in erythropoiesis, *Klf2* plays a role in endothelial growth, vascular remodelling and inflammation responses(25), which is vital for embryonic development.

### 1.3 B1 B cells and B2 B cells

B1 B cells were originally given this name as they were thought to appear earlier in ontogeny compared to B2 B cells. B1 B cells secrete majority of the IgM and play a vital role in pathogen-induced immunity. B1-a B cells express surface CD5<sup>+</sup> whereas B2 cells lack CD5, a marker initially only thought to be specific for T cells(26). Nevertheless, there also exist CD5<sup>+</sup> B1 cells termed B1-b cells which
have similar phenotypes to B1-a cells. B1 B cells are thought to be ‘rarer’ and are not considered the ‘conventional’ B cells. B1 B cell heterogeneity is not restricted to CD5 expression, and different populations within B1 B cells have been identified, wherein increased levels of B cell receptor (BCR) signalling induced antigen-presenting cells (APCs) whereas other subtypes had a diminished BCR signalling alluding to cell quiescence(27).

B1 B cell precursors are considered to originate in the FL, whereas B2 precursor cells are said to originate in FL which later moves onto the BM after birth. However, B1 B cell generation has been shown in other-haemopoietic regions such as the blood island yolk sacs in the embryo, in the FL and in the BM after birth. Nevertheless, these B1 B cell pools in the BM do not contribute to B1 B cell development after 3-6 wk of birth(28) supporting previous work highlighting B1 B cell lineage to be a foetal/neonatal developed population. It also suggests that this population is maintained by self-renewal in the BM and not by de novo development.

Therefore, from hereon, B cell development and other aspects of B cells presented will refer to the ‘conventional’ B cell population - B2 B cells.

1.4 B cell development

B cells are a subtype of lymphocytes involved in the humoral immunity in the adaptive immune response of the body. B cell development comprises several phenotypic stages enabling B cell lineage commitment/maturation from HSCs initially in the FL during embryogenesis and then in the BM.

1.4.1 TFs involved in B cell development

Pu.1 is a vital TF most likely expressed during the MPP stage and is vital for determining lineage fate. Playing a role in lineage fate decisions between erythroid and myeloid lineages as seen in section 1.2, the graded expression of this TF has shown to determine B cell fate as high expression of Pu.1 has shown to bias a myeloid lineage and lower expression of Pu.1 has shown to bias to a B cell lineage(29).
Flt3 expression is present at the MPP stage and plays an important role in deciding B cell fate. Nevertheless, constitutive Flt3 expression at later stages abrogates B cell development alluding to the importance of paired-box-protein 5 (Pax5) mediated repression of Flt3. Indeed expression of Flt3, IL7 is essential for B cell development, mediated by Ikaros TF(30). Additionally, transition from the LMPP to the CLP phase is associated with an increase in IL7-receptor α (Il7Rα) expression as Il7R-deficient mice have a block in B cell development at the pre-proB cell stage suggesting Il7R expression is vital in initiating immunoglobulin (Ig) rearrangement(31,32).

IKAROS has shown vital roles for B cell development as Ikaros-deficiency has shown to block B cell development at the pre-proB cell stage. Ikaros-deficiency has also shown to regulate Il7-Ra and Flt-3 expression as Ikaros knockout (KO) leads to a decreased expression of these proteins suggesting the expression of both these proteins is vital for B cell development(33). Il7Ra has been shown to promote the expression of early B-cell factor 1 (Ebf1) further highlighting the importance of IKAROS in normal B cell development(34).

E12 and E47 are helix-loop-helix proteins which comprise E2A. E2A TF is essential for lymphoid lineage development as it promotes the expression of Ebf1. Indeed, mice lacking Ebf1 did not undergo Ig recombination suggesting the importance of the expression of this gene to induce the transition from the pre-proB to proB cell stage (35). E2A interactions with EBF1 induce Pax5 expression, which positively regulates Ebf1 expression along with E2A(32). Interestingly, it has also been shown that E2A interactions with Forkhead box O1 (Foxo1) (via the mTOR-AKT signalling pathway) together with E2A-Ebf1 interactions induce Pax5 expression (36). Pax5 expression encodes various components responsible for the transition from pre-proB to preB cells by aiding pre-BCR expression. It also promotes expression of co-receptors CD19 and CD21(30). Pax5 has shown to negatively regulate Flt3 expression, as constitutive expression of Flt3 is associated with impaired B lymphopoiesis, highlighting internal mechanisms of regulating B cell development(37). E2A-FOXO1 interactions have been shown to activate Rag1 and Rag2, the main drivers of VDJ recombination and therefore Ig rearrangement and transition from the preB cell stage to the immature B cell stage(38).
Figure 1.2 Diagram showing the summary of B cell development. HSCs develop into MPPs which give rise to LMPPs which, under the appropriate signals, develop into CLPs, enabling B cell development. Pre-proB cells give rise to proB cells due to the interactions of E2A and Ebf1 and E2A and Foxo1. These TFs induce Pax5 expression, promoting CD19 expression and RAG1/2 expression, and subsequent IgVH re-arrangement. Functional VDJ re-arrangement leads to the maturation of the pre-BCR complex to a BCR complex and the development of preB cells into immature B cells. These cells then migrate into secondary lymphoid organs to further mature into different B cell subtypes via transitional 1, 2, and 3 stages (T1-3). These give rise to mature B cells subtypes including marginal zone (MZ) follicular 1 (fol1), fol2 B cells.
1.4.2 Developmental stages

At the CLP stage, stem cell factor (SCF) is released from the stromal cells in the microenvironment, binding to its receptor CD117 on early B cell precursors (39). Lymphoid precursors express CD117 and IL7Rα and are capable of developing into B, T or natural killer (NK) cells, but not erythrocytes/myeloid lineages. After the CLP stage, the earliest B cell precursors express B220, along with early NK cells. However, these lineages can be separated using other surface markers such as AA4.1, which is expressed on B cells up to the immature stage (31,40).

1.4.2.1 Early B cell development

It is after Pax5 expression which promotes sequential recombination of the Ig gene segments of the heavy and light chains, forming the platform for B cell development. This functional rearrangement comprises the VDJ gene segments of the heavy chain (µ locus) and the VJ segments of the light chain (κ locus) initiated by recombination-activating genes 1 and 2 (Rag1 and Rag2). Functional rearrangement of these genes enables the cell to generate antibodies which recognise various cell specific antigens. The rearrangement pattern of the Ig heavy chain (IgH) gene segments is associated with distinct stages of B cell development - pre-proB cell, proB, preB cells (Figure 1.2, Figure 1.3). B precursors with no rearrangement are in the pre-proB cell stage. The
rearrangement of DJ segments in the H chain is correlated with the proB cell stage. *Mb1* expression at the proB cell stage is vital for Ig rearrangement as *Mb-1* encodes the Ig-α subunit, deficiency of which leads to BCR deficiency(41). *CD19* expression is also expressed at the proB cell stage, under the regulation of *Pax5*. V chain addition to the DJ segment(42) marks the large preB cell stage. *CD19* expression is marked by BCR dependent and independent events. CD19 interacts with the BCR to enhance BCR activity.
1.4.2.2 Late B cell development

After immature B cell development, the cells undergo one of three processes dependent on Ig interactions. Cells which undergo cross-linking of the BCR leading to high affinity interactions are associated with elimination via clonal deletion (negative selection). Low affinity interactions lead to non-responsive anergic cells which are short lived, or it could also lead to cells editing their BCR to become non-reactive(43). All other immature B cells, expressing surface bound IgM, migrate into the spleen where they mature into naïve, follicular (fol) or marginal zone (MZ; CD19⁺CD21⁺CD23⁻IgM⁺) B cells via transitional phases (T1-T3). Cariappa et al., have shown there to be a transition from T1 (CD19⁺CD21⁺CD23⁻IgM⁺) to T2 (CD19⁺AA4.1⁺CD21⁺CD23⁺CD1d⁻IgD⁺IgM⁺) to T3 (CD19⁺CD21⁺CD23⁻CD1d⁻IgD⁺IgM⁺) cells.
which develop into fol2 B cell populations. Fol2 B cells give rise to MZ progenitors (MZP; CD19+CD21hiCD23+CD1dhi) and ultimately MZ B cells together with fol1 cells. Nevertheless, T1 cells also transition to T3 cells to give rise to fol1 cells (44). Association of Toll-like receptor (TLR) signalling together with pattern-associated molecular patterns (PAMPs) leads to MZ B cell development into IgM plasma cells forming the first line of innate immunity against pathogens(45). Fol1 B cells (CD19+AA4.1+CD21loCD23+CD1dintIgDhiIgMlo) form the bulk of the circulating population whereas fol2 cells (CD19+AA4.1+CD21loCD23+CD1dintIgDhiIgMhi) form one-third of the circulating population, being more quiescent and considered to be more primitive(44) residing in B cell follicles (Figure 1.2, Figure 1.4). It is the interaction of T helper (Th) cells with these fol B cells which leads to the expansion of B cells comprising the germinal centres (GCs) in secondary lymphoid organs(45). CD19 expression is vital for the maintenance of peripheral B cells as CD19-null mice have shown to have decreased survival compared to normal B cells. This maintenance is partially via the BCR/B cell lymphoma-2 (Bcl-2) axis, as increasing Bcl-2 expression in CD19-null mice rescued MZ and fol B cell generation(46). Phosphoinositide 3-kinase-delta (PI3Kδ) expression is restricted to B and T cells and has shown to play a role in late B cell development. PI3Kδ-null mice show block in B cell development at the preB cell stage. It has been shown that PI3K expression is regulated by pre-BCR signalling, and PI3K isoforms, p110α and p110δ, modulate Pax5 expression, absence of which arrests B cell development at the preB cell stage(47), making PI3Kα and PI3Kδ redundant for early B cell development. PI3Kδ has shown to be vital for late B cell development, particularly for MZ cells(48,49). There is a significant reduction in MZ B cells with PI3Kδ-deficiency due to reduced CXCR5 mediated migration(50) as PI3Kδ-deficient mice have a reduction in MZ B cell homing into proliferative centres suggesting a role of PI3Kδ in MZ B cell maturation and homing capacity.

1.5 mTOR signalling pathway

The BCR signalling pathway regulated B-cell proliferation and survival and it is known for its crosstalk between other signalling pathways including MAPK, NFκB and mTOR signalling pathways. BCR engagement leads to the phosphorylation of tyrosine residues located on immunoreceptor tyrosine-based activation motifs (ITAMs) of CD79a and CD79b by protein tyrosine kinases including Lyn, Syk.
Through this, downstream proteins including BCAP and BLNK are activated\(^{(51)}\). Additionally, CD19 engagement is vital for BCAP binding to p85 which is essential for the PI3K phosphorylation\(^{(52)}\). Moreover, CD19 is a surface protein, coligation of which to the BCR, is known to modulate BCR signalling positively and negatively by attenuating PI3K activity\(^{(53)}\). BLNK is responsible for PLCy1, VAV and BTK, whereas BCAP is responsible for the activation of PI3K, downstream which, is the mechanistic target of rapamycin (mTOR) signalling pathway.

mTOR is a serine/threonine kinase, which is involved in various signalling pathways regulating metabolism. mTOR, as the name suggests, is targeted by rapamycin which is an anti-fungal macrolide first characterised in *Streptomyces hygroscopicus*. Due to the anti-proliferative properties of rapamycin, extensive research was carried out on this and TOR was then discovered. Its consequent purification in mammals also showed the vast application of TOR in mammals, known as the mTOR signalling pathway\(^{(54)}\). It is involved in protein synthesis, mitochondrial function, autophagy, cytoskeleton organisation, and cell survival mechanisms. However, how mTOR signalling is regulated is not fully understood.

The mTOR pathway is activated by a variety of signals including insulin/insulin growth factors (IGF), glucose, amino acid, tumour necrosis factor (TNF) and BCR signalling (Figure 1.5). mTOR belongs to the PI3K family and it forms two different complexes - mTORC1 and mTORC2. mTORC1 comprises of 6 proteins and mTORC2 of 7 proteins. Of these, they share the common mTOR subunit, along with GBL, DEPTOR, TTI1/TEL2 complex. The subunits which make the respective complexes unique are RAPTOR (rapamycin TOR sensitive), PRAS40 which are specific to mTORC1 and RICTOR (rapamycin TOR insensitive), mSIN1, and PROTOR1/2 specific to mTORC2\(^{(55)}\). The complexes, RAPTOR and RICTOR are what make mTORC1 and mTORC2 sensitive or insensitive to rapamycin respectively\(^{(56)}\). Rapamycin is an allosteric inhibitor of mTORC1, as recent co-crystal structures of mTOR-mLST8 show that rapamycin binds to the FKBP-Rapamycin binding (FRB) domain thereby highly recessing the active site\(^{(57)}\). Therefore, it is responsible for partial, not full mTORC1 inhibition.
Figure 1.5 Diagram of the AKT/mTOR signalling pathway.

Downstream signalling from the B cell receptor (BCR) and growth factor receptors is shown. Activation of these receptors results in phosphorylation and activation of AKT, which leads to the activation of mTORC1 (PRAS40, RAPTOR), thereby initiating cell processes such as protein synthesis and proliferation. The downstream target of mTORC1, S6K negatively regulates mTORC2 (PROTOR1/2, mSIN1, RICTOR), which is responsible for the activation of AKT. This creates a negative feedback loop, which regulates this pathway. mTORC1 and mTORC2 share the subunits mTOR, GβL, DEPTOR and TTI1/TEL2 (not shown). AKT negatively phosphorylates FOXO1/3, which regulates cell cycle. Kinases such as AMPK are activated in stress responses and inhibit the mTORC1 pathway. Allosteric inhibitors such as rapamycin and other rapalogs partially inhibit mTORC1 activity whereas ATP competitive inhibitors such as AZD2014 are pan mTOR inhibitors. Abbreviations: PLC (Phospholipase C), BLNK (B-cell linker protein), BTK (Bruton’s tyrosine kinase), BCAP (B-cell adaptor for PI3K).

Rapamycin has similar structure to FK506 which blocks Ca²⁺/calcineurin dependent signalling in T cells required for growth and proliferation. Rapamycin on the other hand binds to FKBP12 and inhibits mTORC1 activity by blocking the cytokine signalling required for growth.

The upstream mediator of mTOR is PI3K (Figure 1.5). PI3K can bind to Insulin receptor substrate proteins (IRS) and converts phosphatidylinositol-4,5-
phosphate (PIP$_2$) to phosphatidylinositol-3,4,5-phosphate (PIP$_3$). Phosphatase and tensin homolog (PTEN), a tumour suppressor, blocks PIP$_3$ accumulation and PIP$_3$ phosphorylates and activates 3-phosphoinositide-dependent protein kinase 1 (PDK1) and AKT. AKT then activates mTORC1 via the inhibition of the tuberous sclerosis proteins TSC1 and TSC2. They form a heterodimer and inhibit RHEB which then binds to mTORC1 causing conformational changes in the protein and activation(58). However, whether RHEB binds and activates mTORC2 has not been determined.

1.5.1 mTOR signalling and its functions

1.5.1.1 mTORC1 signalling:

RAPTOR binds mTOR to enhance its' activity, as indicated by the finding that RAPTOR inhibition using RNAi, leads to decreased mTOR activity(59). In a low-energy state (low ATP:AMP ratio), AMPK, a conserved energy sensor, is activated leading to TSC2 phosphorylation and the subsequent inhibition of mTORC1 activity(60). However, in a high-energy state, the mTORC1 pathway is activated, promoting protein synthesis, lipogenesis and mitochondrial biogenesis and function(8-11). Indeed, mTORC1 plays a pivotal role in mitochondrial oxidative function through regulation of the transcription factor yin-yang1 (YY1), which subsequently controls gene expression of mitochondrial transcriptional regulators including PGC-1$\alpha$(10). Additionally, mTORC1 controls mitochondrial biogenesis and respiration through phosphorylation/inhibition of the eukaryotic initiation factor 4E (eIF-4E) binding proteins (4EBPs) and regulation of the translation of nucleus-encoded mitochondrial-related mRNAs, which in turn increases ATP generation in the cell(11) (Figure 1.5). In the absence of mTORC1 activity, 4EBP1 is hypo-phosphorylated and interacts with the mRNA cap binding protein eIF-4E, inhibiting translation of cap-dependent proteins. Upon mTOR activation, hyper-phosphorylation of 4EBP1 releases eIF-4E, enabling its association with eIF-4A (RNA helicase) and the scaffolding protein eIF-4G to form the eIF-4F complex. The mTORC1-eIF-4E pathway is upregulated in most cancers and thus represents an attractive therapeutic target(61).

mTORC1 also phosphorylates/activates S6 Kinase 1 (S6K1) at T389, which was initially thought to play a role in protein/ribosomal biogenesis by activating 40S
ribosomal protein. However, it is now appreciated that S6K1 is important in a number of mechanisms, together with S6K2, including transcription, cell proliferation, apoptosis and potential mRNA splicing(62). S6K phosphorylates programmed cell death 4 protein (PDCD4) at S67 targeting it for proteosomal degradation(63). PDCD4 is a tumour suppressor responsible for inhibiting eIF-4E.

Moreover, a recent study in a colorectal cancer model shows that S6K phosphorylates and inhibits elongation factor-2 kinase (EF2K), in turn relieving EF2K inhibition of EF2 and thus elongation of nascent polypeptide chains(15). S6K also plays a role in actin organisation by the direct binding to F-actin. A role in cytoskeletal rearrangement is also seen as S6K activates Rho family members regulating this - CDC42 and RAC1 and their downstream target PAK1. As deletion of S6K leads to a decrease in activation of the Rho family members, cytoskeletal organisation and migration in ovarian cancer cells, S6K is a promising target for enabling reduction of tumour progression(64). An additional target of S6K1 is RICTOR(65), which when phosphorylated at T1135, leads to mTORC2 inhibition, establishing a negative feedback loop between mTORC1 and mTORC2(66).

1.5.1.2 mTORC2 signalling

AKT can be considered the hub of the PI3K pathway as its downstream signalling leads to mechanisms controlling a multitude of diverse functions within the cell. AKT is only activated in response to receptor signalling via phosphorylation of two key sites, T308 by PDK1 and S473 by mTORC2, via growth factor (GF) receptor activation(67). The majority of mTORC2 functions occur through AKT regulation, including activation of mTORC1, placing AKT both upstream and downstream of mTOR regulation. During low-energy conditions, AMPK activation leads to an upregulation of mTORC2 and its downstream targets(68). Such downstream targets include the FOXO family of transcription factors, which are phosphorylated by AKT leading to an inhibition of their function. FOXOs play an important role in the repression of cell proliferation and survival, but in certain cell contexts are considered to play a role in tumorigenesis(69). FOXOs regulate apoptosis in distinct ways, repressing apoptosis through the downregulation of the pro-apoptotic BCL-2 family member BIM, or promoting apoptosis through transcriptional upregulation of FAS ligand(70). mTORC2-FOXO1 signalling also regulates innate immune responses as RICTOR deletion leads to attenuated AKT signalling, thereby increasing nuclear FOXO1, resulting in hyper-inflammatory...
responses via TLR4(71). mTORC2 has been shown to localise at the mitochondria-associated endoplasmic reticulum membranes (MAM) in a GF-dependent manner, and RICTOR deletion disrupts AKT-dependent phosphorylation of mitochondria associated proteins. These events lead to a reduction in mitochondrial function, increasing mitochondrial membrane potential and effecting energy metabolism and cell survival, thereby demonstrating a vital role of mTORC2 signalling in mitochondrial physiology(25). The importance of mTORC2 in AKT activation was highlighted by a recent study demonstrating that deletion of the AKT binding site within the mTORC2 component mSin1 greatly reduced AKT$^{5473}$ phosphorylation, rendering it unable to phosphorylate FOXO1/3a, while other targets such as glycogen synthase kinase 3 (GSK3) and mTORC1 were unaffected(72) (73). These findings suggest that mTORC2 activation is important for AKT-mediated cell survival mechanisms.

Further downstream targets of mTORC2 include protein kinase C-alpha (PKC$\alpha$) as mTORC2 inactivation reduced PKC$\alpha$ phosphorylation(74), which is responsible for functions including cell proliferation, differentiation, motility, apoptosis and inflammation(75). mTORC2 also regulates growth and ion transport by phosphorylating the hydrophobic motif of serum and glucocorticoid-induced protein kinase 1 (SGK1)(76). SGK1 inhibition induces autophagy, apoptosis and cell cycle arrest in the G$_2$/M phase in prostate cancer cell lines, at least in part through an mTOR-FOXO3a-mediated pathway(31). SGK1 regulates Th2 differentiation and negatively regulates interferon gamma (IFN$\gamma$) production, thereby highlighting the importance of mTORC2 in T cell effector function(77). mTORC2 has also shown to play a role in cytoskeletal organisation by activating RhoA GTPases(78).

1.5.2 mTOR in embryogenesis

The mTOR complexes are essential for cell survival and growth, and studies generating KO mice established that mTOR kinase and individual complexes mTORC1/2 were essential for normal embryogenesis(79,80). A homozygous KO of \textit{mTOR} (\textit{mTOR$^{-/-}$}) resulted in the death of mouse embryos soon after implantation (E5.5-6.5). Despite normal blastocyst development, the embryo did not develop further due to limited cell proliferation and survival signalling. Nevertheless, \textit{mTOR$^{-/-}$} mice developed fertile and normal embryos. Similarly, \textit{Raptor$^{-/-}$}
embryos die during early development (E7) whereas the Rictor−/− mice survived slightly longer (E10.5) (80). These studies indicate mTOR function is mediated mainly through mTORC1 during early embryogenesis, but both mTORC1/2 play critical roles.

1.5.3 mTORC1 and mTORC2 signalling in HSCs/HSPCs

Targeted deletion of mTORC1 and/or mTORC2 in mouse models demonstrate a critical role for the mTOR pathway in haemopoiesis and highlight the importance of the individual mTOR-containing complexes at specific stages of HSC homeostasis and haemopoietic lineage commitment and maturation, as discussed below.

1.5.3.1 HSCs

Conditional knockout (cKO) mouse models of PTEN and TSC1, upstream negative regulators of mTORC1 in HSCs, revealed an increase in short-term HSC cycling and a concomitant decline in LT-HSC quiescence and self-renewal through constitutive activation of mTORC1 (81,82). TSC1−/− in HSCs led to an elevation in mitochondrial biogenesis, resulting in increased reactive oxygen species (ROS) production, driving HSCs from quiescence to rapid cell cycling thereby reducing self-renewal capacity (83). These studies identify the importance of mTOR regulation in HSC quiescence through ROS regulation. Interestingly, similar findings were reported in mTOR cKO mice, in which BrdU labelling revealed rapid cell cycling in HSC leading to a loss of quiescence and defective HSC engraftment and repopulation upon transplantation into NSG mice (84). Recent studies establish crosstalk between the extracellular regulated mitogen activated protein kinase (ERK) and mTOR signalling pathways, with ERK activity regulating mTORC1 activation, thus limiting its strength to promote HSC cycling in favour of quiescence. Indeed, HSCs derived from MEK1 cKO mice exhibit exhaustion due to increased mTORC1-mediated ROS production resulting in increased mitochondrial damage (85). These studies identify the importance of precise mTOR regulation during HSC maintenance and haemopoiesis.

The WNT signalling pathway can activate the mTOR pathway by inhibiting GSK3-mediated phosphorylation of TSC2 independently of β-catenin transcription.
GSK3 inhibits mTOR activation by phosphorylating TSC2 in a manner coordinated by AMPK (86). Knockdown (KD) of Gsk-3 disruption initially resulted in an increase in LSK populations due to an activation of both WNT-signalling (β-catenin dependent) and mTOR pathways. However, long-term disruption of GSK3 expression/activity led to a depletion of HSC populations due to mTOR activation, which could be reversed through inhibition of mTORC1 and β-catenin(87). Inhibition of the mTOR pathway together with activation of the WNT-β-catenin pathway led to increased LT-HSC numbers and the potential to culture HSCs ex vivo in a cytokine free environment, highlighting the importance of appropriate regulation the WNT and mTOR signalling pathways in stem cell renewal(88).

Reduction in signalling downstream of mTOR enhances HSC self-renewal and repopulating properties: mice lacking S6K1(89) or mice treated with rapamycin, a partial mTORC1 inhibitor(90), exhibit increased life- and health-span compared to controls due to an increase in repopulating LT-HSCs. Collectively, these findings suggest that the loss in mTOR function during haemopoiesis primarily represents a loss of mTORC1 activity, with mTORC2 not playing a key role in HSCs.

### 1.5.3.2 Haemopoietic stem/progenitor cell (HSPCs):

Assessing the role of mTOR on haemopoietic lineage commitment using an mTOR cKO model in adult mice revealed significant aberrations in the development of haemopoietic lineage populations, resulting in a reduction of splenic weight and size. Closer analysis revealed that mTOR disruption led to pancytopenia, including a block in erythrocyte development at the pro-erythroblast stage, and anaemia(84). The decline in haemopoietic lineage commitment was accompanied by increased apoptosis and decreased myeloid cell leukaemia 1 (MCL-1) expression. Within BM HPC populations, there was a skew towards CMPs and a decrease in CLPs in mTOR-deficient mice. While there was an increase in the LSK population, the colony forming ability of these LSKs was impaired. There was also an attenuation in S6K and 4EBP1 phosphorylation/activation and increased phosphorylation of AKT, implicating an aberration in the S6K-mediated negative feedback loop regulation of mTORC2 activity(66,84).
The mTORC1 cKO model (\(Mx1\)-cre\(^{\ast}\)Raptor\(^{fl/fl}\); \(Mx1\)-Raptor cKO) exhibited an increased LSK population in the spleen in addition to the BM, suggesting extramedullary haemopoiesis. The LSKs were arrested at the G\(_1\) phase of cell cycle compared to controls, suggesting a reduction in cell division(91).

Metabolite analysis of LSKs revealed an increase in intermediates used in lipid metabolism, and in AMP and NADP\(^+\) involved in redox homeostasis, and a decrease in nitrogen metabolism(91). LSK\(^{CD48^-CD150^+}\) cells derived from the \(Mx1\)-Raptor cKO BM failed to engraft into recipient mice. While these cells were able to home to the BM, they localized further from osteoblast cells, indicating a role for mTORC1 in the integration of niche signals. \(Mx1\)-Raptor cKO HSCs also possessed regenerative and self-renewal aberrations compared to controls and those cells that ‘escaped deletion’. A compound \(Rictor/Raptor\) cKO in adult mice exhibited similar results as \(Mx1\)-Raptor cKO mice in haemopoiesis, however this mouse model did not develop BM failure and retained the deletion of alleles of \(Raptor\) and \(Rictor\) for almost one year after KO induction(91). These results suggest that the mTOR pathway is not essential for survival and haemopoietic maintenance in adult mice but is essential for haemopoiesis initiation during embryonic development.

Genetic targeting studies to ablate mTORC2 function in haemopoiesis revealed a more subtle role compared to mTORC1. Studies in \(Mx1\)-Rictor cKO (\(Mx1\)-cre\(^{\ast}\)Rictor\(^{fl/fl}\)) mice indicated that mTORC2 does not play a significant role in HSCs and progenitor populations(92). However, Magee \textit{et al.}, elegantly demonstrated that after \(Pten\)-deletion, which activates the mTOR-signalling pathway, deletion of \(Rictor\) abrogates leukemogenesis and HSC depletion in adult, but not neonatal mice(93), highlighting that the PTEN-mTORC2 signalling axis has a role in activating these processes in a temporally-dependent manner.

1.5.4 mTORC1 and mTORC2 signalling in Erythrocytes

The mTOR cKO model revealed a block in erythropoiesis at the proE stage, highlighting the importance of mTOR signalling in red blood cell (RBC) development(84). Interestingly, results from this model are similar to that observed in the \(Tsc1\) cKO mouse, which exhibited a reduction in erythrocytes in the BM(82), through activation of mTORC1-mediated signalling. These studies indicate that a complex regulation of mTOR signalling is required for appropriate
RBC development. Analysis of the importance of mTOR function in erythropoiesis revealed that loss of FOXO3 in erythroblasts results in an overactivation of the mTOR pathway thereby compromising erythroid maturation(94). FOXO3 regulates Gata1 expression and represses Exosc8 expression which are both involved in erythroid maturation(95). Additionally, ectopic expression of microRNA9 (miR9) disrupts erythropoiesis via the suppression of FOXO3-mediated pathways, causing an increase in ROS due to the downregulation in ROS scavenging enzymes(96).

Recent studies show that mTORC1 plays a critical role in RBC commitment, growth, proliferation and homeostasis. Knight et al., demonstrated that mTORC1 activity is regulated by dietary iron, and a loss or overexpression of mTORC1 in HSCs leads to microcytic or macrocytic anaemia respectively with a loss of proliferation in RBC progenitors(97). Furthermore, mice treated with the ATP competitive mTOR inhibitor MLN0128, and subsequently treated with phenylhydrazine to induce haemolysis, was shown to be lethal, demonstrating the reliance of the mTOR pathway in RBC development(97). Zhang et al., have shown that the heme-regulated elf2α kinase (HRI)-activating transcription factor 4 (ATF4) pathway, which regulates heme uptake for haemoglobin production and stress response genes, suppresses mTORC1 activity in iron deficiency anaemia. The HRI-ATF4 pathway promoted RBC progenitor differentiation, and pharmacological inhibition of mTORC1 rescued RBC counts and haemoglobin content in the blood(98). mTOR also plays a role in microenvironmental homeostasis associated with RBC development through regulation of neutral essential amino acids (NEAA) uptake into cells during erythropoiesis for haemoglobin production. mTORC1/4EBP1 signalling regulates Lat3, a transporter of NEAA in RBCs(99).

1.5.5 mTORC1 and mTORC2 signalling in Myeloid cells

cKOs of Mtor or Raptor in HSCs lead to a significant accumulation of CD11b^Gr1^- population(84,100). Mtor cKO mice on a severe combined immunodeficiency (SCID) background exhibited reduced monocyte/macrophage populations in in vitro and in vivo assays. However, removal of mTOR expression specifically in myeloid cells (Mtor-Lyzs-cre), revealed normal levels of monocyte/macrophage populations, suggesting that mTOR plays a role during lineage commitment, but not during survival and maturation(101). Following mTOR deficiency, a decrease
in the expression of macrophage-colony stimulating factor (M-CSF) receptor CD115 was noted, which may result in decreased monocyte/macrophage populations due to overactive STAT5 and downregulation of IRF8(101). M-CSF promotes mTORC1 activation which further promotes CD115 expression, and expression of Pu.1 and Irf8 to promote myelopoiesis. In the absence of mTORC1 activity there is a block in glucose uptake and lipid metabolism thereby abrogating myeloid differentiation along with an impaired immune response to bacterial infection(102). Constitutive activation of mTORC1 in Tsc KO BM-derived macrophages (BMDMs) attenuated AKT signalling through the negative feedback loop via mTORC2 leading to a defect in IL4-induced M2 polarisation. These BMDMs produce more pro-inflammatory responses compared to controls suggesting an important role of mTORC1 in the regulation of inflammation(103). Additionally, it has recently been shown that Raptor cKO, but not granulocyte-specific KO (Raptor-Lyz2-cre) mice lead to a significant increase and accumulation of innate myelo-lymphoblastoid effector cells (IMLECs). This suggests that IMLEC accumulation driven by Raptor-deficiency occurs earlier in development, caused by reduced expression of Myb in CMPs(104).

A myeloid lineage specific KO model of Rictor (LysM-cre) revealed a significant decrease in monocytes, while the neutrophil population was unaffected. BM monocytes and peritoneal macrophages displayed decreased proliferation and increased susceptibility to pro-apoptotic stimuli. Furthermore, stimulation of TLR4 on Rictor⁻/⁻ macrophages with lipopolysaccharide (LPS) potentiated a pro-inflammatory response, with cells skewing towards an M1 phenotype and downregulating IL10 expression, suggesting that mTORC2 signalling is a negative regulator of TLR signalling in macrophages(105,106). Interestingly, the inflammatory response observed in Rictor⁻/⁻ cells was reversed by the inactivation of Raptor, indicating that mTORC1 regulates inflammatory responses in macrophages(105).

1.5.6 mTORC1 and mTORC2 signalling in B cells

The importance of mTOR signalling during B cell development is evident from a study analysing mice in which mTOR expression is reduced. Reduced expression was achieved by the neomycin insertion at exon 12 of mTOR thereby creating a mTOR-knock-in (KI) model partially disrupting mTOR transcription(107).
reduction in progenitors B cells was observed in these mTOR-KI mice, with a
block between large preB cells (B220+CD24+CD43-) and small preB cells
(B220+CD24+CD43+). Within the spleen, an increased number of mature B cells
(B220+IgD\text{high}CD21+IgM-) and decreased T1 and T2 transitional B cells were
observed compared to wildtype (WT) mice(107). Deletion of the TSC1 complex in
B cells (CD19-cre) renders mTOR constitutively active, resulting in a partial block
in B cell maturation as indicated by an elevation in T1 and T2 transitional B
cells, and a depletion of MZ B cells(108).

Assessing mTORC1 signals more directly, Raptor cKO mice exhibit a significant
decrease in B cell generation, due to an early block in lineage
commitment(100,109). For this reason, the effect of Raptor ablation on B cells
was analysed using B cell specific models (Mb1-Cre), which resulted in a
profound block at the preB cell stage abrogating B cell maturation, proliferation,
GC reaction and antibody production(109). Additionally, a cKO of Raptor
specifically in B cells (hCD20-Tam-Cre) resulted in a decrease in GC B cells and
nascent antibody secreting plasma cells, and the elimination of GCs resulting in
a decline in serum-antibodies(110). These studies illustrate the importance of
mTORC1 at multiple stages of B cell maturation, and highlights the critical role
played by mTOR in mounting an appropriate humoral immune response.

Rictor KO models revealed a role for mTORC2 during B cell maturation, resulting
in a decrease in mature B cells(111). Studies demonstrate an increase in early B
cell populations including the proB, preB and immature B cells in Rictor cKO
mice, characterised by elevated FOXO1 and RAG1 expression and a subsequent
reduction in mature splenic B cells(92). However, HSCs isolated from Sin1\text{-/-} mice
reconstituted haemopoietic lineages suggesting a minimal role for mTORC2 in B
cell development during early stages. However, these mice exhibited increased
IL7 production and RAG1/2 expression at the proB stage and fewer IgM+ immatue B cells suggesting a role for mTORC2 after B lineage
commitment(112). mTORC2 has also been shown to play an important role in B
cell survival, as Rictor-null mice display increased caspase-3 and PARP
expression, together with increased cell death and a decrease in B-cell
activating factor (BAFF) expression in mature B cells(111). Lee et al., proposed
that mTORC2 regulates canonical and non-canonical nuclear factor kappa B
(NFkB) signalling pathways responsible for mature B cell maintenance and
survival(111). Interestingly, *Rictor*-null mice possess increased CIP2A binding to protein serine/threonine phosphatase A (PP2A) leading to increased c-myelocytomatosis viral oncogene (C-MYC) phosphorylation and expression, and decreased E2F1 expression, which leads to apoptosis(113).

1.5.7 mTORC1 and mTORC2 signalling in T cells

T cells develop in the thymus, undergoing rigorous positive and negative selection processes at the CD4+CD8+ double positive (DP) stage of development, to generate a pool of T cells that recognise foreign peptides in the context of self-major histocompatibility complex 1 (MHC-I) (CD8+ cytotoxic T cells) or MHC-II (CD4+ helper T cells). Analysis of mTORC1 signalling inhibition during T cell development showed that rapamycin treatment and *Raptor*-deletion in cKO mice resulted in reduced thymic cellularity and a decrease in the proportion of DP cells, coupled with a concomitant increase in CD4+CD8+ double negative (DN) cells(114). Within the DN population, rapamycin blocked T cell development at the DN3 stage, likely prior to the proliferative burst associated with β-selection, while development was arrested at the DN1-DN2 transition in *Raptor*-null mice both *in vitro* and *in vivo*. This block was associated with a reduction in proliferation due to an instability of cyclinD/cyclin-dependent kinase 6 (CDK6) complexes. Similar results were noted with an *Mtor* cKO mouse model, while *Rictor* cKO mice exhibited a block in proliferation at the DN3 stage of development (115,116), suggesting that mTORC1 plays a critical role, which is distinct from mTORC2, during the early stages of T cell development.

The thymic microenvironment plays a critical role in enabling the appropriate development of nascent T cells, particularly thymic epithelial cells (TECs). Selective *Rictor* cKO in TECs results in a reduction in thymic mass and cellularity of TECs, and decreased generation of specific T cell lineages: T-cell receptor αβ (TCRαβ), TCRγδ, invariant NK-T(117) and regulatory T cells thereby revealing an important role of mTORC2 in thymopoiesis and T cell lineage generation(118).

In the periphery, reduced mTOR expression/activity decreased T cell numbers, T cell activation and proliferation(107). Furthermore, TSC1 ablation drove naïve T cells from quiescence to a poor immune response, altering the cell size and cycling(119). mTORC1 activation, through TSC2 deletion, led to increased,
terminally-differentiated effector CD8+ T cell formation not capable of conforming to a memory T cell phenotype. However, mice deficient in mTORC1 activity, through deletion of RHEB, led to loss of effector CD8+ T cell formation with no change in memory T cell expression, suggesting a role of mTORC1 in the differentiation of specific T cell subsets (120). Indeed, mTORC1 is involved in Th1 and Th17 differentiation from naive CD4+ T cells, as deletion of RHEB blocks Th1 and Th17 differentiation, but not Th2 differentiation in vivo and in vitro (121). Moreover, mTORC1-mediated signalling plays a critical role in CD4+ T cell proliferation, by enhancing PPARγ activity, which in turn activates fatty acid metabolism, thus enabling the metabolic reprogramming required to activate CD4+ T cells (122).

mTORC2 controls CD8+ T cell differentiation in a FOXO1-dependent manner as ablation of mTORC2 led to an increase in memory precursor effector cells (MPEC) and not in the short lived effector cells (SLEC) driven due to Eomes and Tcf-1 upregulation caused by FOXO1 (120, 125). Recently, Velde and Murray demonstrated that mTORC2 plays an important role in microenvironment sensing in CD4+ T cells. In a normal setting, CD4+ T cells require essential and non-essential amino acids (AAs) to undergo cell division. Limiting arginine and leucine resulted in cell cycle disruption, which could be bypassed in the absence of Rictor. This resulted in cells initiating cell cycle regardless of limiting AA, thus bypassing micro-environmental sensing (126).

1.5.8 mTOR signalling in leukaemogenesis

The PI3K/AKT/mTOR pathway plays a major role in the haematopoiesis as constitutive activation of the mTOR pathway led to impairment of HSC function. Additionally, deletion of mTORC1 leads to pancytopenia and is vital for HSC regeneration. The AKT/mTOR axis has shown to play a role in leukaemogenesis as in a mouse model of leukaemia evoked by Pten-loss, mTORC1 deletion resulted in a significant increase in survival (91). mTOR signalling is not only
involved in leukaemia, but lymphoma too. For instance, mantle cell lymphoma (MCL) has activated BCR signalling with increased activation of Src family kinases (SFKs) including Lyn. Consequently, treatment of MCL murine models with dasatinib (SFK inhibitor) leads to reduction in tumour size(127). Recent research shows that this pathway is upregulated in CLL patients from distinct cohorts and this can also be seen in CLL murine models. Inhibition of this pathway with AZD8055 (dual mTORC1/2 inhibitor) led to a greater level of apoptosis when compared to rapamycin in primary CLL patient samples(128).

Rapamycin, along with its analogues, ‘rapalogs’ have shown promise in targeting CLL. Rapamycin has shown to induce cell cycle arrest by modulating the mTOR/S6K pathway and abrogating cyclin E, cyclin D3 and cyclin A expression. Additionally, survivin a protein upregulated in CLL along with other cancers, is associated with disease survival. Survivin has also become a therapeutic target for many cancers. Rapamycin has shown the potent inhibition of this protein suggesting a potent role in CLL abrogation(129). Moreover, due to the known role of the microenvironment in CLL maintenance, rapamycin could play a potent role in abrogating microenvironmental signals. Rapamycin was first identified as an immunosuppressant of T cell mediated signals including IL2 and IL4 signalling(130). These signalling pathways are upregulated in CLL and have shown to mediate CLL survival highlighting the importance of rapalogs in CLL maintenance. Indeed, Decker et al. have demonstrated a block in proliferating CLL cells with rapamycin treatment. Rapamycin treatment led to a decrease in cyclin D3 and a decrease in CDK2 via the suppression of cyclinE and cyclinA leading to cell cycle arrest. Although rapamycin did not induce apoptosis, impairment of cell cycle regulating proteins blocked proliferation of CLL cells(131).

FOXO1 is the main isotype observed in CLL patients responsible for cell cycle arrest. AKT activation phosphorylates FOXO1 to inactivate it thus halting its translocation into the nucleus. However, AZD8055 (but not rapamycin) treatment led to an increased translocation of FOXO1 into the nucleus thus inducing apoptosis in cells. Cosimo et al., have recently shown that microenvironment signals enable constitutive activation of PI3K/AKT/mTOR signalling in chronic lymphocytic leukaemia cells, which inactivates FOXO1. This may assist in disease progression. Moreover, dual mTOR complex inhibitors
AZD8055/2014 enable a reduction in disease progression and an activation of FOXO transcriptional program which was enhanced by combination with ibrutinib (128).

### 1.6 Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world, which exhibits a monoclonal expansion of B cells. CLL-B cells are characterised by CD19^+CD23^+CD5^+IgM^+IgD^{lo} surface expression, a phenotype of mature B cells (132). It is known to mainly affect the elderly, displaying a median age of 70 years and is 1.5 times as prevalent in males as in females, with about 3,200 patients diagnosed with CLL in the UK in 2011 (133). Current diagnosis of the disease is based upon the morphology of lymphocytes, >5X10^9 circulating B cells for more than 3 months, and a characteristic immunophenotype (134). This scoring system is the CLL scoring system based on the immunophenotypic characteristics. Immunophenotype of CLL patients are mostly positive for CD5, with dim expression for CD20, along with dim or no expression of surface Ig, CD79b, CD22, MFC7. CD38 has shown to be overexpressed in some cases along with increased 70 kDa zeta associated protein (ZAP-70) which are correlated with patients having a poorer prognosis with unmutated IgV_H gene. For instance patients are scored depending on the immunophenotype the present, if the scoring reaches or exceeds 3, they present true CLL (135). Typically, the Rai and Binet staging system is used for assessing the prognosis of the disease. Rai staging is mostly used in the USA and the system is divided into 5 stages where lymphadenopathy, lymphocytosis and anaemia are taken into account. Binet staging system is mostly followed in the UK and Europe and is divided into three stages, A-C, which is dependent upon the levels of anaemia and white blood cell count (136). Regardless of the staging system, patients with a more advanced disease have a median survival of 1-2 yr as opposed to patients with a more benign disease with a median survival of more than 10 yr (137, 138). Despite extensive research on CLL in the past decade, it remains incurable with standard therapy, demonstrating the need to develop novel strategies for CLL therapeutic research.
1.6.1 Mutational status and prognosis

The differential clinical behaviour of the disease has been associated with the somatic mutational status of the IgV\(H\) regions of the BCR. It has been shown that patients with CLL cells carrying unmutated IgV\(H\) regions display a poorer prognosis with a diminished survival time (median survival time of ~8 yrs) as compared to those patients with somatic IgV\(H\) mutations with a median survival time of ~24 yrs (139). Patients with poorer prognosis have also been shown to express upregulated levels of CD38 (140) and ZAP-70 and activate key signal transduction pathways more readily in response to BCR signalling(141).

While chromosomal abnormalities are not required for the development of CLL, 80 percent of patients with CLL have chromosomal deletions/gene mutations at diagnosis. With the progression of the disease, the cells can acquire increasing deletions showing a poorer prognosis of the disease. The most common chromosomal deletion, occurring in about 55% of cases, is the 13q band deletion which displays a benign phenotype. This region (13q14) encodes for the \(miR16-1\) and \(miR15a\) which have shown to play a role in leukemogenesis and the \(miRs\) regulate BCL proteins. However, patients with deletions in the 11q chromosomal band (in 10% patients with early stage and 25% with advanced disease stage) have a more aggressive phenotype with rapid progression and reduced survival. The 11q23 region harbours the \(ATM\) gene, which encodes a DNA damage response kinase, the lack of which leads to a progression of the disease. Another chromosomal deletion (found in about 5-7% patients) is deletion in the 17p band which deletes the \(TP53\) tumour suppressor gene and displays the most aggressive form of the disease(142). Of note, in patients carrying a 17p deletion, the accompanying allele has a mutated copy of \(TP53\) in 60% of cases, therefore rendering the CLL cells with no functional p53. This makes p53 mutated CLL cells highly chemorefractory.

1.6.2 Role of microenvironment

Although, CLL was initially classified as a disease of accumulation of B-lymphocytes(143), since the identification of CLL as a dynamic(144), and not a static disease, cross-talk between the microenvironment and malignant B cells have shown to further cause clonal expansion of the disease. CLL cells have been
shown to migrate to lymphoid organs and proliferate in centres through signals further enhanced by the microenvironment. CD4+CD40L+ T cells have shown to interact with CD40 receptors on malignant cells in the proliferation centres to increase survival by increasing expression of anti-apoptotic proteins BCLxL and MCL-1. CD40+ stimulated CLL cells were resistant to drug induced apoptosis(145) suggesting that the microenvironment interactions enhances disease progression. Furthermore, activated BCR signalling in CLL is responsible for upregulating MCL-1 via PI3K/AKT signalling(146).

T cells are known to play a critical role in CLL progression. CLL is associated with an increase in CD8+ and CD4+ T cells along with their exhaustion linked with an increase in programmed death 1 (PD-1) expression(147). CLL cells have an increased expression of PDL1/PD1 with increased CD40 stimulation(148) PD/ suggesting a potential role of PD-1/PDL1 in CLL therapy. Indeed, PDL1 inhibitors are in clinical trials for other Hodgkin and non-Hodgkin lymphomas(149,150) showing promising results which could also prove to be effective in CLL. Additionally levels of CCL3 and CCL4 have also shown to be upregulated in CLL(151), behaving as chemoattractants for monocyte derived nurse-like cells (NLCs), enhancing CLL survival and homing in secondary lymphoid organs. In CLL, these chemokines may help to enhance microenvironment to induce anti-apoptotic signals thereby further protecting the disease. CCL3 has also been associated with a poor prognosis of CLL.

BM stromal cells (BMSCs) have also shown to protect CLL cells due to an increase in anti-apoptotic signals (152) with increasing CLL cell affinity towards BMSCs. Increased migration towards stromal cell-derived factor 1 (SDF-1)/ CXCL12 (released by BMSCs) is due to the increased expression of CXCR4 (153). In normal B cells, CXCR5 is responsible for the homing of B cells into the GCs of secondary lymphoid organs via the affinity of CXCL13 released by NLCs in these organs. In leukaemic B cells, there is an increase in CXCR5 expression, leading to increased homing towards CXCL13 leading to changes in actin polymerisation and chemotaxis(154). NLC released BAFF and a proliferation-inducing ligand (APRIL) have also shown to bind to their receptors on malignant B cells and protect the disease in a NFκB dependent manner(155).
Calissano et al., have shown heterogeneity within a CLL disease where there exist two subpopulations with varying phenotypes. One population comprises a CD5\textsuperscript{dim}CXCR4\textsuperscript{hi} resting-cell like population whereas the second subtype has a CD5\textsuperscript{hi}CXCR4\textsuperscript{dim} phenotype with a proliferative characteristic with increased Ki67 suggesting increased cell cycling and an increase in anti-apoptotic genes\textsuperscript{(156)}.

This is termed the Calissano model which highlights the spectrum of CLL cells within the same disease. Interestingly, ibrutinib and idelalisib have been shown to target the CXCR4-SDF-1 axis and potentially disrupt the `resting CLL cells’ leading to an increase of these cells from the lymphoid organs into the peripheral circulation (lymphocytosis) post ibrutinib treatment\textsuperscript{(157,158)}. These findings suggest a targeting of a CLL subset with current drugs in clinics.

### 1.6.3 Current therapy

Current therapy has evolved drastically over the past few years and has become increasingly heterogeneous depending on the aggressiveness of the disease and the fitness level of the patients. How ‘fit’ a patient is depends on other diseases and co-morbidities such as cardiac issues, etc. Some clinical trials use the Co-morbidity illness Rating scale (CIRS) to assess fitness objectively. According to current guidelines, all CLL patients are tested for both TP53 mutations and deletions as recent research has shown that attenuated TP53 affects therapy\textsuperscript{(159)}. This brings in into question the use of the scoring system altogether in an age of molecular testing. Currently, the use of the scoring system is reassuring with the novelty of molecular testing, in the future, perhaps the scoring system will be redundant.

First line therapy differs between patients depending on patient fitness and TP53 mutations. How ‘fit’ they are which alludes to other diseases and co-morbidities such as cardiac issues, etc. In the pivotal CLL8 study, Hallek et al., demonstrated that the addition of Rituximab (R) (anti-CD20 antibody that specifically targets B cells) to the backbone of chemoimmunotherapy comprising cyclophosphamide (C) which is an alkylating agent interfering with DNA synthesis, and fludarabine (F) which is a purine analogue interfering with DNA synthesis improved the progression-free survival (PFS) and overall survival (OS) of fit CLL patients without TP53 alterations\textsuperscript{(134,160)}. Therefore, FCR is approved for first line therapy for fit CLL patients without TP53 alterations and
is approved by the National Institute for Health and Care Excellence (NICE). Indeed, the mechanism of action of FC drugs require p53 activity, therefore patients with 17p deletions or TP53 mutations require different treatments(161).

Less fit patients, two major clinical trials CLL11 by the German CLL study Group and COMPLEMENT-1 led to the introduction of chlorambucil in combination with Obinutuzumab or Ofatumumab for less fit CLL patientsa and are NICE approved. CLL11 demonstrated superiority of chlorambucil-obinutuzumab over chloambucil-R or chlorambucil alone (162). COMPLEMENT-1 study demonstrated superiority of chlorambucil-ofatumumab over chlorambucil alone(163). Moreover, ibrutinib is licensed for front-line use in CLL patients without TP53 aberrations as patient showed increased OS with ibrutinib over chlorambucil alone in the RESONATE-2 trial but has not received approval from NICE as of now(164).

Recent therapeutic strategies for CLL patients with TP53 aberrations have focused on inhibiting signalling and survival pathways which are important in CLL initiation and development. Indeed, BCR signalling plays a central role in the survival of CLL, and in the prognostic outcome of patients, therefore making this signalling pathway an attractive therapeutic target(165). Furthermore, recent findings demonstrating that autonomous BCR signalling is evident independent of cell-antigen interactions makes this pathway an important therapeutic target(166). Two major drugs, ibrutinib and idelalisib, which have been introduced in clinics are inhibitors of the downstream kinases, Bruton’s tyrosine kinase (BTK) and PI3Kδ respectively of the BCR signalling pathway.

PI3Kδ expression is limited to leukocytes where it plays a role in B cell development(167) and in T-regulatory (T-reg) cell function(168). The constitutive activation of the BCR in CLL makes PI3Kδ an ideal therapeutic target. Indeed, Hoellenriegel et al., have demonstrated an aberration in CLL migration and homing (via CXCL12 and CXCL13 impairment) with idelalisib treatment(169). Although idelalisib had been approved in by NICE for its efficacy and safety profile for patients with TP53 abberations, major side effects of this drug included fatal or severe diarrhoea, colitis and hepatotoxicity(170). Similar side effects were observed in PI3K-deficient mouse model developed by Okkenhaug et al., where the mice developed inflammatory bowel disease together with impaired B and T cell function(171). These results highlight the
need to identify novel therapeutic targets for CLL. This drug was reviewed and has been set as first line therapy with rituximab for CLL patients with TP53 aberrations which are not for for alternative therapy(172). Although BTK was not found to be constitutively active, BTK protein levels were upregulated with increased BCR activity suggesting increased downstream PI3K/mTOR activity in mediating survival signals in CLL(173). Ibrutinib, an irreversible inhibitor of BTK, has shown promise in murine models of CLL, as ibrutinib treatment of Eµ-TCL1 mice (CLL mouse model) leads to a significant increase in survival via a delay in disease development by promoting apoptosis(174). Ibrutinib is now increasingly being prescribed as to patients with poor prognosis and is NICE approved for patients with TP53 aberrations after the RESONATE-17 clinical trial(175).

Nonetheless, side effects such as atrial fibrillation and haemorrhage can lead to discontinuation of treatment in some patients with resistant mutations due to clonal evolution(176) indicating the need for novel agents/therapeutic targets. Recently, ABT-199 (venetoclax), a BH3 mimetic has also entered clinical trials and shown promise in patients with 17p deletions(177).

Currently, ibrutinib synergy with venetoclax, a BH3 mimetic is being tested for alternative therapy for CLL in the CLARITY clinical trial(178). Recently, ARQ-531, a reversible and less potent target of BTK is was assessed for its efficiency in targeting CLL. Despite partial inhibition of BTK, ARQ-531 targeted SFK kinases and ERK signalling thereby targeting multiple pathways involved in CLL. Indeed, ARQ-531 treatment of Eµ-TCL1 mice resulted in increased survival compared to ibrutinib treated mice suggesting global inhibition of signalling pathways leads to more robust results(179).

The BCL family, including anti-apoptotic proteins BCL-2, MCL-1, and the counterbalancing pro-apoptotic proteins (eg. BID, BAX), contain BH3 domains in their structure. BH3 mimetics such as venetoclax that inhibit the function of BCL-2, has recently been approved as second line therapy for relapsed patients treated with ibrutinib(180). BCR inhibitors and BH3 mimetics improve outcome in patients with a more aggressive disease and improve disease conditions in poor prognostic patients, particularly in patients with 17p deletions(181). However, resistance mutations are already evident in patients treated with venetoclax due recurrent Gly101Val mutations(182), suggesting the need for additional therapeutic targets or combination therapies.
Haematopoietic stem cell transplantation (HSCT) is another CLL therapy procedure. However, it can only be considered for the younger/fitter patients with an aggressive form of the disease as the older populations with the disease cannot undergo such harsh treatments. It is known to decrease treatment-related mortality but has known to have relapses (183). However, more emphasis has been put on the reduced intensity conditioning (RIC) HSCT which can also be given to the elderly population (184). RIC-HSCT has led to a decreased relapse mortality rate by 16-23% and seems to be a powerful therapeutic regime (183). According to NICE recommendations, transplants are only recommended to patients who have failed chemoimmunotherapy and therapy using BCR inhibitors.

Chimeric antigen receptor-T (CAR-T) cells have recently shown promising results in treating various Hodgkin and non-Hodgkin lymphomas. CAR-T cell therapy involves the re-engineering of self T cells to recognise specific tumour associated antigens including targets such as CD19, CD20 (185). Recently, a small cohort of patients (18 patients) with relapsed CLL who had been treated with ibrutinib, were treated with CD19 CAR-T cells. Results were very promising which showed high CAR-T CD4:CD8 ratio with complete responses in patients. However, this treatment was only introduced to the clinic in 2016 and thus is in an early phase and needs to be monitored for a longer duration (186).

1.7 Mouse models commonly used in haemopoiesis

1.7.1 Cre-loxP KO system

Naturally present in bacteriophage P1, the cre-loxP system is extracted from this virus and is now widely used in murine studies and in other mammals for genome editing/omitting. Cre (causes recombination) recombinase (cre) re-combines two loxP (locus of crossover in P1) sites in the genome, the gene is then considered to be ‘floxed’, leading to genome editing depending on loxP orientation.

Embryonic stem (ES) cells are conventionally used to incorporate cre gene. P1 encodes Cre, which is a 38 kDa enzyme and it recognises DNA-base pair (bp) repeats and recombines them by covalent-linking of protein between the two DNA-repeat sites. The expression of cre is usually controlled by a specific
promoter, thereby ensuring a controlled expression. It also allows cre expression in specific tissues, depending on the promoter of choice. Cre can be expressed in the coding sequence of the promoter thereby silencing the gene itself, or it could be present at the flanking end. Cre construct is cloned into ES cells via conventional methods and is subsequently microinjected into the pronucleus of mouse embryos, which can then be injected into mouse oviduct(187).

LoxP are 34-bp long DNA of which there is an 8 bp long core with 13-bp long palindromic DNA repeats at either side. These sites are inserted around a gene of choice, usually target gene of excision. The sites of insertion of these genes are important: loxP sites should not be inserted at important coding regions, thereby ensuring proper functioning of the gene in the absence of cre(187).

There can be various functions of this system. One of the most straightforward uses is gene deletion. Here the gene of interest will be floxed and cre-expression will be regulated by a promoter of choice. This can be done both in vivo and in vitro. Mice harbouring either loxP sites or cre are bred together to obtain either WT mice, mice containing only loxP or cre sites or both, which is the desired model(187). Subtle modifications have also been made within the genome by the insertion of point mutations utilising the cre-loxP system. This is done by the addition of a vector which harbours the mutation along with the flanked loxP site around the target gene. Therefore, when cre expression is induced, insertion occurs of the point mutation and loxP sites remain. Gene/exon replacement is also possible using this model whereby a replacement vector is added to one loxP site, where both loxP sites are flanked around the gene/exon to be replaced. Cre expression excises the original gene/exon leaving the loxP sites together with the replaced vector. Similarly, chromosomal translocations, insertions, inversions and conditional deletion of genes have successfully been demonstrated using the cre/loxP system(188). There are a variety of cre-loxP systems which have been used to assess the role of mTORC1 (via exision of Raptor) and mTORC2 (via exision of Rictor) in haemopoiesis. The most commonly systems used for haemopoietic cells and B cells are summarised in Table 1.1 below:
<table>
<thead>
<tr>
<th>Promoter</th>
<th>Stage</th>
<th>fl/fl</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROSA26-Cre</td>
<td>All cells except brain cells</td>
<td>Raptor/Rictor</td>
<td>(111,114)</td>
</tr>
<tr>
<td>MX1-Cre</td>
<td>All cells except skeletal muscle</td>
<td>Raptor/Rictor</td>
<td>(93,104)</td>
</tr>
<tr>
<td>VAV-Cre</td>
<td>All haemopoietic, embryonic, germ cells</td>
<td>Raptor/Rictor</td>
<td>(93,97)</td>
</tr>
<tr>
<td>CD2-Cre</td>
<td>Common Lymphoid progenitors (CLPs)</td>
<td>Raptor/Rictor</td>
<td>(189)</td>
</tr>
<tr>
<td>MB1-Cre</td>
<td>Pre-proB cell stage</td>
<td>Raptor</td>
<td>(109)</td>
</tr>
<tr>
<td>CD19-Cre</td>
<td>Mature B cells</td>
<td>mTOR, TSC1</td>
<td>(190)</td>
</tr>
<tr>
<td>CD20-Cre</td>
<td>Mature B cells, more specific than CD19</td>
<td>Raptor</td>
<td>(110)</td>
</tr>
<tr>
<td>Aicda-Cre</td>
<td>GC B cell development</td>
<td>Raptor</td>
<td>(191)</td>
</tr>
</tbody>
</table>

Table 1.1 Summary of various promoters used in the cre-loxP system to excise mTORC1 (Raptor) or mTORC2 (Rictor) in haemopoietic cells and in B lymphocytes.

In this thesis, three different promoters have been used which control expression of cre at different stages of development thereby excising mTORC1 (Raptor) or mTORC2 (Rictor) at different stages. These are explained and summarised in Table 1.2 below:
<table>
<thead>
<tr>
<th>Promoter</th>
<th>Cre expression</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vav</strong></td>
<td>In all haemopoietic cells. Also expressed in embryonic stem cells and germ cells (192).</td>
</tr>
<tr>
<td><strong>Mx1</strong></td>
<td>Expressed ubiquitously in all tissues. Minimal expression in the skeletal muscle.</td>
</tr>
<tr>
<td><strong>CD19</strong></td>
<td>Only expressed in mature B cells.</td>
</tr>
</tbody>
</table>

Table 1.2 Summary of promoters used to control cre expression. Table also describes all the organs/cells the cre transgenes will be active.

1.7.1.1 Vav-cre model

*Vav1* gene has previously shown to be expressed in all haemopoietic organs whereas *Vav2* and *Vav3* have a broader gene expression pattern(193). Besides haemopoietic organs, its expression is restricted to developing teeth, ES cells, testicular germ cells (192). The ubiquitous expression of *Vav1* in haemopoietic lineages occurs regardless of their developmental stage. Nevertheless, *Vav* expression is not fundamental for haemopoietic development as *Vav*-null mice still had functional B and T cells but had an aberration in proliferative capacity suggesting a redundant role of *Vav* in haemopoiesis (194). Additionally, *Vav* has shown to play a role in cytoskeletal organisation and proliferation, and has shown to activate the Rac/Jun signalling pathway (195). *Vav* expression also had sporadic reductions at later haematopoietic lineages suggesting a potent expression at developmental stages (192).

*Vav* mediated cre expression has shown to be a very effective method of mutagenesis using the cre-loxP system with a complete KO of floxed gene (196). However, there have been off-target homologous recombination in endothelial cells observed in some laboratories whilst not in others (197). Additionally, there have been rare off-target excisions in BM cells lacking haemopoietic markers suggesting excisions in stromal cells with *Vav*-mediated cre expression (198).
Nonetheless, the high efficiency of this model is well recognised, and it is widely used.

1.7.1.2 Mx1-cre model

MX1 is expressed in most organs (besides skeletal muscle), including all haemopoietic organs(199), and is widely expressed from very early stages of development. It is involved in innate immunity, activated post viral infections, with expression of MX1 being effective against influenza virus(200). It is activated by STAT-1 activation of TLR3 receptors(201). TLR3 activation has been associated with response to virus infiltration within the body. In research, polyinosinic-polycytidylic acid (poly(I:C)) mimics the double stranded RNA structure of some viruses, and activates the TLR3 thereby activating Mx1 expression(202).

Mx1 is widely used in the cre-loxP system to induce a cKO (via poly(I:C) inoculation) thereby controlling time of KO induction which is a beneficial tool in research. Although this model has been shown to induce almost a complete KO in lymphocytes after a few days with complete KO in other haemopoietic lineages, there remain some limitations in using this model. One very important limitation is the spontaneous recombination caused in the Mx1-cre model prior to the inoculation of poly(I:C). This spontaneous recombination has previously been demonstrated to occur due to the constitutive activation of internal tandem duplications of FLT3 (FLT3-ITD) in acute myeloid leukaemia (AML) in mice. This increased the observed recombination prior to poly(I:C) inoculation from 2-3% to 30-50%(203). Therefore, it is very important to have appropriate controls when using this model to determine affects of spontaneous recombination. Another limitation is the phenotype of HSPCs, which is perturbed for a short time following poly(I:C) inoculation in mice. Following poly(I:C) inoculation, there is a transient change in the expression of HSPCs where there is an increase in Sca1+ populations for a short duration (D8), which could disrupt the ‘normal’ HSPC phenotype in short-term studies(204). It is important to consider this if the timepoint of the experiment comprising this model is very short, as it might alter the results.
1.7.1.3 CD19-cre model

CD19 is a surface expressed at the proB cells stage and usually referred to as a marker for mature B cells which is responsible intrinsic signalling mediated via BCR signalling. CD19 is responsible for the Ig-mediated activation of B cells and downstream activation of PI3K and AKT signalling which modulate proliferation and expansion of B cells(205).

CD19-mediated cre excision has also been used in the cre-loxP system. In mice, this system has shown to have a good excision in the spleen (90-95% excision), however a lower deletion efficiency in the BM: 75-80%(206). The Mb1-cre (expressed at the pre-proB cell stage) is the pan-B cell specific KO model for the cre-loxP system with a higher deletion efficiency(41).

1.7.2 Limitations of the cre/loxp system

Although the cre/loxp system is used widely in research, there remain some limitations to this system which should be considered whilst designing the experiments depending on the nature experiment.

The cre/loxp system has shown to have off-target cre-mediated excisions in mammals making the model ‘leaky’. There exist pseudo-loxp sites in human and murine genome leading to various off target excisions(207). Therefore, it is important to determine the level of non-specific excisions ensuring that the off-target excisions (if any) do not hinder or significantly alter the results. Additionally, off-target excisions could occur in cre induced expression in germ-line due to the presence of many lineages in embryogenesis(208).

Cre toxicity is another limitation of the system. Increased cre expression has been associated with tissue/cell specific cre mediated toxicity. Research has shown that increased cre expression is associated with decreased proliferation and chromosomal aberrations in certain cell types(209). Additionally Li et al., have shown complete tumour regression due to cre expression suggesting cell toxicity due to expression of cre(210). Conversely, it has been shown that cre excision of target floxed genes may not be completely efficient. This is usually due to cre-loxP models with induced expression of cre. As such, the method of cre induction could affect cre expression and therefore the deletion-efficiency.
For instance, tamoxifen induced inefficient cre-expression could depend on the frequency and volume of the inoculation of tamoxifen (211).

### 1.7.3 NSG/NRG mouse models

Several lymphoid mouse models have been generated for transplantation of cancer cells or human haemopoietic cells into mice in *in vivo* studies, with efficient models being NOD-SCID-IL2Rγ−/− (NSG) and NOD-Rag−/−IL2Rγ−/− (NRG) mouse models.

In 1983, the severe combined immunodeficiency (SCID) mouse model was defined wherein the autosomal recessive mutation of the *Prkcd* gene led to impaired rearrangement of the BCR and the TCR resulting in impaired B and T cell signalling. This is because the *Prkdc* gene encodes a DNA-dependent protein kinase catalytic subunit which is vital for VDJ recombination in developing B and T cells. In fact, there was almost a complete loss of B and T cells with impaired lymph node (LN) development (212). Although the SCID model is efficient at engrafting xenografts, the generation of a mouse model where the ‘eat me not’ signal was constitutively active, led to the efficient binding of signal regulatory protein alpha (SIRPα), ubiquitously expressed, with the human CD47L leading to the inhibition of phagocytosis by macrophages (213). These mouse models were termed non-obese-diabetic (NOD) mice. Backcrossing this strain with SCID mice led to a more effective and efficient xenograft model than SCID mice alone (214). Although these mice lacked functional B and T cells, NK cells were still present in the mouse models. The depletion of NK cells proved to enhance human CD34+ HSC engraftment in NOD-SCID mice without compromising the ability of HSC cells to differentiate into haemopoietic lineages (215).

Consequently, deletion of interleukin 2 receptor common chain gamma (IL2Rγ−/−) led to impaired IL2, IL4, IL7, IL9 and IL15 signalling (216) which are vital for T and NK cell development leading to a drastic decrease in NK cells. This model was incorporated into the NOD-SCID model as the NOD-SCID-IL2Rγ−/− model (NSG) model and has shown to be more effective at xenotransplant engraftment compared to NOD-SCID model alone (217).

Another model that has been shown to have a similar engraftment efficiency as NSG mice is the NOD-Rag−/−IL2Rγ−/− (NRG) mouse. This model is similar to that of
the NSG mouse model. Nevertheless, NRG mice have a deficiency of Rag1 or Rag2 genes as opposed to the Prkcd gene in NSG mice. Recombination-activating genes (Rag), as the name suggests are responsible for the initiation of Ig recombination in B and T cells. Rag1/2-null mice also have aberrations/deletions in IL2Rγ chain(218) leading to a similar phenotype leading to concomitant decline in B and T cells altogether. Human HSC engraftment in NSG and NRG mice are equivalent(218).

1.8 Mouse models in CLL

1.8.1 TCL1 mouse model

T-cell leukaemia 1 (TCL1) was first identified in T-prolymphocytic leukaemia (T-PLL) as it was overexpressed in almost all cases. TCL1 has shown to affect B and T cell differentiation and Tcl1-KO mice have slight effects on B and T cell differentiation. It plays a more potent role in modulating embryonic development, stem cell differentiation and hair follicle generation(219). It has been shown to interact with AKT1/2 downstream of the PI3K signalling pathway and modulate cell proliferation and survival via interactions with DNA methyltransferases (DNMTs), NFκB inhibitor α (NFκBα) and receptor tyrosine kinase-like orphan receptor-1 (ROR1)(219).

Tcl1-overexpression (OE) studies showed roles of TCL1 in development and a slight role in leukocytes. Tcl1-KI led to the development of T and B cell leukaemia in mice depending on the promoter of choice. Lck promoter led to the development of T-PLL in mice(220) whereas Tcl1-tg OE under the VH-promoter IgH-Eμ-enhancer led to the generation of a CLL mouse model(221) (Eμ-TCL1 CLL mouse model) which is the most commonly used CLL-mouse model in research.

It has been shown that this mouse model represents a poor prognostic model of CLL. Disease development is associated with increased surface expression of CD23+IgM+CD19+ together with increased levels of ZAP-70. There was also an increase in unmutated IgVH status with increased BCR signalling. Nevertheless, aggressive disease development has shown to take considerable time as disease proliferation becomes visible in the peritoneal cavity at 2 months with visible disease homing ~4 and ~6 months in the spleen and BM respectively. Monoclonal
expansion was evident at ~8 months and was detectable in the blood after 13-18 months alluding to an aggressive disease(222).

Leukemic survival is caused by the interactions in the microenvironment which involves BCR signalling along with other co-interactions between cytokines and CD40L-CD40 signalling(223). The more aggressive CLL phenotype (unmutated IgVH) is associated with sustained BCR signalling which leads to the survival and proliferation of B cells. Recently Hayakawa et al., showed that early B1 B cells taken from an Eμ-T cell leukaemia 1 (Eμ-TCL1; CLL mouse model), develop into CLL with an upregulation in C-MYC, suggesting that the BCR repertoire within B1 B cells is essential for the generation of CLL(224). Other B cell subpopulations were not able to develop into disease alluding to B1 B cells as the cell of origin in CLL in this mouse model.

1.8.2 PKCαKR model in vivo

Protein kinase C (PKC) proteins are serine/threonine kinases which are involved in functions including proliferation, apoptosis, cell differentiation(75). There exist Ca2+-dependent isoforms (α,β,γ), Ca2+-independent isoforms (δ,ε,η,θ), and atypical isoforms (ζ,λ)(225). These kinases modulate B cell functions via well-known signalling pathways such as the PI3K/AKT, NFκB signalling pathways(226,227). PKCs have also shown to play a role in CLL as activation of PKCs in CLL cells leads to protection of the disease from apoptosis due to the induction of differentiation(228). Moreover, it has been shown that the retroviral transduction of a kinase-dead PKCα isoform (PKCαKR), and not the PKCδ or PKCζ isoform, lead to the subversion of B cells into CD19+CD23+CD5*IgMlo CLL-like cells which are refractory to apoptosis(229). This suggests that PKCαKR isoform has this specific characteristic responsible for regulating vital processes involved in CLL. These retrovirally transduced PKCαKR HSPCs led to the generation of a poor-prognostic CLL mouse model. This model exhibited an upregulation of ZAP-70, together with an increase in ERK-MAPK-mTOR signalling and PKCBII expression, resembling a more aggressive disease phenotype(230).
1.8.3 PKCαKR model *in vitro*: OP9 co-culture

Nakagawa *et al.*, have previously shown that the retroviral transduction of HSPCs with PKCαKR leads to the generation of a poor prognostic disease *in vivo*. However, this disease can also be maintained by the co-culture on the OP9 cell line. OP9 cell line is derived from stromal cells from the calvaria of *op/op* mice which lack M-CSF. This cell line is capable of supporting mainly B lineage cells with the generation of myeloid and NK cells lineages early in the co-culture, together with the addition of the respective growth factors(231,232). This cell line was used in co-culture with the PKCαKR retrovirally HSPCs to promote a B cell lineage for the generation of a B-CLL-like disease. Cytokines IL7 and Flt3 have previously been demonstrated to play a vital role in B cell lineage commitment(33). Therefore, these cytokines were supplemented to the co-culture to generate a poor prognostic disease.

1.9 Aims of project

Although the mTOR/AKT signalling pathway has shown to be upregulated in CLL, the exact mechanism of this signalling pathway was not known. Additionally, the individual roles of the mTOR complexes have not been fully determined in normal and malignant CLL-like B cells. Therefore, the aim of my PhD was to:

i) delineate the individual roles of mTORC1 and mTORC2 in normal haemopoiesis utilising specific KO mouse models for *Raptor* (mTORC1) and *Rictor* (mTORC2) *in vivo*.

ii) determine the individual roles of mTORC1 and mTORC2 in leukaemogenesis *in vitro* and *in vivo* via the KO mouse models.

iii) utilise mTOR inhibitors in the presence and absence of current drugs in clinic to assess synergy in reducing CLL *in vivo*. 
Chapter 2

Materials and Methods
2 Materials and Methods

Names of companies/suppliers and their address details from where all the reagents were purchased are listed in Table 2.1.

2.1 Mouse models

B6.SJL mice were used as a background for generating the desired KO mouse models using the cre-loxP system. For transplants of the CLL-like disease, NSG and NRG mice were used as host for the disease.

2.1.1 Cre-loxP System

Mice expressing the cre/loxP system with Raptor (Raptor\textsuperscript{fl/fl}) or Rictor (Rictor\textsuperscript{fl/fl}) were obtained from Prof. Michael N. Hall (University of Basel, Switzerland)(233) and maintained at the Beatson Research Unit (BRU; Glasgow, UK). Prof. Tessa L. Holyoake (University of Glasgow, UK) generously provided transgenic mice expressing Mx1-cre and Vav-cre. The CD19-cre transgenic mice were a gift from Dr. Dinis Calado (Francis Crick Institute, London, UK). The Mx1 and Vav-cre mice were maintained at the Beatson Research Unit (BRU) while the CD19-cre mice were housed at the Veterinary Research Facility (VRF). We crossed Mx1-cre\textsuperscript{+/−}, Vav-cre\textsuperscript{+/−} or CD19-cre\textsuperscript{+/−} transgenic mice with Rictor\textsuperscript{fl/fl} or Raptor\textsuperscript{fl/fl} on a background of B6.SJL mice to obtain the desired KO models. The cre-loxP system excises the floxed gene of interest under the expression of cre by homologous recombination. Cre-recombinase expression can be controlled under a promotor to induce a genetic deletion or KO at a specific developmental stage or lineage (Figure 2.1). The Mx1 promoter is activated upon TLR3 activation(234), by inoculating, for example, the cre\textsuperscript{−/−}-Raptor\textsuperscript{fl/fl} mice with 3,4, or 5 doses of 10 mg/kg TLR3 agonist poly(I:C) (GE Healthcare, WI, USA) to induce Raptor cKO in the mouse. Vav expression is activated at an early HSC stage, therefore the Vav-cre model will induce the KO in HSCs at an early stage thus inducing a KO in all haemopoietic lineages(235). Lastly, CD19 is expressed at the proB cell stage of B lineage development. Thus, CD19-cre\textsuperscript{+/−}-Raptor\textsuperscript{fl/fl} (CD19-cre\textsuperscript{+/−} Raptor KO) mice lack Raptor only in B cells(206). Excessive cre expression has been demonstrated to be leaky by causing widespread recombination depending on tissue specificity(208). Furthermore, there exist pseudo-loxP sites
in the mouse genome, and when cre is highly expressed, it could cause toxicity due to off-target deletions (208). Therefore, we focused on mice carrying heterozygous \((\text{cre}^{+/-})\) and not homozygous \((\text{cre}^{-/-})\) mice for phenotyping and experimental models.

For \textit{Vav-cre Raptor} mice, time matings were carried out where \textit{Vav-cre Raptor}\textsuperscript{wt/fl} were mated with \textit{Vav-cre Raptor}\textsuperscript{wt/fl} mice and if/when the female mouse was pregnant, the mouse was sacrificed at E13, E15, or E18. The mouse was dissected to obtain the FL from the litter.

\subsection*{2.1.2 Organ Processing}

\subsubsection*{2.1.2.1 BM processing}

The BM was obtained by either flushing or crushing the bones of the mouse. For BM obtained by flushing, BM was cut on either ends of the femur with a scissors and was then flushed using a 1 ml syringe and a needle with phosphate buffer saline (PBS). This was repeated 4-5 times to ensure maximum yield. The supernatant was then filtered through a 45 µM sieve. For BM obtained by crushing: ilium, femur, fibula, tibia, humerus and ulna from both limbs were removed from mice and crushed in 2% FBS in PBS using a pestle and mortar. The cells were filtered through a 45 µM sieve to obtain a single cell suspension. This was centrifuged for 10 min at 300g.

\subsubsection*{2.1.2.2 Spleen, LN Thymus, blood, FL processing}

The spleen, LN, thymus and blood was removed from the transgenic mice. The spleen, thymus, LN and FL were crushed to obtain a single cell suspension and all the cells obtained were filtered through a 70 µm nylon mesh (CellMicroSieves™, Thermo Fisher Scientific, Renfrew, UK). All the cell suspensions (excluding blood and FL) were counted in thymus and LN using a haemocytometer chamber (Hawksley, Lancing, UK) and Trypan Blue (Merck Millipore, Livingston, UK) exclusion method.

\subsubsection*{2.1.2.3 Lymphocyte enrichment in BM and Spleen}

The cells collected from the BM and spleen were enriched for haemopoietic cells (excluding red blood cells and dead cells) by density centrifugation via a
gradient solution, Lympholyte-Mammal (Cedarlane, Ontario, Canada). Cells were pelleted for 5 min in 3 ml PBS at 325g. Then cell pellets were re-suspended in 3 ml PBS and 1 ml Lympholyte at room temperature (RT) was carefully added using the underlay method and centrifuged for 20 min at 625g at RT. The leukocytes collect at the interface and this layer was carefully isolated using Pasteur pipette. These cells were washed in 10 ml PBS and centrifuged at 500g for 10 min at RT. The cells were washed once more in 5 ml PBS for 5 min at 325g at RT and counted using a haemocytometer.

2.1.3 Transplants

2.1.3.1 Primary Transplants

BM was taken from either Mx1-cre Raptor mice (without poly(I:C) inoculation), CD19-cre Raptor mice or B6.SJL WT mice, and was processed by crushing the bones (Section 2.1.2.1), and was RV transduced with either PKCaKR vectors as described below (Section 2.1.6). BM cells were co-cultured with OP9-GFP stromal cells supplemented with IL7 and Flt-3 till day 7-9 (D7-9) and then counted. 5x10^5 cells/100µl cells were transplanted into NSG mice via tail vein injections to establish a CLL-like disease in vivo. Disease progression was monitored by sampling the blood of the mice weekly (20 µl/week) and the bloods were analysed for GFP+ CLL-like cells, as described in section 2.3.2, by flow cytometry. Once the health was compromised, these NSG mice were sacrificed and the organs analysed for CLL-like cells.

2.1.3.2 Secondary Transplants

As NSG mice injected with PKCaKR CLL-like cells, retrovirally transduced from B6.SJL WT mice, were sacrificed, the spleens were processed in a sterile hood, and 3x10^5 splenic cells were further transplanted into NSG or NRG mice for secondary transplants.

2.1.3.3 Drug Treatments in vivo

After confirmation of CLL-like disease (≥0.4% GFP+CD19+ cells for primary transplants and ≥10% GFP+CD19+ cells for primary transplants in the blood), NSG or NRG mice (CLL-like disease generated from BM of B6.SJL WT mice) were
treated for 2 wk (primary transplants) and 3 wk (secondary transplants) with individual inhibitors, or combination or vehicle control and then sacrificed. BM, spleen, LN and blood were collected for analysis (as described in section 2.1.2). AZD2014 (a gift from AstraZeneca, Macclesfield, UK) was formulated at 3 mg/mL in 20% Captisol (Ligand Pharmaceuticals, Inc., La Jolla, CA) and administered daily at 15 mg/kg via oral gavage (OG). Ibrutinib (LC Laboratories, MA, USA) was prepared at a concentration of 2.4 mg/ml in 0.5% methyl cellulose (Sigma-Aldrich, Irvine, UK) and administered at a dose of 12 mg/kg. For vehicle controls, captisol and methylcellulose alone or in combination were administered. Rapamycin (rapa) was delivered once daily by intraperitoneal (ip) injection at a dose of 4 mg/kg dissolved in Tween-80 5.2% / PEG-400 5.2% (v/v).

2.1.4 OP9-GFP cell line

OP9 was derived from the new born calvaria of C57BL/6XC3H F2-op/op mice which lack the production of M-CSF due to a genetic mutation in the M-CSF gene(231). OP9 cell line supports the differentiation of HSCs into B cells when culture is supplemented with IL7 and β-mercaptoethanol (BME)(236). OP9 cell line was retrovirally-transduced with GFP and grown in culture in complete media: alpha-MEM (Gibco, Thermo Fisher Scientific) media supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 10 µg/ml gentamycin, 50 µM BME, 100 µg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine, 20% foetal bovine serum (FBS). The cells were kept in culture at 37°C in a humidified incubator with 5% (v/v) CO₂ and passaged every 2 - 3 days.

2.1.5 Retroviral packaging lines

The cell line derived from mouse embryonic fibroblast cells, NIH-3T3 cells were transfected with gag, pol and env genes to produce GP+E.86 cells(237). These cells were retrovirally-transduced to express MIEV (empty vector control; GP+E.86-MIEV), or PKCαKR (GP+E.86-PKCKR)(238). These were cultured at 37°C in a humidified incubator with 5% (v/v) CO₂ in complete DMEM media containing 10 mM HEPES, 1 mM sodium pyruvate, 10 µg/ml gentamycin, 50 µM BME, 100 µg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine, 10% FBS.
2.1.6 Retroviral transduction

2.1.6.1 Mitomycin C preparation and treatment

Mitomycin C (2mg/ampule) (Sigma-Aldrich, Irvine) was prepared to a stock concentration of 200 µg/ml (20x) in serum free DMEM and was stored in 4°C for up to 6 wk in the dark.

GP+E.86-MIEV and GP+E.86-PKCaKR packaging lines were cultured in T75 flasks in DMEM complete media and when cells reached 70% confluence, they were treated with 10 µg/ml mitomycin C in DMEM complete media for 3 hr. Thereafter, mitomycin C was removed and 10 ml PBS was added to each flask. This was repeated 3-4 times until no residual media was visible and was replaced by complete DMEM media for recovery overnight in culture at 37°C in a humidified incubator with 5% (v/v) CO₂.

Three hours prior to retroviral transduction, mitomycin C treated GP+E.86-MIEV and GP+E.86-PKCaKR cells were trypsinised and plated in individual 6 well plates at 70-80% confluence. This enabled the GP+E.86 cells to adhere to the plates.

2.1.6.2 CD117 enrichment using magnetic assorted cell sorting (MACS)

BM was obtained by crushing as mentioned in section 2.1.2.1 and was enriched for lymphocytes as described in section 2.1.2.3. Post lymphocyte enrichment from BM, cell pellets were re-suspended in 80 µl MACS buffer (2% FBS, 2 mM EDTA in PBS) and 20 µl CD117 MicroBeads (MACS Miltenyi Biotec, Surrey, UK) were added and incubated for 15 min at 4°C in the dark. Post incubation, 2 ml MACS buffer was added to each sample and was centrifuged for 10 min at 500g.

MS columns (MACS Miltenyi Biotec) were used for CD117 enrichment as described in the manufacturer’s protocol. Briefly, the plunger was removed, and the columns were placed on a MS column-holding magnet. The columns were first activated using 500 µl MACS buffer. Subsequently, each sample was re-suspended in 500 µl MACS buffer and pipetted onto the top of the MS columns. Once all the flow-through was collected, 500 µl MACS buffer was added onto each column to wash the column. This was repeated 3 times. Subsequently, the MS column was removed from the magnet and placed onto a 15 ml falcon tube.
ml MACS buffer was added onto the column and the plunger was immediately inserted into the column to elute CD117⁺ cells within the column. The plunger was then removed and an additional 500 µl buffer was added and then plunged. The CD117⁺-purified cells were then centrifuged at 500g for 10 min.

### 2.1.6.3 Retroviral transduction

HSC-enriched cell pellets of individual samples were re-suspended in 4 ml complete DMEM media containing IL7 and Flt3 (10 ng/ml of each; Peprotech, London, UK) and hexadimethrine bromide (Polybrene) (4 µg/ml) (Sigma-Aldrich).

The supernatants of GP+E.86-MIEV and GP+E.86-PKCαKR cells, when adhered to 6 well plates, were removed by pipetting and 2 ml of each sample of HSCs was added onto individual MIEV and PKCαKR wells. These were then cultured overnight at 37°C in a humidified incubator with 5% (v/v) CO₂ (Figure 2.2).

### 2.1.6.4 Post transduction and growth of MIEV and PKCαKR transfected cells

The retrovirally transduced HSC-enriched cells were removed from the plates and centrifuged at 400g for 10 min. The pellets were then re-suspended in complete alpha-MEM media supplemented with IL7 and Flt3 (10ng/ml of each) and plated onto OP9-GFP cells at 20% confluency. The day the BM samples were co-cultured with OP9-GFP stromal cells is D1 of culture. These cells were re-plated with fresh OP9-GFP cells every 3-4 days, and Flt3 was removed after D7 of culture.

### 2.1.7 In vitro KO induction

The *Mx1*-cre-*Raptor/Rictor*fl/fl models were used to induce KO in vitro to assess disease maintenance. RV-transduced BM cells were cultured in vitro until D10 for *Raptor*fl/fl or D20 for *Rictor*fl/fl. Wells containing between 0.5-1x10⁶ cells were treated with 50 units (U)/well interferon B (IFNβ) (Pbl Assay Science, NJ, USA) for 2 or 3 days, or 200 U/well IFNB for 24 hr, and harvested 4 days post treatment.
2.2 K562 cell lines

K562, a chronic myeloid leukaemia (CML) cell line which is derived from a CML patient in blast crisis by pleural effusion (239). This cell line was used to induce erythroid differentiation. Differentiation was induced by hemin (240) treatment or by galactose supplementation (241) in media.

2.2.1 Hemin treatment induced erythroid differentiation

2x10^5 K562 cells were cultured in either K562 media comprising RPMI-1640 media, no glutamine, supplemented with 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and 2 mM L-Glutamine, in a 6 well plate. The cells were treated with 50 μM Hemin (or 20 mM NaOH as control) to the culture. Erythroid differentiation was confirmed by pellet colour (red).

2.2.2 Galactose supplemented erythroid differentiation

2x10^5 K562 cells were cultured till D7 in either K562 media, or with K562 media supplemented with galactose (Gal-media) comprising RPMI-1640, no glucose, supplemented with 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, 2 mM L-Glutamine and 11 mM galactose (Figure 2.3A).

2.2.3 Drug treatment

2x10^5 K562 cells were cultured with either K562 media or Gal-media to induce erythroid differentiation. Each was also treated with either DMSO, 10 nM rapamycin (LC Laboratories) or 100 nM AZD8055 (Stratech Scientific Ltd., Suffolk, UK). The cells were cultured till D7 and analysed by either qPCR or by flow cytometry (Figure 2.3B, C).

2.3 Flow cytometry

Data was acquired using the fluorescent assorted cell sorting (FACS) Canto II using the BD FACS DIVA software and analysed using the FlowJo software (Oregon, USA).
2.3.1 Assessing K562 differentiation

5x10^5 K562 cells were stained with 3 µl GlycophorinA (GlyA) (BD Biosciences, Clone: GAR2) and 10 µl CD71 (Miltenyi Biotec, Clone: AC102) and incubated on ice in the dark for 25-30 minutes. The cells were then washed twice with 1 ml PBS at 300g for 5 min and analysed.

2.3.2 CLL and lineage phenotyping

Single cell suspensions obtained by in vivo or in vitro experiments (sections 2.1.2, 2.1.7) were stained with cocktails of antibodies containing cell surface markers for either CLL disease comprising CD23, CD5, CD19, CD45, CD11b surface markers, lineage detection with CD19, CD4, CD8, CD11b, NK1.1, Gr1 as surface markers, early B and myeloid markers (CD45, B220, CD19, Lineage (Table 2.3), sca-1, CD117, CD16/32, CD34) (Figure 2.4), or late B cell markers (CD19, CD23, CD1d, IgD, IgM, CD21, AA4.1) (Figure 2.5) (Table 2.2). 5x10^5 cells obtained from cell suspensions were initially stained with FcγRII/III (CD16/32) antibody (except for the early B and myeloid staining cocktail) to block any non-specific staining for 2 min. Proceeding this, a cocktail of antibodies was added to the cells and incubated on ice, in dark for 25-30 min. The cells were washed once with 2 ml PBS, resuspended in 100µl and analysed using the flow cytometer (Canto II, BD Biosciences, Berkshire). For the early B and myeloid staining, cells were then stained with V450 streptavidin (SA, BD Biosciences) for 20 min in the dark on ice to bind the lineage biotin antibody mix. Cells were washed in 2 ml PBS, resuspended in 100µl and analysed.

2.3.3 Fixation and permeabilization

After cell culture/treatment or single cell suspensions obtained from tissues, 0.5-1x10^6 cells were harvested and washed twice in PBS by centrifugation at 325g for 5 min. Then 1 ml 80% ethanol was added dropwise to each sample while vortexing to minimise cell stress. Of note, 80% ethanol was added in order to make the final concentration of ethanol 70% with the residual supernatant in each sample after centrifugation. The cells were then stored in -20°C overnight or for up to 2-3 wk.
2.3.4 Assessing intracellular markers

After fixing and permeabilization (section 2.3.3), each sample was stained with the recommended amount/Test (listed in Table 2.4) of either isotype control or phospho-AKT, phospho-4EBP1, phospho-S6 or Ki67 and stained for 30 min on ice in the dark. The samples were then washed with 2 ml PBS and centrifuged for 5 min at 325g. Cells were then analysed using flow cytometry.

2.3.5 Assessment of Apoptosis

5x10^5 cells were counted and were washed with 1x Hank’s Balanced Salt Solution (HBSS) (Thermo Fisher Scientific) at 300g for 5 min at RT. 100 µl HBSS containing 2.5 µl AnnexinV and 2.5 µl 7AAD (BD Biosciences) was added into each ample and was incubated for 10 min at RT in the dark (Table 2.5). The samples were then analysed using the flow cytometer (Figure 2.6).

2.3.6 Assessment of Cell Cycle

After fixing and permeabilization (section 2.3.3), cells were pelleted by centrifugation at 350g for 5 min and were washed twice in PBS by centrifugation at 350g for 5 min to remove any excess ethanol. 350-500µl propidium iodide (PI)/RNAase Staining Buffer (BD Biosciences) was added to each sample and was incubated at RT in the dark for 15 min. The samples were then analysed using the flow cytometer (Figure 2.7).

2.3.7 Assessment of proliferation

A 5 mM stock concentration was prepared by adding 20 µl DMSO (component B) to one vial of CellTrace™ Violet reagent (Component A) and mixing (Invitrogen, Paisley, UK). Then, 1 µL 5 mM CellTrace™ Violet stock solution in DMSO was added to each mL of 1x10^6 cell suspension in PBS/2% FBS for a final working concentration of 5 µM. The cells were incubated for 20 min at 37°C, protected from light. Five times the original staining volume of culture medium (containing at least 1% protein) was added to the cells and incubated for 5 min at 37°C in the dark, to remove any free dye remaining in the solution. The cells were pelleted by centrifugation and were re-suspended in pre-warmed complete
medium and kept in culture for at least 20 min before analysis (d0 timepoint) to allow the CellTrace™ Violet reagent to undergo acetate hydrolysis.

300 µL of each sample was then transferred into FACS tubes and analysed with flow cytometry, where 10,000 events were collected on the machine for 3 consecutive days (every 24 hr) to assess proliferation levels (Figure 2.8).

### 2.4 Colony Forming Cell (CFC) Assay

MethoCult™ (Stem Cell, Cambridge, UK) was thawed and frozen at -20°C in 4 ml aliquots. When needed, MethoCult was thawed at RT. Single cell suspensions of 1x10^5 HSC-enriched BM cells (Section 2.1.2.1) /100µl IMDM containing 20% FBS were added per ml of MethoCult into the falcon tube containing 4 ml of MethoCult aliquot. Tubes were then vortexed for 3-4 sec to homogenise the mixture. To set up colony formation units (CFUs), a 5 ml syringe attached to a 16-gauge blunt-end needle was used. Most of the MethoCult was taken up in the syringe, and the plunger was gently depressed completely (to remove air bubbles). This was repeated 3 times in 5 min intervals. More than 3.3 ml of MethoCult media (from a total of 4ml) was taken up in the syringe and 1.1 ml was gently expelled into a 35mm dish in a spiral motion. This was repeated twice to make three technical replicates. These dishes were rotated to evenly spread the solution across the total surface area. 3-6 dishes were kept in a 150mm petri dish along with 2 dishes (without a lid) filled with 3-5 ml sterile deionised water (dH2O). The lid of the 150mm petri dish was added on top to maintain humidity and was incubated at 37°C, 5% CO₂ and ≥95% humidity till D7-10. Colonies were counted after D7 (Figure 2.9). Colonies included: CFU-GEMM (colony formation unit-granulocyte-erythroid-megakaryocyte-macrophage), CFU-GM (colony forming unit-granulocyte macrophage), CFU-G (colony forming unit-granulocyte), CFU-M (colony forming unit-macrophage), CFU-E (colony forming unit-erythroid), BFU-E (burst forming unit-erythroid).

### 2.5 Migration Assay

#### 2.5.1 Cell Starvation

Between 2-5x10^5 cells/100 µl was prepared where each sample was counted and cultured for 2 hr at 37°C in a 48 well plate in 250 µl in starvation media (DMEM
containing 0.5% bovine serum albumin (BSA), 10 mM HEPES, 1 mM sodium pyruvate, 10 µg/ml gentamycin, 50 µM βME, 100 µg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine).

2.5.2 SDF-1 mediated Migration Set-up

During the starvation step, 150 ng/ml SDF-1 (Peprotech) was added to the starvation media to make up the migration media. Transwell® permeable support chambers (Corning Inc, ME, USA) were set up such that the bottom of each well contained 600 µl of migration media and 100 µl of the cells from the starvation step was carefully pipetted onto the chamber in duplicate. For the negative and positive controls, starvation media was used instead of the migration media where starved cells were either pipetted onto the chamber or directly into the bottom respectively. Cells were cultured at 37°C for 4 hr.

To assess migration after 4 hr, the chambers were removed from all wells, and 150 µl media was pipetted from every well into 3 FACS tubes. The cells were then acquired in the flow cytometer on low speed for exactly 30 sec. The live cells counted were then assessed using FlowJo software.

2.6 RNA extraction

Haemopoietic enriched cells removed from BM of Vav-cre Rictor<sup>fl/fl</sup> mice were retrovirally transduced with either MIEV or PKCαKR (section 2.1.6). These cells were co-cultured with OP9-GFP cells till D21 and were harvested for messenger RNA (mRNA) extraction. RNA was extracted from cells using the RNA mini kit columns (Qiagen, Manchester, UK) using the manufacturer’s protocol and RNA (PolyA selection) was eluted in RNA-ase free H<sub>2</sub>O.

2.7 cDNA Synthesis:

2.7.1 cDNA synthesis - RT-PCR

Up to 1 µg RNA was used per 20 µl reverse transcription reaction using the First Strand cDNA Synthesis Kit for real time-polymerase chain reaction (RT-PCR) (Roche, West Sussex, UK). Each sample was diluted in 1x Tris-EDTA (TE) buffer.
2 μl cDNA was used per 10 μl PCR reaction containing 2x PowerUp™ SYBR® Green Master Mix (Thermo Fisher Scientific) and 300 nM of forward and reverse primer for each gene (listed in Table 2.6). All reactions were performed in technical triplicates and at least three biological replicates using the 7900HT Fast Real-Time PCR system (Applied Biosystems, Warrington, UK) programmed to complete 40 cycles as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, and 60°C for 1 min. After normalization to the endogenous control gene, levels of gene mRNA expression in each sample were determined by the ΔΔCT method of relative quantification (242). TATA-Box binding protein (TBP) was used as the reference gene unless otherwise stated.

2.7.2 One-step cDNA synthesis:

2.7.2.1 Sample, master mix and primer mix preparation:

Retrovirally transduced cells (MIEV or PKCαKR) were stained with anti-CD45 antibody (Table 2.2) on ice for 30 min in the dark. Samples were then washed once with 2 ml PBS for 5 min at 300 g and resuspended in 500 µl PBS. From each sample, 300 cells GFP+CD45+ cells were sorted into the PCR tubes containing the master mix.

For the master mix, a 2x reaction mix of 5 µl was added to each PCR tube per sample containing: Cells direct 2x reaction (2.8 µl), 0.2x Primer mix (1.4 µl), RNAase out (0.056 µl), Superscript III RT/Platinum Taq Mix (0.112 µl), TE Buffer (0.672 µl) (part of SuperScript™ III Platinum™ One-Step qRT-PCR Kit, Invitrogen).

For the primer mix, all primers of interest were selected (Table 2.6) and each forward and reverse primer were added to a master mix with a final concentration of 0.125 µM for each primer in a total volume of 200 µl (made up with TE buffer).

2.7.2.2 FACS and PCR:

After sorting, the tubes were vortexed and centrifuged at 500 g for 30 sec. The samples were then run on a PCR with the following conditions: 50°C for 15 min, 95°C for 2 min followed by 20 cycles of 95°C for 15 sec and 65°C for 4 min. After
these cycles, the samples were brought to a hold at 4°C. After the completion of the PCR, the samples were diluted 10x with TE buffer (45 μl).

Quantitative PCR was performed to assess gene expression of genes included in the primer mix (Table 2.6).

**2.8 DNA extraction and Gel electrophoresis**

DNA was extracted for samples using the Qiagen DNA blood/tissue extraction kit and following the manufacturer’s protocol (Qiagen). The DNA was quantified using a spectrophotometer (Nanodrop ND1000 Spectrophotometer; Labtech International Ltd, East Sussex, UK).

240 ng/25 μl of DNA was amplified in a PCR reaction with a hot start of 95°C for 2 min followed by 35 cycles of: 30 sec denaturation at 95°C, 30 sec annealing at 59°C, 1 min extension at 72°C; and a final extension at 72°C for 5 min. The primers used are listed in Table 2.6. Products were separated by 1% agarose gel electrophoresis in 1x Tris-acetate-EDTA (TAE) buffer and visualised by the addition of SYBR Safe DNA (Invitrogen) in the agarose gel (1:10,000). Gel electrophoresis was performed at 100 volts (V) for 45 min and the gel was imaged using the Odyssey® Fc Imaging system (LI-COR Biosciences, Germany).

**2.9 Western blotting**

Single cell suspensions from organs were counted and 1x10⁷ cells were pelleted and were re-suspended in 100 μl lysis buffer (20 mM Tris pH 7.4, 2mM EDTA, 1% Triton, 1mM DTT) containing protease inhibitor cocktail (Roche) (Table 2.7) and phosphatase inhibitor cocktail (Roche) on ice for 30 min. Lysates were then spun at 21900g for 10 min at 4°C and supernatant was collected. Quantification of protein concentration in the lysates was calculated using the Bradford assay (243). BSA standards with concentrations of 0, 2.5, 5, 7.5, 10, 15, 20 μg/ml were prepared in 1 ml Bradford dye in 1.5 ml eppendorfs. Following this, 1 μl of each unknown sample was added to 1 ml Bradford dye in 1.5 ml eppendorfs. These were then vortexed and then 100 μl from each standard and unknown sample was loaded on a flat bottomed 96 well plate in duplicate. Absorbance was read at 562 nM on a Spectramax M5 plate reader (MDS Analytical...
Technologies, Berkshire, UK) and analysed with SoftMax Pro 5.2 software (MDS Analytical Technologies).

Equal amounts of protein (typically 10 µg/10 µl) were incubated with 4x NuPage LDS Sample buffer and 10x DTT used as a reducing agent at 70°C for 10 min. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-12% NuPAGE Novex BisTris precast gel (Invitrogen) (unless otherwise stated), using 1x solution of 20x 50 mM 3-(N-morpholino) propane sulfonic acid (MOPS) SDS Running Buffer (50 mM TrisBase, 3.5 mM SDS and 1.0 mM EDTA (pH 7.7)) supplemented with NuPAGE antioxidant (Invitrogen). Samples were run alongside HyperPAGE pre-stained protein marker (Bioline, TN, USA) at 80 V for 45 min and then at 180 V for 1 hr. Gels were then transferred onto Immun-Blot polyvinyliden difluoride (PVDF) membranes (Bio-Rad Laboratories, Hertfordshire, UK) using a 1x solution of 20x NuPAGE transfer buffer (25 mM Bicine, 25 mM Bis-Tris, 1.0 mM EDTA, 50 µM Chlorobutanol (pH 7.2)) supplemented with 20% (v/v) methanol (Merck Millipore). Briefly, the PVDF membrane was soaked in 100% methanol for 1 min, rinsed in distilled water (dH2O) and equilibrated in transfer buffer prior to assembly of gel/membrane sandwiches using 1.0 mm gel blotting paper (Whatman plc, Kent, UK) and sponges in an XCell IIITM Blot Module (Invitrogen, Paisley). Transfer was performed at 30 V for 1 hr.

Blots were washed with 1x Tris-buffer saline (TBS) (20 mM Tris HCl pH 7.4, 150 mM NaCl), blocked in TBS containing 5% milk for 1 hr at RT, and incubated with primary antibody overnight at 4°C (Table 2.8). Thereafter, the blots were washed 2 times with TBS and 2 times with TBST (TBS+ 0.01% Tween 20) for 5-10 mins each and incubated with horseradish-peroxidase (HRP)-labelled secondary antibodies for 1 hr at RT. After 2 washes with TBST and 2 washed with TBS for 5-10 mins each, the blots were developed with Immobilon Forte Western HRP substrate (Merck Millipore) for 1 min and imaged with the Odyssey® Fc Imaging system (LI-COR Biosciences). Western blot antibodies were purchased from Cell Signalling Technology (Herts, UK) unless otherwise stated.
2.10 Immunohistochemistry

Immunohistochemistry (IHC) was performed by the Beatson Institute of Cancer Research. Organs were removed from the mouse and drop-fixed in 5ml 10% neutral buffered formalin (NBF) (Cellpath, Newtown, UK) prior to tissue infiltration, a process whereby the tissue is suspended in a series of graded ethanol baths (70-100% ethanol) to displace water in the tissue. Proceeding this, the tissue is paraffin-embedded onto a paraffin wax block. Once the wax has solidified and set (takes 1 hr), the block is then sectioned into 5 µM sections and placed onto clean glass slides and left for 20 min in a 65°C oven to just melt the paraffin into the glass slide. Slides are left overnight at RT to cool. To assess the expression levels of various proteins (Table 2.9), sectioned slides are immersed in 100% xylene for 5 min to remove paraffin and subsequently placed in 100% ethanol baths twice, 70% ethanol, and dH₂O bath for 1 min each to rehydrate the tissue.

2.10.1 Antigen retrieval:

Slides were kept in washing containers with 1x Citrate retrieval buffer (Thermo Fisher Scientific) and were kept in a water bath at 98˚C for 30 min. Containers were then removed from the water bath and allowed to cool at RT. Slides were washed in dH₂O for 5 min.

Endogenous peroxidase quenching and blocking: slides were treated with 3% H₂O₂ solution for 10 min (Agilent Dako) followed by a 5 min wash with TBST. Sections were blocked with 5% normal goat serum in TBST for 30 min at RT.

2.10.2 Antibody staining:

pAKT\textsuperscript{S473}, p4EBP\textsubscript{1T37/T46}, pS6\textsuperscript{S235/236} or Ki67 antibody was added to the sections in 5% NGS O/N at 4˚C and left overnight (Primary Antibody diluent, Agilent Dako) (Table 2.9). The sections were then washed twice in TBST for 5 min. Biotinylated anti-rabbit secondary antibody (Table 2.9) was added to the sections for 30 min at RT (Vector Labs, Peterborough, UK). Sections were then washed twice in TBST for 5 min.
NB: Haematoxylin and eosin (H&E) staining was performed by the IHC department at the Beatson (Colin Nixon). This was done via standard procedures.

2.10.3 Amplification and Visualisation:
Sections were then incubated with pre-mixed avidin/biotin complex (ABC) (HRP tagged) (Vector ABC Kit, Vector Labs) for 30 min at RT followed by 2 washes in TBST for 5 min. For visualisation, sections were treated with 3,3’-Diaminobenzidine tetrahydrochloride (DAB), which forms a brown precipitate on oxidation by HRP, for 10 min followed by a wash in dH₂O for 1 min.

2.10.4 Counterstaining and dehydration:
The slides were counterstained by staining with haematoxylin Z for 7 min for nucleus visualisation, followed by dH₂O wash for 1 min. The slides were then dehydrated by placing the slides in 70% ethanol for 1 min twice and then in 100% ethanol for 5 min. The slide was then treated with one drop of distyrene, polystyrene, xylene (DPX) solution to mount and preserve the staining and left to dry for 5 min. The slides were visualised under an inverted microscope at x4 magnification (Olympus Life Sciences, Japan).

2.11 Statistics
Statistical analyses were carried out between the data sets by using GraphPad Prism 6 Software (San Diego, California, USA). The analysis carried out was, either paired or unpaired, student t-test or one-way ANOVA. Data is represented as mean±standard error of mean (SEM) or as mean±standard deviation (SD) where p≥0.05, as stated in the figure legends.
## 2.12 Tables and Figures

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Supplier Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applied Biosystems</td>
<td>Part of Thermo Fisher Scientific Lingley House, 120 Birchwood Boulevard, Warrington, WA3 7QH, UK</td>
</tr>
<tr>
<td>Agilent Dako</td>
<td>5301 Stevens Creek Blvd, Santa Clara, CA 95051, United States</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Charter Way, Macclesfield, SK10 2NA</td>
</tr>
<tr>
<td>BD Biosciences</td>
<td>1030 Eskdale Road, Winnersh Triangle Wokingham, Berkshire, RG41 5TS</td>
</tr>
<tr>
<td>Bio-Rad Laboratories Ltd.</td>
<td>Bio-Rad Laboratories Ltd. The Junction, Station Road, Watford, Hertfordshire, WD17 1ET</td>
</tr>
<tr>
<td>eBioScience</td>
<td>Part of Thermo Fisher Scientific 3 Fountain Dr, Inchinnan, Renfrew PA4 9RF, UK</td>
</tr>
<tr>
<td>Clarivate Analytics</td>
<td>1500 Spring Garden, Philadelphia, PA 19130, United States</td>
</tr>
<tr>
<td>Cedarlane</td>
<td>4410 Paletta Court, Burlington, Ontario L7L 5R2, Canada</td>
</tr>
<tr>
<td>Cellpath</td>
<td>Mochdre Enterprise Park, Mochdre, Newtown SY16 4LE</td>
</tr>
<tr>
<td>Cell Signaling Technology c/o New England Biolabs</td>
<td>75-77 Knowl Piece, Wilbury Way, Hitchin, Herts SG4 0TY, UK</td>
</tr>
<tr>
<td>Corning Incorporated</td>
<td>2 Alfred Road, Kennebunk, ME 04043 USA</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>3000 N Grandview Blvd Waukesha, WI 53188 United States</td>
</tr>
<tr>
<td>Greiner Bio-One Ltd.</td>
<td>Unit 5, Stroudwater Business Park, Gloucestershire, GL103SX, UK</td>
</tr>
<tr>
<td>Hawksley</td>
<td>25 Marlborough Rd, Lancing BN15 8TN</td>
</tr>
<tr>
<td>Illumina Inc.</td>
<td>5200 Illumina Way, San Diego, CA 92122, United States</td>
</tr>
<tr>
<td>Invitrogen, Paisley, UK Ltd.</td>
<td>Part of Thermo Fisher Scientific 3 Fountain Dr, Inchinnan, Renfrew PA4 9RF, UK</td>
</tr>
<tr>
<td>LC Laboratories</td>
<td>165 New Boston Street, Woburn, MA 01801, USA</td>
</tr>
<tr>
<td>Company</td>
<td>Address</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>LI-COR Biosciences</td>
<td>Siemensstraße 25, 61352 Bad Homburg vor der Höhe, Germany</td>
</tr>
<tr>
<td>Merck Millipore</td>
<td>Fleming Rd, Livingston EH54 7BN, UK</td>
</tr>
<tr>
<td>Miltenyi Biotech</td>
<td>Almac House, Church Lane, Bisley, Surrey, GU24 9DR, UK</td>
</tr>
<tr>
<td>Olympus Life Sciences</td>
<td>Shinjuku Monolith, 2-3-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-0914, Japan</td>
</tr>
<tr>
<td>Pbl Assay Science</td>
<td>131 Ethel Road West #6, Piscataway Township, NJ 08854, USA</td>
</tr>
<tr>
<td>PeproTech EC Ltd</td>
<td>PeproTech House, 29 Margravine Road, London, W6 8LL, UK</td>
</tr>
<tr>
<td>Polyomics, University of Glasgow</td>
<td>Switchback Road, Bearsden, Glasgow, G61 1BD, UK</td>
</tr>
<tr>
<td>Qiagen</td>
<td>Skelton House, Lloyd St N, Manchester M15 6SH, UK</td>
</tr>
<tr>
<td>R&amp;D Systems</td>
<td>R&amp;D Systems Europe Ltd., 19 Barton Lane, Abingdon Science Park, Abingdon, OX14 3NB, UK</td>
</tr>
<tr>
<td>Sigma-Aldrich Co Ltd</td>
<td>Second Ave, Heatherhouse Industrial Estate, Irvine, KA12 8NB</td>
</tr>
<tr>
<td>Stem Cell Technologies</td>
<td>Building 7100, Cambridge Research Park, Beach Drive, Waterbeach, Cambridge CB25 9TL</td>
</tr>
<tr>
<td>Strattech Scientific Ltd.</td>
<td>Cambridge House, St Thomas' Pl, Ely CB7 4EX</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>3 Fountain Dr, Inchinnan, Renfrew PA4 9RF</td>
</tr>
<tr>
<td>Vector Labs</td>
<td>Bakewell Rd, Peterborough PE2 6XS</td>
</tr>
</tbody>
</table>

Table 2.1: List of companies and their addresses from where reagents and materials were purchased.
Table 2.2: Antibodies used for flow cytometry. Master mixes (MM) made for phenotypic identification.

<table>
<thead>
<tr>
<th>Name</th>
<th>Reactive Species</th>
<th>Clone</th>
<th>Format</th>
<th>Manufacturer</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD19</td>
<td>Mouse</td>
<td>1D3</td>
<td>APC-Cy7</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD11b</td>
<td>Mouse</td>
<td>M1/70</td>
<td>Pacific Blue</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD45</td>
<td>Mouse</td>
<td>30-F11</td>
<td>PerCP</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD5</td>
<td>Mouse</td>
<td>53-7.3</td>
<td>APC</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD23</td>
<td>Mouse</td>
<td>B3B4</td>
<td>PeCy7</td>
<td>BioLegend</td>
<td>1:200</td>
</tr>
<tr>
<td>Gr1</td>
<td>Mouse</td>
<td>RB6-8C5</td>
<td>PerCP-Cy5.5</td>
<td>eBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD4</td>
<td>Mouse</td>
<td>RM4-5</td>
<td>PE</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD8a</td>
<td>Mouse</td>
<td>53-6.7</td>
<td>APC</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>NK1.1</td>
<td>Mouse</td>
<td>PK136</td>
<td>PECy7</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>Ter119</td>
<td>Mouse</td>
<td>TER-119</td>
<td>FITC</td>
<td>BioLegend</td>
<td>1:200</td>
</tr>
<tr>
<td>CD34</td>
<td>Mouse</td>
<td>RAM34</td>
<td>FITC</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>B220</td>
<td>Mouse</td>
<td>RA36B2</td>
<td>PE</td>
<td>BDBiosciences</td>
<td>1:400</td>
</tr>
<tr>
<td>CD117</td>
<td>Mouse</td>
<td>2B8</td>
<td>APC</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>Sca-1</td>
<td>Mouse</td>
<td>D7</td>
<td>Pe-Cy7</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD16/32</td>
<td>Mouse</td>
<td>2.4G2</td>
<td>BV510</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>Streptavidin</td>
<td></td>
<td></td>
<td>V450</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>IgD</td>
<td>Mouse</td>
<td>11-26c.2a</td>
<td>BV510</td>
<td>BioLegend</td>
<td>1:200</td>
</tr>
<tr>
<td>CD1d</td>
<td>Mouse</td>
<td>1B1</td>
<td>PerCP-Cy5.5</td>
<td>BioLegend</td>
<td>1:200</td>
</tr>
<tr>
<td>AA4.1</td>
<td>Mouse</td>
<td>AA4.1</td>
<td>PE</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>IgM</td>
<td>Mouse</td>
<td>II/41</td>
<td>APC</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD21</td>
<td>Mouse</td>
<td>7E9</td>
<td>Pacific Blue</td>
<td>BioLegend</td>
<td>1:200</td>
</tr>
</tbody>
</table>

Table 2.2: Antibodies used for flow cytometry. Master mixes (MM) made for phenotypic identification.

CLL disease MM: CD23, CD5, CD19, CD45, CD11b; Lineage MM: CD19, CD4, CD8a, CD11b, NK1.1, Gr1, Ter119; Early B and myeloid MM: CD45, B220, CD19, Lineage

Table 2.3:), sca-1, CD117, CD16/32, CD34; Late B cell MM: CD19, CD23, CD1d, IgD, IgM, CD21, AA4.1.
<table>
<thead>
<tr>
<th>Name</th>
<th>Reactive Species</th>
<th>Clone</th>
<th>Format</th>
<th>Manufacturer</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4</td>
<td>Mouse</td>
<td>GK1.5</td>
<td>Biotin</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD8a</td>
<td>Mouse</td>
<td>53-6.7</td>
<td>Biotin</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>CD3e</td>
<td>Mouse</td>
<td>145-2C11</td>
<td>Biotin</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>NK1.1</td>
<td>Mouse</td>
<td>PK136</td>
<td>Biotin</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>TCR</td>
<td>Mouse</td>
<td>H57-597</td>
<td>Biotin</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
<tr>
<td>Ter119</td>
<td>Mouse</td>
<td>Ter119</td>
<td>Biotin</td>
<td>BDBiosciences</td>
<td>1:200</td>
</tr>
</tbody>
</table>

Table 2.3: Biotinylated antibodies used to delineate early B and myeloid developmental stages and lineages for flow cytometry.
<table>
<thead>
<tr>
<th>Name</th>
<th>Reactive Species</th>
<th>Clone</th>
<th>Format</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>anti-4EBP1 (pT36/pT45)</td>
<td>Mouse</td>
<td>M31-16</td>
<td>PE</td>
<td>15µl/Test</td>
</tr>
<tr>
<td>anti-S6 (pS235/pS236)</td>
<td>Mouse</td>
<td>N7-548</td>
<td>V450</td>
<td>3µl/Test</td>
</tr>
<tr>
<td>anti-AKT (pS473)</td>
<td>Mouse, Human</td>
<td>M89-61</td>
<td>Alexa Fluor® 647</td>
<td>3µl/Test</td>
</tr>
<tr>
<td>anti-Ki67</td>
<td>Mouse, Human</td>
<td>B56</td>
<td>PE-Cy™7</td>
<td>3µl/Test</td>
</tr>
<tr>
<td>κ Isotype Control</td>
<td>Mouse</td>
<td>MOPC-21</td>
<td>V450</td>
<td>3µl/Test</td>
</tr>
<tr>
<td>IgG1 κ Isotype Control</td>
<td>Mouse</td>
<td>MOPC-21</td>
<td>Alexa Fluor® 647</td>
<td>3µl/Test</td>
</tr>
</tbody>
</table>

Table 2.4: List of antibodies used for phospho-flow cytometry. All antibodies were purchased from BD Biosciences, unless stated otherwise.
<table>
<thead>
<tr>
<th>Name</th>
<th>Format</th>
<th>Manufacturer</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>AnnexinV</td>
<td>APC</td>
<td>BDBiosciences</td>
<td>2.5µl/Test</td>
</tr>
<tr>
<td>7-AAD</td>
<td></td>
<td>BDBiosciences</td>
<td>2.5µl/Test</td>
</tr>
</tbody>
</table>

Table 2.5: Antibodies used for viability assays on the flow cytometer.
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse Complement</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actb</td>
<td>ctcctcctga gcgcaagtac</td>
<td>gccatgcaat gttgtctct</td>
<td>Mouse</td>
</tr>
<tr>
<td>Bcl2</td>
<td>a tgactgagta cctgaaccg</td>
<td>tcaaacagagttcgatgct</td>
<td>Mouse</td>
</tr>
<tr>
<td>Bid</td>
<td>gccagattctg aaagtcagg</td>
<td>gctagctgtc tcaccaggtg</td>
<td>Mouse</td>
</tr>
<tr>
<td>Ccd1</td>
<td>gtc ccacagatgt gaagttc</td>
<td>gtc cacacctgat gactcttg</td>
<td>Mouse</td>
</tr>
<tr>
<td>Ccd2</td>
<td>caagatcacc cacactgtag</td>
<td>gtt atgctgtct tgacgga</td>
<td>Mouse</td>
</tr>
<tr>
<td>Ccd3</td>
<td>atg cggagaatgc tggcata</td>
<td>gaagct gcaattgccg cttt</td>
<td>Mouse</td>
</tr>
<tr>
<td>Cdkn1a</td>
<td>cggtgaaacttcttgctg</td>
<td>agagtgcacaagcagcaca</td>
<td>Mouse</td>
</tr>
<tr>
<td>Cdkn1b</td>
<td>gata cgagtggcag gagggt</td>
<td>tctga cgagtgcagc atttg</td>
<td>Mouse</td>
</tr>
<tr>
<td>Cebpa</td>
<td>aaga acagcaacga gtacccg</td>
<td>ttctgtt gcgtctccaat gtt</td>
<td>Mouse</td>
</tr>
<tr>
<td>Ebf1</td>
<td>tac agaaggtcat tctctgg</td>
<td>atccccatacagggcttc aac</td>
<td>Mouse</td>
</tr>
<tr>
<td>Gata1</td>
<td>atgatt gtacgcaaac ggcc</td>
<td>aggcatttgcataccggga tct</td>
<td>Mouse</td>
</tr>
<tr>
<td>Gata2</td>
<td>gacgcaaccc accaccttat</td>
<td>ggt cagttggctg ttaacat</td>
<td>Mouse</td>
</tr>
<tr>
<td>Gusb</td>
<td>ta agacgctgat cacccaca</td>
<td>cagataacatccagtcag g</td>
<td>Mouse</td>
</tr>
<tr>
<td>Hba-a1</td>
<td>aaccttcag ctcctgagcca</td>
<td>tgctca agaggcaaggaat</td>
<td>Mouse</td>
</tr>
<tr>
<td>Klf1</td>
<td>ctaagagg cagggccacat</td>
<td>ctgacgcagcgaacctcc</td>
<td>Mouse</td>
</tr>
<tr>
<td>Klf2</td>
<td>ccaagagc tgcaccttaag</td>
<td>gttgcactgaa aaggctgt</td>
<td>Mouse</td>
</tr>
<tr>
<td>Pax5</td>
<td>acagga catggaggag tga</td>
<td>tgacacctttg atgggcaagt</td>
<td>Mouse</td>
</tr>
<tr>
<td>Prkcb</td>
<td>catcgacaga gagtttctca</td>
<td>g gatcaggat cagtttctag</td>
<td>Mouse</td>
</tr>
<tr>
<td>Pu.1</td>
<td>cagcgatgga gaaagccata</td>
<td>ctctgtgaagttgcttctcag</td>
<td>Mouse</td>
</tr>
<tr>
<td>Rptor</td>
<td>atggtagcagggcactcttctag</td>
<td>gctaaacattcagtctcctaactc</td>
<td>Mouse</td>
</tr>
<tr>
<td>Rptor-Del</td>
<td>ctcagagaactgcagttgctgaagg</td>
<td></td>
<td>Mouse</td>
</tr>
<tr>
<td>Rictor</td>
<td>ttattaact gtgtgtggttg</td>
<td>cgtctttagt gtgtgctgctag</td>
<td>Mouse</td>
</tr>
<tr>
<td>Rictor-Del</td>
<td>cagattcagga tgtccttaacgc</td>
<td></td>
<td>Mouse</td>
</tr>
<tr>
<td>Tbp</td>
<td>gtacccctcaacatgtcact</td>
<td>cagcccaagctccag gtaga</td>
<td>Mouse</td>
</tr>
<tr>
<td>HBB</td>
<td>gcaaggtga acgtgg atgaa</td>
<td>agcact ttcttg ccatgagc</td>
<td>Human</td>
</tr>
<tr>
<td>GATA1</td>
<td>tattcc tcctcc aagctcctg</td>
<td>catctt gtgtata gaggcc gca</td>
<td>Human</td>
</tr>
<tr>
<td>GATA2</td>
<td>gacgacaacc accaccttat</td>
<td>ggt cagttggctg ttaacat</td>
<td>Human</td>
</tr>
<tr>
<td>RNF20</td>
<td>ggtgtc tctctca acgagag</td>
<td>tagtgagcc atccatc agtgcc</td>
<td>Human</td>
</tr>
</tbody>
</table>

Table 2.6: List of primers used for PCR reactions. The full sequence for each gene was obtained from PubMed website. Each primer was designed to have close to 10 C=G and 10 A=T bonds. The length between the forward and reverse primer is between 150-300 base pairs (bp). Rptor-Del and Rictor-Del are reverse primers designed to complement the gene of interest (Raptor and Rictor respectively) between the two loxP sites.
<table>
<thead>
<tr>
<th>Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aprotinin</td>
</tr>
<tr>
<td>Bestatin</td>
</tr>
<tr>
<td>Calpain Inhibitor I</td>
</tr>
<tr>
<td>Calpain Inhibitor II</td>
</tr>
<tr>
<td>Chymostatin</td>
</tr>
<tr>
<td>E-64</td>
</tr>
<tr>
<td>Leupeptin</td>
</tr>
<tr>
<td>α2-Macroglobulin</td>
</tr>
<tr>
<td>Pefabloc SC</td>
</tr>
<tr>
<td>Pepstatin</td>
</tr>
<tr>
<td>PMSF</td>
</tr>
<tr>
<td>TLCK-HCl</td>
</tr>
<tr>
<td>Trypsin Inhibitor (chicken, egg white)</td>
</tr>
<tr>
<td>Trypsin Inhibitor (soybean)</td>
</tr>
</tbody>
</table>

Table 2.7: List of protease inhibitors in the cOmplete mini, EDTA-free protease inhibitor cocktail from Roche.
### Table 2.8: List of antibodies used for western blotting.

List of antibodies and their dilutions in 5% BSA in TBST (except for S6 ribosomal protein, which was in 5% milk in TBST). All antibodies were purchased from Cell signalling (Herts, UK).

<table>
<thead>
<tr>
<th>Name</th>
<th>Reactive Species</th>
<th>Clone</th>
<th>Dilution</th>
<th>Secondary Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAPTOR</td>
<td>Human, Mouse, Rat</td>
<td>24C12</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>RICTOR</td>
<td>Human, Mouse</td>
<td>D16H9</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>pAKT(S473)</td>
<td>All</td>
<td>23C8D2</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>AKT (pan)</td>
<td>Human, Mouse, Rat</td>
<td>C67E7</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>pS6(S235/236)</td>
<td>Human, Mouse, Rat</td>
<td>D57.2.2E</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>S6</td>
<td>Human, Mouse, Rat</td>
<td>54D2</td>
<td>1:1000</td>
<td>Mouse</td>
</tr>
<tr>
<td>p4EBP1(T37/T46)</td>
<td>Human, Mouse, Rat</td>
<td>53H11</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>4EBP1</td>
<td>Human, Mouse, Rat</td>
<td>53H11</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Human, Mouse, Rat</td>
<td>D16H11</td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>B-ACTIN</td>
<td>Human, Mouse, Rat</td>
<td></td>
<td>1:1000</td>
<td>Rabbit</td>
</tr>
<tr>
<td>Anti-mouse IgG, HRP-linked Antibody</td>
<td></td>
<td></td>
<td>1:10000</td>
<td></td>
</tr>
<tr>
<td>Anti-rabbit IgG, HRP-linked Antibody</td>
<td></td>
<td></td>
<td>1:10000</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Reactive Species</td>
<td>Clone</td>
<td>Dilution</td>
<td>Manufacturer</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>---------</td>
<td>----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>pS6^5235/5236</td>
<td>Mouse</td>
<td>D57.2.2E</td>
<td>1:800</td>
<td>Cell signalling</td>
</tr>
<tr>
<td>Ki67</td>
<td>Mouse</td>
<td>RM-9106-S</td>
<td>1:100</td>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>pAKT^5473</td>
<td>Mouse</td>
<td>9DE</td>
<td>1:25</td>
<td>Cell signalling</td>
</tr>
<tr>
<td>p4EBP1^T37/T46</td>
<td>Mouse</td>
<td>236B4</td>
<td>1:500</td>
<td>Cell signalling</td>
</tr>
<tr>
<td>Biotinylated goat anti-rabbit</td>
<td>Mouse</td>
<td></td>
<td></td>
<td>Vector Labs</td>
</tr>
</tbody>
</table>

Table 2.9: List and details of antibodies used for IHC.
Figure 2.1: Cre-loxP system and excision of Rictor/Raptor under promoters including Vav, Mx-1 and CD19.

Upon the expression of the promoters, cre is expressed and it excises the floxed gene flanked by loxP sites thereby generating a KO of the gene of interest (in this case gene of interest being Raptor and Rictor).
Figure 2.2 In vitro system for the retroviral transduction of BM removed from KO mouse models. BM is enriched for CD117 by MACS, and co-cultured overnight with GFP tagged GP+E.86 MIEV/PKCαKR supplemented with IL7, Flt3, and polybrene in complete DMEM media to retrovirally transduce the enriched BM cells. Post transduction, cells are co-cultured on OP9-GFP+ stromal cells supplemented with IL7 and Flt3 cytokines to promote B cell lineage generation.
Figure 2.3 K562 cell line and its differentiation into an erythrocyte-like lineage.
A. Flow cytometry representative plot of K562 demonstrating the increase in CD71^+GlyA^+ surface expression with the substitution of glucose with galactose in media. Live cells were gated by looking at forward scatter and side scatter area (FSC-A and SSC-A). Doublet cells were excluded by FSC-A and forward scatter height (FSC-H). Representative flow cytometry plots showing the change in size and granularity through FSC-A and SSC-A plots of K562 cells (B) or K562 cells cultured with galactose (C) and treated with 10 nM rapamycin or 100 nM AZD8055.
Figure 2.4 Representative flow cytometry graphs and gating strategy.
Flow cytometry graphs demonstrating gating strategy for various haematopoietic lineages (A), early B cells (B), early myeloid populations (C). Various organs obtained from Mx1-cre Raptor<sup>fl/fl</sup> mice stained for lineage, and early B and myeloid surface markers. Live cells were gated by looking at FSC-A and SSC-A. Doublet cells were excluded by FSC-A and FSC-H. Mature B cells (CD11b<sup>-</sup>CD19<sup>+</sup>), CD4<sup>+</sup> T cells (CD19 CD8a CD4<sup>+</sup>), CD8<sup>+</sup> T cells (CD19 CD4 CD8a<sup>+</sup>), NK cells (CD19 CD4<sup>-</sup>CD14<sup>-</sup> NK1.1<sup>+</sup>), mature myeloid cells (CD19 CD11b<sup>-</sup>Gr1<sup>+</sup>), pre-proB cells (lin<sup>-</sup>CD19 B220<sup>-</sup>), proB cells (lin<sup>-</sup>CD19<sup>-</sup>B220<sup>-</sup>), LSK (lin<sup>-</sup>CD19 B220 Sca-1<sup>+</sup>CD117<sup>+</sup>), sca<sup>hi</sup>CD117<sup>hi</sup> (lin<sup>-</sup>CD19 B220 sca-1<sup>lo</sup>CD117<sup>hi</sup>), CMP (lin<sup>-</sup>CD45<sup>-</sup>Sca<sup>lo</sup>CD117<sup>hi</sup>CD34<sup>+</sup>CD16<sup>+</sup>CD12<sup>+</sup>), GMP (lin<sup>-</sup>CD45<sup>-</sup>Sca<sup>lo</sup>CD117<sup>hi</sup>CD34<sup>-</sup>CD16<sup>-</sup>CD12<sup>-</sup>), MEP (lin<sup>-</sup>CD45<sup>-</sup>Sca<sup>lo</sup>CD117<sup>hi</sup>CD34<sup>+</sup>CD16<sup>+</sup>CD12<sup>-</sup>).
Figure 2.5 Representative flow cytometry plots showing the gating strategy for late B cell subsets.
Spleens obtained from Mx1-cre Raptor<sup>fl/fl</sup> mice stained for late B cell surface markers. Live cells were gated by looking at FSC-A and SSC-A. T1 cells (CD19<sup>+</sup>CD23<sup>-</sup>IgM<sup>+</sup>CD21<sup>-</sup>), T2 (CD19<sup>+</sup>CD23<sup>-</sup>CD21<sup>-</sup>CD1d<sup>+</sup>IgD<sup>-</sup>IgM<sup>+</sup>AA4.1<sup>+</sup>), T3 (CD19<sup>+</sup>CD23<sup>-</sup>CD21<sup>-</sup>CD1d<sup>+</sup>IgD<sup>-</sup>IgM<sup>-</sup>AA4.1<sup>-</sup>), MZP (CD19<sup>+</sup>CD23<sup>-</sup>CD21<sup>-</sup>CD1d<sup>-</sup>), MZ (CD19<sup>+</sup>CD23<sup>-</sup>IgM<sup>+</sup>CD21<sup>-</sup>), Fol1 (CD19<sup>+</sup>CD23<sup>-</sup>CD21<sup>-</sup>CD1d<sup>-</sup>IgD<sup>-</sup>IgM<sup>-</sup>AA4.1<sup>-</sup>), Fol2 (CD19<sup>+</sup>CD23<sup>-</sup>CD21<sup>-</sup>CD1d<sup>-</sup>IgD<sup>+</sup>IgM<sup>-</sup>AA4.1<sup>-</sup>). Abbreviations: T1-3 – Transitional cells, fol – follicular cells, MZP – marginal zone progenitors.
Figure 2.6 Representative flow cytometry plot showing AnnexinV and 7AAD staining. AnnV+7AAD- are viable cells, AnnV-7AAD- are apoptosing cells, AnnV-7AAD+ are dead cells. BM cells obtained from CD19-cre Raptorfl/fl mice.
Figure 2.7: Flow cytometry representative plot showing the different phases of cell cycle by propidium iodide (PI) staining.

Retrovirally transduced PKCaKR cells, which were derived from BM of Vav-cre Rictor<sup>fl/fl</sup> mice. PI assay was set up at D22 in vitro. Live cells were gated by looking at FSC-A and SSC-A. Doublet cells were excluded by FSC-A and FSC-H. GFP cells were excluded and then PI was observed in the graph above. Sub G<sub>0</sub> phase contains apoptotic cells, cells in G<sub>0</sub> phase are quiescent cells, cells in G<sub>1</sub> phase are in preparation for doubling the chromosomal levels for mitosis, cells in S phase indicate DNA synthesis, G<sub>2</sub> phase is where mitosis preparation occurs, and M phase is where mitosis occurs. RCN - Relative cell number.
Figure 2.8 Representative plot showing cell trace violet (CTV) fluorescence over 3 days thereby measuring the proliferation of a population. Retrovirally transduced PKCaKR cells, which were derived from BM of Mx1-cre Raptor^fl/fl^ mice. Cells were treated with 200 U/well interferonβ (IFNβ) for 24 hr in vitro. This proliferation assay was set up 3 days after treatment. Live cells were gated by looking at FSC-A and SSC-A. Doublet cells were excluded by FSC-A and FSC-H. GFP cells were excluded and then CTV fluorescence was observed in the graph. Red, blue and yellow peaks represent CTV fluorescence at D1, 2, and 3 respectively. RCN - Relative cell number.
Figure 2.9 Different colonies formed by Vav-cre Rictor<sup>fl/fl</sup> BM (CD117 enriched cells) using the m3434 and m3334 MethoCult media. CFU-GM (colony forming unit-granulocyte macrophage), CFU-G (colony forming unit-granulocyte), CFU-M (colony forming unit-macrophage), CFU-E (colony forming unit-erythroid), BFU-E (burst forming unit-erythroid). Pictures are taken using an inverted microscope (Olympus Life Sciences, Japan) at x4 magnification.
Chapter 3

The Role of mTOR in Erythropoiesis and Myelopoiesis
3 Role of mTOR in erythropoiesis and myelopoiesis

3.1 Aims and objectives

The mTOR pathway has previously been shown to play a role in RBC development (97). The aims of this chapter are to determine the role of mTORC1 and mTORC2 in RBC development and the role of mTORC1 in myelopoiesis using mouse models:

i) The Vav-cre \textit{Raptor}/Rictor\textsuperscript{fl/fl} mouse model, which excises either \textit{Raptor} or \textit{Rictor} (inactivating mTORC1 or mTORC2 respectively) at the HSC stage under the \textit{Vav} promoter.

ii) The Mx1-cre \textit{Raptor}\textsuperscript{fl/fl} mouse model which excises \textit{Raptor} (thus rendering mTORC1 inactive) in all tissues in a time controlled manner by the inoculation of poly(I:C) (Section 1.7.1.2).
3.2 Results

3.2.1 Mice lacking mTORC1 within the haemopoietic lineage do not survive after birth and Raptor-null adult mice display splenomegaly

To assess the role of mTORC1 at the HSC stage we used the Vav-cre model. To obtain the desired Raptor KO model, Vav-cre<sup>−/−</sup>Raptor<sup>wt/fl</sup> were mated with Vav-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> to obtain the possible mendelian phenotypic filial generations: Vav-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> (Vav-Raptor control), Vav-cre<sup>−/−</sup>Raptor<sup>wt/fl</sup>, Vav-cre<sup>−/−</sup>Raptor<sup>wt/fl</sup>, or the desired KO model Vav-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> (Vav-Raptor KO). From previous literature, it is preferable to use heterozygous cre expression for the KO models, as homozygous expression of cre has shown to be ‘leaky’, leading to non-specific deletions due to the presence of pseudo-loxP sites present in the mouse genome(208). Therefore, cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> was the desired KO model.

Analysis of Vav-cre matings demonstrated a lack of Vav-Raptor KO mice specifically at weaning age (4 wk) (Table 3.1). We thus performed time-matings, obtaining foetus’ at E13, E15 and E18, to determine whether the Vav-Raptor KO mice were present at these embryonic stages. Indeed, between E13-18, we obtained the desired model/phenotype of interest in the expected mendelian ratios (Table 3.1). This suggests that mice with Raptor KO at the HSC do not survive much longer after birth and undergo perinatal lethality. Post birth genotyping then revealed that Vav-Raptor KO mice do not survive more than 2 days (D2) after birth. Genotyping Vav-Raptor KO FL confirmed the KO as these FLs had a significant downregulation in Raptor expression (Figure 3.1A). Additionally, the Raptor-null foetus’ had a much increased pallor (Figure 3.1B) alluding to a fundamental role of mTORC1 in RBC development.

To assess the role of mTORC1 at a later developmental stage, the Mx1-cre Raptor<sup>fl/fl</sup> model was used where Mx1-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> mice were mated with Mx1-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> to obtain the desired KO model Mx1-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> (Mx1-Raptor cKO), along with the control Mx1-cre<sup>−/−</sup>Raptor<sup>fl/fl</sup> (Mx1-Raptor control). Compared to Vav-Raptor KO mice, both possible genotypes Mx1-Raptor control and cKO models (without poly(I:C) inoculation) were obtained in the filial generations (Table 3.2) and induction of mTORC1 cKO, by poly(I:C) inoculations, in adult mice did not result in lethality (data not shown). The Mx1 promoter is
only expressed under the activation of TLR3. Therefore, poly(I:C), an RNA mimetic which activates TLR3 was used to induce the cKO(202,244). Upon successful cKO, which was confirmed by a significant downregulation of \textit{Raptor} gene expression in BM and spleen of \textit{Mx1-Raptor} cKO compared to \textit{Mx1-Raptor} control (Figure 3.1C), \textit{Mx1-Raptor} cKO mice exhibited splenomegaly and a significant increase in spleen weight and spleen cellularity compared to \textit{Mx1-Raptor} controls (Figure 3.1D-F).

\subsection*{3.2.2 \textit{Raptor}-null mice have a disruption in RBC, myeloid, and B cell lineages \textit{in vivo}}

Analysis of haemopoietic lineages isolated from primary lymphoid organs in these mouse models, by flow cytometry, revealed a significant decrease in the percentage of Ter119$^+$ erythroid populations in \textit{Vav-Raptor} KO FL at E15 compared to \textit{Vav-Raptor} controls (Figure 3.2A-D, Figure 3.3A). Additionally, there was a trend in decrease in the percentage of Ter119$^+$ erythroid populations in the BM (Figure 3.2E-F), together with a significant increase in percentage of Ter119$^+$ population in the spleen in \textit{Mx1-Raptor} cKO mice compared to \textit{Mx1-Raptor} controls (Figure 3.3B). A significant increase in percentage of Ter119$^+$ expression in the spleen in \textit{Mx1-Raptor} cKO mice suggests either a compensatory mechanism of the organism to overcome the loss in erythrocytes, or a functional role of the spleen in erythrocyte metabolism. Given the ability for mice to survive in the absence of white blood cell populations, and supported by previous literature(97) we concluded that the absence of \textit{Vav-Raptor} KO mice was due to the critical role of mTORC1 in erythropoiesis.

Further assessing the mTORC1 KO models, both the mTORC1 KO models showed a significant increase in percentage of CD11b$^+$ Gr1$^-$ immature myeloid population along with a decrease in percentage of CD11b$^+$Gr1$^+$ mature myeloid populations compared to controls (Figure 3.2, Figure 3.3C-E). This suggests that mTORC1 is not important for myeloid lineage commitment but is essential for myeloid maturation. Looking at the role of mTORC1 in B cell lineage generations, our results demonstrate that both the \textit{Vav-Raptor} KO FL and \textit{Mx1-Raptor} cKO mice exhibit a significant decrease in the percentage of CD19$^+$ B cell populations in E15 and E17 FL of \textit{Vav-Raptor} KO and in the BM, spleen and a trend in decrease in the blood of \textit{Mx1-Raptor} cKO mice compared to their respective controls.
These data suggest a vital role of mTORC1 in B cell lineage commitment at early and late stages of development.

### 3.2.3 Mice lacking *Raptor* at the HSC stage have a disruption in early B cell population and a block in RBC development at the MEP stage *in vivo*

To gain a deeper understanding of the stage at which *Raptor*-deficiency blocks lineage commitment/development we carried out flow cytometry analysis of the haemopoietic progenitor populations. Supporting the lack of CD19+ B cells, a significant reduction in the percentage of proB cells was noted across E13-18 of *Vav-Raptor* KO FL (Figure 3.4, Figure 3.5A) and *Mx1-Raptor* cKO BM, along with a significant reduction in percentage of pre-proB cells in *Mx1-Raptor* cKO BM (Figure 3.5D), and trends in reduction in percentage of pre-proB cells across E13-18 of *Vav-Raptor* KO FL compared with their respective controls (Figure 3.5B). This was coupled with a trend in increase in percentage of LSK population at E13, along with a significant elevation at E15, while no significant difference was noted at E18 in *Vav-Raptor* KO FL. There was a significant elevation in the percentage of LSK in BM of *Mx1-Raptor* cKO adult mice compared to cre-controls (Figure 3.4, Figure 3.5C&D), suggesting a block in B cell development prior to lineage commitment with *Raptor* deficiency, at an early stage in gestation and in adult mice.

Analysis of the proportion of myeloid progenitors revealed a significant elevation in the percentage of Sca-1loCD117hi population in *Vav-Raptor* KO FL at E13 and E15 (Figure 3.7A), a population consisting of CMP population, which gives rise to GMP and MEP populations (Figure 3.6). There were no changes in the percentages of CMP and GMP populations at E13, E15 or E18 of *Vav-Raptor* KO FL (Figure 3.7B, C). However, there was a trend towards an increase in percentage of GMP populations at E13, and E15 suggesting a skew towards myeloid lineages in *Raptor*-deficient mice at the HSC stage, which alludes to the observed accumulation of CD11b+ immature myeloid population. Comparatively, the *Mx1-Raptor* cKO BM exhibit a decrease in the percentage (but not cellularity) of Sca-1loCD117hi population, with no significant changes in the CMPs, but with a significant decrease in the percentage (but not cellularity) of GMPs compared to controls (Figure 3.6, Figure 3.8A&B), which confirms the decrease in percentage
of CD11b+Gr1+ mature myeloid population in BM of Mx1-Raptor cKO mice as GMPs give rise to myeloid lineages. The difference in progenitor populations between the FL and BM with Raptor-deficiency illustrates the varied functioning of the two organs and highlights that mTORC1 plays similar but not identical roles in lineage maintenance at different stages of development and ontogeny. Assessing the MEP population, there was an elevation in the percentage of MEPs at E13 and E15, with no observed change at E18 (Figure 3.7D) indicating a developmental block for erythropoiesis at the MEP stage in the absence of Raptor expression in vivo at the early HSC stage. The lack of change in early progenitors at E18 may be due to the shift of haemopoiesis towards the BM after E16.5 to prepare for birth (245). Adult mice with Raptor-deficiency exhibit a significant decrease in the percentage (not cellularity) of MEP population in the BM, which confirms the block in erythropoiesis at an earlier developmental stage in the BM. There is a significant decrease in the cellularity and trends in reduction in the percentage of MEP population in the spleen (Figure 3.8C&D), which suggests that there is a depletion of erythrocytes in the spleen. Therefore, the significant increase of erythrocytes in the spleen could allude to an acceleration in erythrophagocytosis, which occurs in the spleen(246).

Interestingly, there is a significant increase in percentage and cellularity of MEP population with Rictor-deficiency at the HSC stage at 2 wk (Vav-Rictor KO mice) with similar trends at 8 wk compared to cre- controls (Vav-Rictor control mice, Figure 3.8E&F). These are opposing trends to what is observed with Raptor-deficiency, suggesting a regulatory mechanism of erythropoiesis between mTORC1 and mTORC2 where mTORC1 is fundamental for the development of erythrocytes whereas mTORC2 suppresses erythrocyte generation.

In support of our phenotypic analysis showing a block in B cell and RBC development, expression analysis of key genes at the HSC stage responsible for enabling differential lineage commitment revealed a significant downregulation in the B cell specific transcription factors Ebf1 and Pax5, while expression levels of the myeloid regulator Cebpα was unaltered. Assessing expression levels of vital TFs involved in erythroid lineage commitment, Pu.1 and Gata1 expression levels were significantly downregulated in the FL of Vav-Raptor KO mice with trends in an increase in Gata2 levels alluding to aberrations in Gata-factor switching. Additionally, there was a significant downregulation in the expression
of β-Globin, e-Klf/Klf1 and Klf2, TFs which play a role in embryonic and adult erythropoiesis and development (Figure 3.7E-G). Collectively, these results indicate an aberration B and RBC lineage commitment with Raptor deficiency in Vav-Raptor KO FLs.

3.2.4 Exploiting K562 CML cell line as an in vitro model for erythropoiesis

In order to further analyse the role of mTORC1 in RBC development in vitro, we made use of the BCR-Abl+ human CML cell line K562, an erythroleukaemia line that differentiates towards a RBC lineage when exposed to stressful environments(247-249). To induce differentiation, cells were treated with either 50 μM hemin(240) or 11 mM glucose was replaced with 11 mM galactose in complete media(241) and cultured till D5-7 in vitro. Hemin treatment showed the differentiation towards a RBC-like lineage as seen by the colour change in cells with hemin treatment (Figure 3.9A). As hemin is strongly auto-fluorescent, moving forward, we supplemented glucose for galactose in the media (Gal-media) to induce stress and thus RBC differentiation (as described in section 2.2.2). Indeed, we observed a significant increase in the percentage of CD71+GlyA+ cells (erythroid markers), an elevation in CD71 expression and a reduction in granularity (cell scatter - SSC-A) (Figure 3.9B-D, Figure 3.10A-C) in K562 cells cultured in Gal-media, coupled with a significant increase in gene expression of β-GLOBIN, and GATA2, which are involved in erythropoiesis (Figure 3.10D). Interestingly, we see a change in the activity of the mTOR pathway with erythroid differentiation in vitro as was indicated by an increase in expression of pAKT\textsuperscript{S473}, coupled with a decrease in RAPTOR and p4EBP1\textsuperscript{T37/T46} expression in K562 cell cultured in Gal-media, suggesting an increase in mTORC2 and a decrease in mTORC1 activity (Figure 3.11A-D).

3.2.5 K562 cell line differentiation into RBCs is blocked with mTOR inhibition in vitro

To assess the role of mTORC1 in RBC differentiation, K562 cell line was treated with a partial mTORC1 inhibitor, rapamycin and the dual mTOR complex inhibitor AZD8055, and cultured in either complete media or Gal-media to induce RBC differentiation. Treatment of K562 cells with rapamycin or AZD8055 blocked erythroid differentiation in vitro, as indicated by a significant decrease
in the percentage of CD71\(^+\)GlyA\(^+\) erythroid cells, and a reduction in gene expression of erythroid markers \(\beta\)-GLOBIN, GATA1 and GATA2, (Figure 3.10A-D), indicating mTORC1 inhibition blocks RBC differentiation \textit{in vitro}. Interestingly, there was a trend in increase in pAKT\(^{5473}\) and p4EBP1\(^{T37/T46}\) levels with rapamycin treatment in K562 cells cultured in both complete or in Gal-media suggesting there was no change or an increase in activity of the downstream targets of mTORC1 including mTORC2 with rapamycin treatment (Figure 3.11A-D). Consistent with previous literature(250), as rapamycin is an allosteric inhibitor of mTORC1 and a partial inhibitor, these data suggest that even though rapamycin affects erythroid differentiation, the effects are not as potent. However, pAKT\(^{5473}\) is not a direct target of rapamycin and although rapamycin inhibits 4EBP1 function, this function is restored in prolonged treatments depending on the cell type(251).

Nevertheless, there was a significant decrease in pAKT\(^{5473}\) and p4EBP1\(^{T37/T46}\) expression with AZD8055 in K562 cells cultured in complete media, alluding to the potent role of mTOR in leukaemia. There was also a significant decrease in pAKT\(^{5473}\) with an unexpected increase in p4EBP1\(^{T37/T46}\) with AZD8055 in erythroid-like cells (Figure 3.11A-D).

### 3.2.6 mTORC1 and mTORC2 regulate RBC maintenance \textit{ex vivo}.

To assess erythroid colony formation capacity of HPCs in the absence of mTORC1 activity, HPCs were isolated from BM of \textit{Mx1}\(-\text{Raptor}\) control or \textit{Mx1}\(-\text{Raptor}\) cKO mice and CFC assays were performed. We establish that \textit{Mx1}\(-\text{Raptor}\) cKO mice lack CFC capacity, as indicated by the lack of colony formation of CFU-E, BFU-E or CFU-GEMM colonies in the absence of \textit{Raptor} expression, compared to cre\(-\)controls (Figure 3.12A&B). Interestingly, myeloid progenitor CFC assays performed in \textit{Vav}\(-\text{cre}\)\textit{Rictor}\(^{fl/fl}\) (\textit{Vav-Rictor} control) and \textit{Vav}\(-\text{cre}\)\textit{Rictor}\(^{fl/fl}\) (\textit{Vav-Rictor} KO) HPCs to assess the role of mTORC2 in early myeloid/erythroid colony formation demonstrated a significant increase in CFU-E colonies, along with a trend in increase in GEMM colonies in \textit{Vav-Rictor} KO HSPCs compared to controls (Figure 3.12C&D) suggesting a suppressive role of mTORC2 in erythropoiesis.
3.3 Discussion

The data presented in this chapter supports previously published data demonstrating a significant decrease in B cells with mTORC1 deficiency, together with an increase in CD11b+ and decrease in CD11b+Gr1+ myeloid cells (91). Additionally, it has been reported that mTORC1 plays a role in erythropoiesis. Previous literature has identified mTORC1 a critical role in erythropoiesis whereby mTORC1 is regulated by dietary iron and Raptor ablation at the HSC stage leads to perinatal lethality (97). In turn, mTOR also regulates cellular iron homeostasis by its downstream target Tristetraprolin (252).

Furthermore, Raptor−/− and overexpression leads to microcytic and macrocytic anaemia respectively (97). However, there remain discrepancies in the field as there are studies demonstrating the redundant role of mTORC1 in anaemia (253), while others indicate that mTORC1 inhibition improves anaemia in a sickle cell disease model (254). Thus, we proposed to elucidate the mechanism by which this is regulated. This was done by assessing two different KO models of mTORC1 using the cre-loxP system to identify the exact role of mTORC1 in haemopoiesis with a focus on erythropoiesis. The cre-loxP system was used to KO mTORC1 at the HSC stage, by excising Raptor under the Vav promoter, and across all tissues in adult mice using a conditional KO (cKO) system which excises Raptor under the Mx1 promoter, which is expressed upon TLR3 activation. The Mx1-cre Raptor model was time controlled and cKO was induced upon the inoculation of poly(I:C) to activate TLR3. This enabled us to compare the role of mTORC1 at different stages of haemopoietic development.

While assessing the role of Raptor at the HSC stage, we demonstrated that Raptor-deficiency leads to perinatal lethality. Raptor-deficient embryos have an increased pallor, which is seen already at E13, suggesting that Raptor-deficient embryos are severely anaemic. In murine physiology, each foetus within the uterine horn has a dual supply of maternal blood – from the uterine branch of the ovarian artery and the uterine artery, which form a network of irrigation fields within each foetus. Additionally, the female bearing the litter undergoes vascular remodelling depending on the litter-size, as a larger litter size has shown to result in greater vascular remodelling to accommodate each foetus. Foetuses in the periphery of the horn have been shown to receive a greater blood supply as compared to those located in the middle of the horn. However, the
foetus’ in the middle have shown to have a better survival capability, an example of evolutionary preservation of the litter in case of complications in the pregnancy (255). Genetic abnormalities within each foetus cause changes in the blood supply to accommodate for those changes to preserve the litter as best as possible. This could be one reason why Vav-Raptor KO (Raptor-deficient) mice are born but die soon after as they cannot survive after the circulation switch from maternal to new-born circulation, which takes place at birth. Additionally, circulation within the embryo is fully established after E10 in normal murine embryos, which is coupled together with vascular remodelling and vessel branching (256). However, our data shows that mTORC1 activity is involved in this circulation at an early stage due to the observed pallor in murine embryos as early as E13.

The pallor was likely due to a significant decrease in Ter119+ erythrocytes with Raptor-deficiency at the early HSC stage. To assess whether erythropoiesis was blocked at an earlier developmental stage, we looked at surface markers for erythroid progenitors. There was a significant increase in the Sca1loCD117hi population with Raptor-deficiency, which gives rise to CMPs which further divide into GMP and MEPs. Indeed, we observed a significant increase in the MEP population suggesting a block at the MEP stage (the erythroid progenitor population) at E13 and E15 Vav-Raptor KO FL. It is seen that there is a reduction in the progenitor populations in all E18 Vav-Raptor FL, and there is no significant difference between the controls and the Vav-Raptor KO FL at E18. It is important to note here that haemopoiesis, broadly put, occurs in two waves, primitive and definitive. Primitive haemopoiesis mainly involves the formation of primitive erythrocytes from HSC residing in the yolk sac to induce oxygenation. The definitive wave comprises of the formation of other haemopoietic progenitors when haemopoiesis moves to the AGM region followed by the FL. In mice, the transition of haemopoiesis from the FL to the BM occurs before birth at E16.5 (245). This confirms the steady decline in progenitor populations in all E18 FLs thereby diminishing any significant differences observed in FLs at E13 and E15, due to a shift in haemopoiesis from the FL to the BM.

The block in erythropoiesis was further confirmed by the significant downregulation in the gene expression of Gata1, B-Globin, Klf1 and Klf2 genes, which are vital for erythrocyte development, with Raptor-deficiency at the HSC.
stage. *Gata2* is a transcription factor highly expressed in haematopoietic cells. Additionally, literature has shown that both transcription factors *Gata1* and *Gata2* in ‘Gata-factor switching’, which involves the decrease in *Gata2* and increase in *Gata1* expression with erythroid differentiation, occupy the same binding domains(10). *Gata1* plays a vital role in erythroid differentiation, sustaining its own expression and suppressing *Gata2* expression. *Gata1* expression is vital for erythropoiesis as it inhibits *Pu.1* expression(257) thereby repressing myeloid and lymphoid lineage generation and inhibiting *Cebpa* expression, a TF vital for myeloid differentiation. *Klf1* TF is vital for erythropoiesis as it regulates MEP lineage fate during erythrocyte development, is responsible for the globin switching from γ- to β-*Globin* for the maturation of erythrocytes(258) from the yolk sac to the FL(23). Whilst *KLF1* plays a major role in erythropoiesis, *Klf2* has shown to be involved in γ-*Globin* activation (involved in primitive erythropoiesis)(259) and also plays a role in endothelial growth, vascular remodeling(260) and inflammation responses(25), which are vital for embryonic development. Interestingly, there was no significant difference in *Gata2* expression alluding to *Gata*-factor switching, suggesting it is not *Gata2* but *Gata1*, which is affected by mTORC1.

To determine whether this block is apparent only at an early stage, we analysed the *Mx1*-cre *Raptor* model, where poly(I:C) was inoculated into adult mice to induce cKO. *Mx1-Raptor* cKO BM exhibit a decrease in percentages of Sca1loCD117hi and MEP populations with a significant decrease in the splenic MEP cellularity with *Raptor*-deficiency. There could be several reasons for the difference in Sca1loCD117hi and MEP population between the FL and BM. It is possible that haemopoiesis, and lineage potential of progenitors differs in foetal vs. adult mice. Indeed, HSCs residing in the FL differ from HSCs in the BM such that FL HSCs have a higher proliferative and metabolic capacity (increased oxidative phosphorylation) than BM-derived HSCs(261) which could affect Sca1loCD117hi and MEP primitive populations. Nevertheless, there is a trend in decrease in Ter119+ erythroid population in the BM of adult mice with *Raptor*-deficiency. However, looking at the spleen, there is a significant increase in Ter119+ population. Similar trends are seen literature where there is a decrease in the BM and an increase in the spleen in Ter119+ expression in *Raptor*-deficient *Mx1*-cKO mice(262), which could suggest a possible compensatory mechanism
wherein the organism drives for erythropoiesis due to a lack in erythrocytes. Kalaitzidis et al., also observe splenomegaly with Raptor-deficiency in adult mice and refer to the spleen as a site for extramedullary haemopoiesis due to an increase in splenic LSK cells(262). Therefore, the spleen could be a secondary site for haemopoiesis driving erythropoiesis. Additionally, as the spleen is known to be a main site for erythrophagocytosis, and it is possible that the function of erythrocytes is compromised and are accumulating in the spleen for phagocytosis(246). We observe splenomegaly and an increase in red pulp. As the red pulp is one of the major sites of erythrocyte destruction, it is a possibility that an accumulation of erythrocytes in the spleen indicates erythrocyte depletion.

To assess other haemopoietic lineages affected by Raptor deletion, surface markers for various lineages were assessed at the HSC stage and in adult mice lacking mTORC1. We observed a significant reduction of mature myeloid population CD11b+Gr1+ and an increase in immature myeloid (CD11b+) population in the FL and BM suggesting a block in myelopoiesis with Raptor KO at both the HSC stage and in adult mice. Guo et al., have shown a similar reduction in CD11b+Gr1+ myeloid population, together with a decrease in CMP population with conditional mTOR deletion in the BM(263), which suggests that mTORC1, and not mTORC2, is vital for myeloid maturation. Literature has also shown that Mx1-cKO of Raptor leads to a decline in CD11b+Gr1+ myeloid population with the accumulation of CD11b+Gr1mid/lo immature myeloid population(262). However, whether this population is an immature myeloid population is debatable as a similar increase in CD11b+Gr1+ population with Mx1-Raptor cKO is classified as being a novel innate myelo-lymphoblastoid effector cell (IMLEC) population. This novel leukocyte population has similar phenotypic characteristic to myeloid cells and are produced by CMP progenitors which cause self-destructive innate immunity by producing excess IMLECs(104).

A significant decrease in mature B cell lineages was observed with Raptor-deficiency in the FL and BM at the HSC stage and in adult mice, together with a decrease in proB cell lineages. Furthermore, there was a significant reduction in pre-proB cells in Raptor-deficient BM along with trends in decrease in pre-proB cells in Vav-Raptor KO FL. The increase in LSK population, which give rise to pre-proB cells, in both BM and E15 FL (with trends increase in E13 FL) suggest a block
at the LSK stage in B cell development with Raptor-deficiency at the HSC stage and in adult mice. A similar trend has been observed, where mTOR cKO in the BM leads to an increase in LSK cells and a decrease in B cells. The increased LSK population was in S phase suggesting increased cell cycling thereby leading to HSC exhaustion with mTOR deficiency(263). Indeed, there was a decrease in mature B cells with an increase in LSK population in the spleen of Mx1-Raptor cKO mice which exhibit cell cycling and metabolic changes(262). Iwata et al., demonstrate a block in B cell development at the preB cell stage with cKO of Raptor in B cells in adult mice (Mb1-Raptor cKO), which is not rescued by the introduction of an anti-apoptotic BclXL transgene, suggesting that this block caused due to the lack of mTORC1 is independent of BclXL(109). Our data suggest a block in B cell development at an earlier LSK stage, as the Mb1-Raptor cKO model was specific to B cells and could have led to differing stages of B cell development block, with similar results.

Analysing the key master TFs that regulated lineage commitment, we show a significant downregulation in Pu.1. High levels Pu.1 expression inhibit Gata1 expression and is correlated with a myeloid population along with the expression of Cebpα. Cebpα KO causes an expansion in erythropoiesis(264) and its expression has shown to be a determining factor responsible for myeloid lineage generation by inhibiting erythropoiesis(15). As Cebpα levels were not altered in Vav-Raptor KO FL, it suggests that either Raptor does not regulate erythropoiesis via Cebpα, or that the significant downregulation of Pu.1 prior to Cebpα expression is sufficient to abrogate myeloid lineage generation. Moreover, lower expression levels of Pu.1 give rise to lymphoid populations and a decrease in Pu.1 expression by Gata1 is associated with a drive towards an erythroid lineage(14). The fact that Pu.1 is a vital TF in regulating haemopoiesis, and our data show a reduction in Pu.1 and Gata1, supports the aberrations in RBC and B cell lineage fates. Indeed, we observe a downregulation in Ebf1 and Pax5, TFs responsible for the development of B cells. PU.1 expression enhances the expression levels of E2A, which is a TF involved in the earliest stages of B cell development. Lack of E2A leads to a block in B cell development at the pre-proB and proB stages(32). E2A drives the expression of EBF1, which together with E2A, regulate the RAG and PAX5 genes responsible for V(D)J recombination to form the pre-BCR complex on preB cells(265).
To assess the role of mTORC1 in erythropoiesis in vitro, we exploited the fact that the K562 cell line differentiates into an erythrocyte-like lineage when exposed to stress (247-249, 266). Various methods exist to induce this differentiation, some of which include lactic acid treatment (267), nicotinic acid and by cisplatin analogues. We used two different methods to induce differentiation, hemin treatment (268) and galactose substitution for glucose in complete media (241). Hemin is an iron-porphyrin, protoporphyrin IX, and has a ferric ion with a chloride ligand. Upon treatment of K562 cells with hemin till D5 in culture, the cell pellet turned red indicative of RBC differentiation. However, as hemin is auto fluorescent, analysis of surface markers by flow cytometry was not possible. Therefore, erythrocyte differentiation was induced by replacing glucose in complete media with galactose (Gal-media) to initiate differentiation. Indeed, we observed an increase in CD71+GlyA+ erythroid-like population and a decrease in cell granularity with galactose substitution along with an increase in GATA2, and B-GLOBIN gene expression levels. We used established mTOR complex inhibitors to assess the role of mTORC1 in erythrocyte differentiation. We used rapamycin, which is an allosteric (269) and partial inhibitor of mTORC1 (270), and AZD8055, which is a competitive and dual mTOR complex inhibitor (271). Treatment of K562 cells with either rapamycin, or AZD8055, led to a significant decrease in the gene expression levels and surface markers of erythroid-like cells suggesting a block in erythropoiesis with mTORC1 in vitro. The significant decrease in GATA1, GATA2, and B-GLOBIN expression levels with mTOR inhibitors is consistent with the results observed in Raptor-deficient FL thereby confirming the role of mTORC1 in erythrocyte development. As erythrocytes are less granular compared to K562 cells, it was reassuring that we observed a decrease in cell granularity between K562 cells cultured in complete media and Gal-media. As mTORC1 plays an important role in maintaining cell size (272), we also observed a decrease in cell granularity in K562 cells with both mTOR inhibitors regardless of erythroid differentiation confirming mTORC1 plays a role in cell size, regardless of the cell type.

K562 cells cultured in Gal-media to induce erythropoiesis have an increased mTORC2 functionality coupled with a decrease in mTORC1 activity, as there is an increase in pAKT\textsuperscript{S473} protein expression along with a decrease in RAPTOR and p4EBP1\textsuperscript{T37/T46} protein expression. This suggests increased mTORC2 activity during
RBC differentiation. As not much is known about the role of mTORC2 in erythropoiesis, this is an interesting finding, which suggests that both mTORC1 and mTORC2 modulate erythrocyte development. FOXO3 has shown to be vital for erythrocyte maturation, and metabolic regulation as a lack of Foxo3 leads to increased ROS mediated by an increase in expression of Cdkn1a and a shortened life span of animals(273). As AKT lies upstream of FOXO3, mTOR/AKT/FOXO3 cross-talk has shown to be vital for erythrocyte maturation(274). This directly implicates a role of mTORC2 in erythrocyte maturation.

We would have expected to see a decrease in expression in downstream targets of mTORC1 targets with rapamycin treatment in K562 cells. However, rapamycin treatment did not have any significant change on RAPTOR, p4EBP1T37/T46 levels with a trend in increase in pAKT5473 expression, suggesting that rapamycin treatment leads to a strong induction of the mTORC2 complex. Carayol et al., see similar results of rapamycin treatment on K562 cells with no changes and trends in increase in pAKT5473 and p4EBP1T37/T46 expression(250). This could be because rapamycin is a partial inhibitor of mTORC1, and the data suggest a continuous activation of the mTOR pathway regardless of the inhibitor. Indeed, rapamycin inhibits mTORC1 via 4EBP1 and S6K inhibition. However, prolonged treatment with rapamycin increased 4EBP1 phosphorylation which is insensitive to rapamycin, whereas S6K inhibition remains constant(251) making p4EBP1T37/T46 an unfavourable target to assess rapamycin function. Therefore, as we observe phenotypic (CD71+GlyA+ expression) and genotypic (GATA1, GATA2, βGLOBIN) changes suggesting a block in erythropoiesis with rapamycin treatment, S6K or pS6S235/S236 expression levels could be assessed to determine the effects of rapamycin on downstream mTORC1 targets. However, there was an expected decrease in pAKT5473 levels with the dual mTOR complex inhibitor, AZD8055 in both K562 cells and erythrocyte-like cells alluding to the antileukemic potential of the drug in K562 cells and the role of mTOR in erythropoiesis. Interestingly, there was a significant increase in p4EBP1T37/T46 expression with rapamycin and AZD8055 treatment in cells differentiated into an erythrocyte-like lineage. 4EBP1, when dephosphorylated binds to elf-4E cap-protein which is a part of the elf-4F complex. This binding inhibits the interaction of elf-4E with elf-4G (part of the complex), thereby inhibiting protein translation (275). The activation of the mTOR pathway has shown to directly influence and increase 4EBP1
phosphorylation (276). However, protein phosphatases (PP) including PP1, PP2A (277), and PPM1G (278) have been shown to be responsible for the dephosphorylation of 4EBP1 thereby inhibiting translation thereby regulation translation. As we see an unexpected increase in 4EBP1 phosphorylation at T37/T46 with rapamycin and AZD8055 mTOR inhibitors in erythrocite-like cells, an evaluation of the functional levels of these PPs (PP1, PP2a and PPM1G) would give us more information about the reasons for increase in 4EBP1 phosphorylation. Previous literature has demonstrated that PP1 and PP2a are important for erythroid colony formation (279). Additionally, PP2A is known to be important for the maintained survival of mature erythrocytes (280). There is a possibility of abrogated PP levels with a block in erythrocyte-like cells with mTOR inhibitors which lead to an increase in 4EBP1T37/T46 phosphorylation.

Lastly, we wanted to assess the colony formation capacity of Raptor-deficient cells. Thus, we harvested Mx1-cre Raptorfl/fl BM to assess erythroid colony formation capacity. As expected, Raptor-deficient BM lacked colony formation capacity altogether demonstrating a lack in formation of CFU-E, CFU-GEMM or BFU-E colonies. This also confirms the perinatal lethality in Vav-Raptor KO mice due to their inability to generate haemopoietic lineages to survive. Interestingly, when we assessed Rictor-deficient BM and their capacity of myeloid colony formation, we observed that HPCs from the BM of Vav-Rictor KO mice formed significantly higher CFU-E erythroid colonies than their controls together with a trend in increase in CFU-GEMM colonies. Furthermore, there was a significant increase in the percentage and cellularity of the MEP population in Vav-Rictor KO BM compared to controls, suggesting a skew in erythrocyte generation in the absence of Rictor. This suggests a possible regulatory system for erythroid regulation wherein mTORC1 drives erythroid formation, whereas mTORC2 limits erythropoiesis suggesting mTORC1 and mTORC2 play opposing roles in regulating erythropoiesis. Interestingly, a conditional mTor KO results in diminished CFU-E and BFU-E colonies, with a block in erythropoiesis at the proerythroblast stage compared to controls (263) suggesting that mTORC1 is vital for the generation of erythrocytes whereas mTORC2 might be involved in the regulation of erythrocytes. As a future direction, it would be interesting to culture erythroid cells or an erythroid cell line: Bristol Erythroid Line Adult (BEL-A) (281) to directly test the role of mTORC1 and mTORC2 in erythropoiesis by performing
shRNA or CRISPR knock down (KD) of mTORC1 and mTORC1 *in vitro*. From our data, we would expect to see an enhanced erythrocyte generation with mTORC2 KD with a concomitant decline in RBC generation with mTORC1 KD.
### 3.4 Tables and Diagrams

<table>
<thead>
<tr>
<th>Breeding</th>
<th>Ratios</th>
<th>Vav^{cre}_Raptor^{wt/}</th>
<th>Vav^{cre}_Raptor^{fl/fl}</th>
<th>Vav^{cre+}_Raptor^{wt/}</th>
<th>Vav^{cre+}_Raptor^{fl/fl}</th>
<th>Chi Test Value ($x^2$)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At weaning (n=26)</td>
<td>Expected mendelian ratios</td>
<td>6.5</td>
<td>6.5</td>
<td>6.5</td>
<td>6.5</td>
<td>14.92</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Actual Genotypes</td>
<td>13</td>
<td>9</td>
<td>4</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryonic Day 13 (n=49)</td>
<td>Expected mendelian ratios</td>
<td>12.25</td>
<td>12.25</td>
<td>12.25</td>
<td>12.25</td>
<td>2.92</td>
<td>0.50 (ns)</td>
</tr>
<tr>
<td></td>
<td>Actual Genotypes</td>
<td>12</td>
<td>8</td>
<td>15</td>
<td>14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3.1: Vav^{cre+}Raptor^{fl/fl} mice do not survive to weaning (4 wk old), exhibiting perinatal lethality.

Timed-mated mice were generated where Vav^{cre+}Raptor^{wt/} mice mated with Vav^{cre+}Raptor^{fl/fl} to obtain filial generations with Vav^{cre+}Raptor^{wt/}, Vav^{cre+}Raptor^{fl/fl}, Vav^{cre+}Raptor^{wt/}, or Vav^{cre+}Raptor^{fl/fl} genotypes according to Mendel’s law. Table shows expected mendelian ratios and the actual genotyped ratios of the mice at weaning and E13, together with chi test values and whether they are statistically different. (p, **≤0.001).
Table 3.2: Mx1-cre Raptor<sup>fl/fl</sup> mice genotypes at weaning (4 wk).
Mx1-cre<sup>+/−</sup> Raptor<sup>fl/fl</sup> mice were mated with Mx1-cre<sup>+/+</sup> Raptor<sup>fl/fl</sup> mice and the obtained genotypes of the filial generations were recorded. Table shows the expected medelian ratios and the actual genotyping of the filial generations upon matings, together with chi test values and whether they are statistically different. (p, *≤0.05).

<table>
<thead>
<tr>
<th>Breeding (n=76)</th>
<th>Ratios</th>
<th>Expected mendelian ratios</th>
<th>Mx1-cre&lt;sup&gt;−/+&lt;/sup&gt; Raptor&lt;sup&gt;fl/fl&lt;/sup&gt;</th>
<th>Mx1-cre&lt;sup&gt;−/−&lt;/sup&gt; Raptor&lt;sup&gt;fl/fl&lt;/sup&gt;</th>
<th>Chi Test Value (x&lt;sup&gt;2&lt;/sup&gt;)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At weaning</td>
<td></td>
<td>38</td>
<td>38</td>
<td>0.053</td>
<td>3.84 (ns)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Actual Genotypes</td>
<td>37</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 3.1: *Vav-Raptor* KO mice are perinatally lethal and *Raptor*-null adult mice exhibit splenomegaly *in vivo.*

A. Gene expression data showing expression of *Raptor* with cre expression in *Vav-cre* *Raptor*^fl/fl* (Vav-Raptor KO) compared to *Vav-cre* *Raptor*^+/+* (Vav-Raptor control) E15 FL. B. Picture showing the difference in pallor in E13 FL between *Vav-cre* *Raptor*^+/+* and *Vav-Raptor* KO foetal mice. C. Gene expression of *Raptor* in the BM and spleen in *Mx1-cre* *Raptor*^+/+* (Mx1-Raptor control, blue bar) and *Mx1-cre Raptor*^fl/fl* mice (red, Mx1-Raptor cKO). D. Picture showing splenomegaly in Mx1-Raptor cKO mice compared to Mx1-Raptor control. Graphs showing spleen weight (mg) (E) and cellularity (F) of Mx1- Raptor control and Mx1-Raptor cKO mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 3.2: Gating strategy of haemopoietic lineages in Vav-cre Raptor and Mx1-cre Raptor<sup>+/−</sup> primary lymphoid organs.

Representative flow cytometry plots demonstrating the proportion of B cells (CD19<sup>+</sup>CD11b<sup>−</sup>), mature myeloid cells (CD19<sup>−</sup>CD11b<sup>−</sup>Gr1<sup>+</sup>), myeloid cells (CD19<sup>−</sup>CD11b<sup>+</sup>), and erythroid (CD19<sup>−</sup>CD11b<sup>−</sup>Ter119<sup>+</sup>) lineages in Vav-cre Raptor<sup>+/−</sup> (A), Vav-Raptor control (B), Vav-cre<sup>−/−</sup> Raptor<sup>+/−</sup> (C) and Vav-Raptor KO (D) E15 FL, and the same of Mx1-Raptor control (E) and Mx1-Raptor<sup>−/−</sup> KO (F) BM. Plots are live and size (FSC−A/SSC−A) gated prior to the gating shown. RCN – relative cell number.
Figure 3.3: Vav/Mx1-cre*Raptor^{fl/fl} mice exhibit a disruption in haemopoiesis in vivo.

Graph demonstrating the percentage of surface expression of Ter119 in Vav-Raptor KO FL (n=7, cre+ ; loxP +/-) compared to Vav-cre Raptor^{fl/fl} (n=10, cre- ; loxP -/+) and Vav-Raptor control (n=8, cre- ; loxP +/-) of E15 FL (A), and in the BM and spleen of Mx1-Raptor cKO (cre+, red bars) compared to Mx1-Raptor control mice (cre-, blue bars) (B). Flow cytometry graphs showing surface expression of percentage of CD11b^{+} myeloid population, and CD11b^{+}Gr1^{+} myeloid lineage (C) in Vav-Raptor KO (n=8) compared to Vav-cre Raptor^{fl/fl} (n=11), Vav-Raptor control (n=8) and Vav-cre- Raptor^{fl/fl} (n=6, cre+ ; loxP +/-) E15 FL. Flow cytometry data of BM and spleen of Mx1-Raptor cKO and Mx1-Raptor control mice showing surface expression of percentage of CD11b^{+} myeloid population (D) and CD11b^{+}Gr1^{+} myeloid lineage (E). Bar graphs showing expression of percentage of CD19^{+} B cells in Vav-cre Raptor^{fl/fl}, Vav-Raptor control, Vav-cre+Raptor^{fl/fl}, and Vav-Raptor KO FL at E15 (F) and E17 (G), together with expression of percentage of CD19^{+} B cell population in the BM, spleen and blood in Mx1-Raptor cKO compared to Mx1-Raptor controls (H). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 3.4: Gating strategy of progenitor cells and early B haemopoietic lineages in Vav- and Mx1-cre Raptor models.
Representative flow cytometry plots demonstrating the proportion of proB (Lin+B220⁺CD19⁺), pre-proB (Lin+B220⁺CD19⁺), Sca-1loCD117hi (Lin−B220−CD19−Sca-1loCD117hi) and LSK (Lin−B220−CD19−Sca-1hiCD117hi) cell populations in Vav-cre Raptorwt/fl (A), Vav-Raptor control (B), Vav-cre Raptorwt/fl (C) and Vav-Raptor KO (D) E15 FL, and the same in BM of Mx1-Raptor control (E) and Mx1-Raptor cKO (F) mice. Lin− gating is done by taking into account the unstained control (blue peak), where the red peak represents Lin− cells. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. RCN – relative cell number.
Figure 3.5: Mx1- and Vav-crereRaptorfl/fl mice exhibit a block in B cell development at the LSK stage.
Surface expression of percentage of proB (CD19^+B220^+) (A), pre-proB (B220^+CD19^-) (B) and LSK (C), populations in E13, E15, E18 in Vav-crereRaptorfl/fl (cre-, loxP -/+), Vav-Raptor control (cre-, loxP +/+), Vav-crereRaptorfl/fl (cre+, loxP -/+), Vav-Raptor KO (cre+, loxP +/+), and in BM of Mx1-Raptor control (blue, cre-) compared to Mx1-Raptor cKO (red, cre+) mice (D). Data are expressed as mean±SEM (p ^*^ ≤0.05, p ^**^ ≤0.001, p ^***^ ≤0.0001, p ^****^ ≤0.00001).
Figure 3.6: Gating strategy of early myeloid progenitors in Vav- and Mx1-cre Raptor models. Representative flow cytometry plots demonstrating the proportion of Sca-1<sup>-</sup>CD117<sup>+</sup> cells, common myeloid progenitors (CMP) (CD45<sup>+</sup>Lin Sca<sup>-</sup>CD117<sup>+</sup>CD34<sup>-</sup>CD16/32<sup>-</sup>), megakaryocyte-erythrocyte progenitors (MEP) (CD45<sup>+</sup>Lin Sca<sup>-</sup>CD117<sup>+</sup>CD34<sup>-</sup>CD16/32<sup>-</sup>) and granulocyte-macrophage progenitors (GMP) (CD45<sup>+</sup>Lin Sca<sup>-</sup>CD117<sup>-</sup>CD34<sup>-</sup>CD16/32<sup>+</sup>) cell populations in Vav-cre Raptor<sup>wt/fl</sup> (A), Vav-Raptor control (B), Vav-cre<sup>-</sup>Raptor<sup>wt/fl</sup> (C) and Vav-Raptor KO (D) in E15 FL. and in BM of Mx1-Raptor control (E) and Mx1-Raptor cKO (F) mice. Plots are live and size (FSC/SSC) gated prior to the gating shown.
Figure 3.7: Vav-Raptor KO mice exhibit a block in RBC development at MEP stage in vivo.
Graph showing surface expression of percentage of Sca-1loCD117hi (Sca-1loCD117hi) (A), CMP (B), GMP (C), MEP (D) populations in E13, 15, 18 FL in Vav-cre Raptor^+/+ (light blue, cre-, loxP -/+ ) and Vav-Raptor control (blue, cre-, loxP +/+ ), Vav-cre Raptor^+/+ (pink, cre+, loxP -/+ ) and Vav-Raptor KO (red, cre+, loxP +/+ ). Gene expression of E17 FL demonstrating the fold change (log_{10}) in Pu.1, early B cell factor 1 (Ebf1), and Pax5 (E), along with fold changes (log_{10}) in gene expression of Cebpα, Gata1, Gata2, βGlobin (F), and Krüppel-like factor (Klf1) and Klf2 (G) at E15 FL in Vav-Raptor KO (cre+) compared to Vav-Raptor control (cre-) FL. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 3.8: Mx1-Raptor cKO mice have aberrations at the MEP stage with opposite trends in Vav-Rictor KO mice in vivo.

Graph showing surface expression of the percentage (A) and cellularity (B) of S1^loCD117^hi (Sca-1^loCD117^hi), CMP, GMP populations in BM of Mx1-Raptor control (cre-) or Mx1-Raptor cKO (cre+) mice. Graph showing surface expression of the percentage (C) and cellularity (D) of MEP in BM of Mx1-Raptor control or Mx1-Raptor cKO mice. Graph showing surface expression of the percentage (E) and cellularity (F) of MEP in BM of Vav-cre Rictor^fl/fl (Vav-Rictor control, cre-) or Vav-cre- Rictor^fl/fl (Vav-Rictor KO, cre+) mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 3.9: K562 cells differentiate into an erythrocyte-like lineage with changes in surface markers and size, which are changed with mTOR inhibitors.

A. Picture showing the colour change in the cell pellet confirming RBC-like differentiation upon treatment of 5X10⁵ K562 cells with 50 μM hemin treatment till D5 (right) compared with the white pellet observed in untreated K562 cells (NDC – no drug control, left). B. Flow cytometry plots showing expression of CD71⁺GlyA⁺ population in K562 cells cultured in either complete media (-Galactose) or in Gal-media (+Galactose). Representative flow cytometry plots demonstrating changes in FSC-A and SSC-A in K562 cells cultured in complete media (C) or in Gal-media (D) with no drug (untreated; left) or treated with rapamycin (middle) or AZD8055 (right).
Figure 3.10: mTOR inhibitors abrogate RBC differentiation in a human cell model.
Percentage of CD71+GlyA+ surface expression (A), mean fluorescent intensity (MFI) ratio of CD71+ erythroid cells (B) and MFI of side scatter area (SSC-A) (C) of K562 cells and K562 cells treated with mTOR inhibitors cultured in either complete media or in Gal-media. D. Gene expression data showing fold changes (log_{10}) of β-GLOBIN, GATA1 and GATA2 in K562 cells cultured in complete media and in Gal-media with or without mTOR inhibitors – rapamycin (mTORC1 inhibitor), AZD8055 (dual mTOR complex inhibitor). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 3.11: Proving the role of mTORC1 in the differentiation of RBCs in K562 cells at the phenotype and molecular level.
Representative western blot (A) and ratios of protein expression levels of RAPTOR/GAPDH (B), pAKT\(^{S473}\)/GAPDH (C), and p4EBP1\(^{T37/46}\)/GAPDH (D) in K562 cells either cultured in complete media (with glucose) or in Gal-media and treated with AZD8055 (AZD) or rapamycin (rapa). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001).
Figure 3.12: Demonstrating a functional block in RBC development in Mx1-Raptor cKO mice, together with an increase in RBC generation in Vav-Rictor KO mice.

A. CFCs which optimise for the growth of erythroid cells were carried out on Mx1-Raptor control (left) and Mx1-Raptor cKO (right) BM enriched for HPCs. B. Colony counts of different erythroid colonies: CFU-E, BFU-E and CFU-GEMM in Mx1-Raptor cKO models and in Mx1-Raptor controls. C. CFCs which optimise for the growth of HPCs were carried out on Vav-Rictor control (left) and Vav-Rictor KO (right) BM enriched for HPCs. D. Colony counts of different haemopoietic colonies: CFU-E, BFU-E and CFU-GEMM in Vav-Rictor KO models and in Vav-Rictor controls. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Chapter 4

Role of mTORC1 and mTORC2 in Lymphopoiesis
4 Role of mTORC1 and mTORC2 in lymphopoiesis

4.1 Aims and Objectives

The mTOR pathway has previously known to play an important role in haemopoiesis (282). Here, we use the cre-loxP system to individually KO Raptor (mTORC1) and Rictor (mTORC2) at different stages of development to assess the individual roles of the mTOR complexes during haemopoiesis. The complexes were removed at the HSC stage (Vav-cre model) resulting in a KO specifically in haemopoietic lineage cells, in the whole organ system in adult mice by using the cKO system (Mx1-cre model) and specifically in B cells by using the CD19-cre model. This enabled us to determine the exact role of mTORC1 and mTORC2 in haemopoiesis and allowed us to elucidate the stages at which these complexes play a role (if any) in lineage development/commitment.
4.2 Results

4.2.1 Mice with induced Raptor deficiency at an adult stage exhibit optimal characteristics of KO when assessed 5 wk post 4 poly(I:C) inoculations.

As the Vav-Raptor KO mouse model is lethal at the perinatal stage (Chapter 3, Figure 3.1), two mTORC1 KO models, the Mx1-cre and CD19-cre models were used to assess the role of mTORC1 in adult mice and specifically in B cells respectively, during normal haemopoiesis. As the cKO system in the Mx1-cre model is dependent upon the inoculation of poly(I:C), it was essential to optimize the cKO system, assessing the dose of poly(I:C) to be given to the mice, and the time taken to induce the cKO. Due to the discrepancies in the dosage of poly(I:C), in terms of number and concentration, along with the timeline at which these mice were assessed in previous literature (91, 263), optimization of this model was carried out with variables being the number of doses (3, 4, 5 inoculations on alternate days) and time of analysis after inoculations (3, 5, 8, 10 wk) at 10 mg/kg poly(I:C).

Mx1-cre^Raptor^{fl/fl} (Mx1-Raptor control) and Mx1-cre^Raptor^{fl/fl} (Mx1-Raptor cKO) mice, inoculated with 3 doses of 10 mg/kg poly(I:C) every alternate day, were assessed at 3, 5, 8 or 10 wk post the last inoculation. There was significant splenomegaly in Mx1-Raptor cKO spleens 5 and 8 wk post poly(I:C) inoculation with similar trends 3 and 10 wk post inoculation compared to Mx1-Raptor controls (Figure 4.1A). Although there was no trend in increase in spleen organ cellularity, there was a greater difference between Mx1-Raptor cKO splenic organ cellularity 5 wk post poly(I:C) compared to analysis at other weeks (Figure 4.1B). Moreover, there was no significant difference in BM or LN organ cellularity over time, however there was a strong trend in decrease in Mx1-Raptor cKO LN organ cellularity 5 wk post poly(I:C), and a significant decrease in thymic cellularity in Mx1-Raptor cKO mice 5 wk after 3 poly(I:C) inoculations compared to control mice (Figure 4.1C-E). These data suggested that the cKO was more pronounced 5 wk post 3 poly(I:C) inoculations compared to earlier or later weeks. To test whether increasing the dose frequency would improve the cKO model, the frequency of the dose was increased from 3 to 5 doses at 10 mg/kg poly(I:C) and the mice were assessed 5 wk post inoculation. Greater
splenomegaly was not in Mx1-Raptor cKO mice with 5 poly(I:C) doses compared to those with 3 doses. These cKO mice exhibited a significant increase in splenic cellularity and a decrease in thymic cellularity, with no changes in BM and LN cellularity compared to 5 wk 5 poly(I:C) control mice (Figure 4.1F&G).

To assess the Mx1-Raptor cKO model treated with 3 and 5 doses of poly(I:C), B cell lineage was assessed at different developmental stages, compared to Mx1-Raptor controls. There was a trend in increase in percentage of lineage-sca-1+CD117+ (LSK) population, and a significant increase in LSK cellularity in the BM of Mx1-Raptor cKO mice compared to Mx1-Raptor controls with 5 doses compared with 3 doses of poly(I:C) (Figure 4.2A,B,E,F). Additionally, with 3 doses of poly(I:C), there was a significant decrease in the percentage of pre-proB cells (linB220+CD19+) after 3 and 10 wk, with a greater significant reduction at 5 wk post inoculation, and a significant decrease in the pre-proB cell cellularity in the BM 5 wk post inoculation in Mx1-Raptor cKO mice compared to controls (Figure 4.2C,D). A similar trend in percentage and cellularity decrease of pre-proB cells was noted in the BM with a trend in increase of the same in the spleen 5 wk post 5 poly(I:C) inoculation in Mx1-Raptor cKO mice compared to controls (Figure 4.2G,H). These results suggested that there may be a block in B cell lineage commitment in the Mx1-Raptor cKO mouse model, which was supported by a significant decrease in the percentage of mature B cell (CD11b+CD19+) lineage in the BM and spleen 3, 5 and 10 wk post 3 poly(I:C) inoculation, coupled with a decrease in B cell lineage percentage in the blood at 5 and 8 wk post 3 poly(I:C) inoculation. Similar trends were seen in the LN across the weeks in Mx1-Raptor cKO mice compared to Mx1-Raptor controls (Figure 4.3A). Mx1-Raptor cKO mice assessed 5 wk post 5 poly(I:C) doses showed a significant decrease in B cell lineage percentage in the BM, spleen and thymus and a decreasing trend in the blood compared to Mx1-Raptor controls (Figure 4.3B). Lastly, to determine whether late stages of B cell development were also affected in Mx1-Raptor cKO mice, and to compare 5 doses of poly(I:C) treatment with 3 doses, the presence of the following B cell populations were assessed. Mx1-Raptor cKO mice treated with 3 poly(I:C) doses showed a significant decrease in percentage of transitional 1 (T1, CD19+CD23+IgMhiCD21int) B cell population after 3 wk, together with a decrease in percentage of fol1 (CD19+CD23+CD21loCD1dintIgDhiIgMloAA4.1+) B cells after 5 wk, and a decrease in
percentage of fol2 (CD19⁺CD23⁺CD21loCD1dintIgDhiIgM⁺AA4.1⁺) B cells after 3, 5 and 10 wk in the spleen compared to controls (Figure 4.4A&B). Similarly, treatment of mice with 5 poly(I:C) doses showed Mx1-Raptor cKO mice exhibit a significant decrease in the percentage of T1, T3 (CD19⁺CD23⁺CD21intCD1dintIgDhiIgM⁺AA4.1⁺), MZ (CD19⁺CD23⁺IgMhiCD21hi) and fol2 B cells with a trend of a decrease in T2 (CD19⁺CD23⁺CD21intCD1dintIgDhiIgM⁺AA4.1⁺), fol1 and MZP (CD19⁺CD23⁺CD21hiCD1dhi) percentages in the spleens compared to controls (Figure 4.4C&D).

These data suggest that analysis of the mice 5 wk post 5 poly(I:C) inoculations results in a more potent cKO compared to 3 poly(I:C) doses. However, treatment of mice aged >18 wk with 5 poly(I:C) doses resulted in death soon after the last poly(I:C) dose (data not shown), therefore 5 poly(I:C) inoculations was considered too severe. Thus, for the remainder of the experiments, we treated mice with 4 poly(I:C) inoculations and assessed them at 5 wk post the last injection. The cKO in mice with 4 poly(I:C) inoculations was as robust as seen in cKO mice with 5 poly(I:C) inoculations as indicated by the spleen weight (mg) in Mx1-Raptor cKO mice with 3, 4 and 5 poly(I:C) injections assessed after 5 wk (Figure 4.6A), and Raptor expression data (see below - Figure 4.7). Before proceeding with additional experiments, it was vital to assess whether the transgenic cre-loxP system initiates phenotypic changes in mice compared to WT mice without the cre-loxP background. Therefore, phenotypic analyses of different haemopoietic lineages were compared between Mx1-Raptor control and WT mice assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculations. As expected, no significant difference was seen between the spleen weight or whole organ counts of the BM, spleen and thymus between the two sets of mice. Furthermore, there was no significant difference in the percentage and cellularity of CD19⁺ B cells and CD11b⁺Gr1⁺ mature myeloid cells in the BM, spleen and thymus along with no difference in CD4⁺CD8⁺ DP and CD4⁺CD8⁻ DN T cell populations in the thymus (Figure 4.5) suggesting that both the Mx1-Raptor control and WT mice are phenotypically similar after treatment with poly(I:C), thereby defining Mx1-Raptor control mice as a ‘wildtype’ reference for comparison to Mx1-Raptor cKO mice.
4.2.2 mTORC1 plays a role in developmental haemopoiesis in vivo.

To assess the role of mTORC1 in normal B lymphopoiesis, Mx1-cre and CD19-cre models were used which KO Raptor in adult mice upon poly(I:C) inoculation (Mx1-Raptor cKO) and specifically in B cells at the proB cell stage (CD19-Raptor KO). As seen in Section 4.2.1, Raptor deficiency in adult mice led to a significant increase in splenic weight and cellularity along with similar trend towards an increase in the BM, and a significant decrease in thymic cellularity (Figure 4.6A&B). To further analyse the spleen in Mx1-Raptor cKO mice with splenomegaly, H&E staining was carried out, which demonstrated a disruption of splenic architecture with a lack of GC and MZ and an increase in red pulp. Ki67 staining was increased suggesting increased cell cycling/proliferation (Figure 4.6C) in Mx1-Raptor cKO mice compared to Mx1-Raptor controls. As the CD19-cre model excises Raptor solely in B cells, there was no difference in the spleen weight between CD19-cre Raptor^{fl/fl} (CD19-Raptor control) and CD19-cre^{+/+} RaptorKO mice. However, there was a significant decrease in the spleen weight along with BM and spleen cellularity in CD19-cre^{+/+} Raptor^{fl/fl} mice (CD19-cre^{+/+} Raptor KO) compared to both the CD19-Raptor control and CD19-cre^{+/+} Raptor KO mice (Figure 4.6D&E).

To confirm the cKO in Mx1-Raptor cKO mice, levels of Raptor were assessed at the protein and genomic levels. Although there was no signal in the BM at the protein level, there was a significant decrease in RAPTOR expression in the spleen and thymus. Furthermore, there was a trend towards a decrease in RICTOR expression in the spleen, and a significant decrease in the thymus of Mx1-Raptor cKO mice compared to controls (Figure 4.7A-C). These data were supported by a significant decrease in Raptor expression in the BM, spleen and liver, coupled with a decreasing trend in Rictor expression in the spleen (Figure 4.7F&G) of Mx1-Raptor cKO mice compared to control mice. These data confirm that Raptor is excised upon treatment with poly(I:C) in adult Mx1-Raptor cKO mice.

The representative Western blot also showed a decrease in t4EBP1 expression in the BM, spleen and thymus and a similar trend in reduction of p4EBP1^{T37/T46}/isotype MFI ratio in the BM, spleen and thymus of mice with
Raptor-deficiency (Figure 4.7A,D). However, no reduction in pAKT$\text{S}^{473}$ or pS6$^{\text{S}235/\text{S}236}$ was seen in the absence of Raptor expression (Figure 4.7A&E).

To assess the effect of Raptor-deficiency in adult mice on all major haemopoietic lineages, surface markers for B, T, myeloid and NK cells were assessed in the BM, spleen, thymus, LN and blood. A significant reduction in CD19$^+$CD11b$^-$ B cell lineage percentage was observed in the BM (Figure 4.8A&B) and spleen, together with a significant decrease in B cell cellularity in the BM and thymus. No difference in the B cell splenic cellularity was seen due to the significant increase in splenic cells altogether in Mx1-Raptor cKO mice compared to controls (Figure 4.6B, Figure 4.9A&B). Furthermore, there was a significant decrease in percentage of CD11b$^+$Gr1$^+$ mature myeloid population in the BM (Figure 4.8A&B) and blood, while significantly increased in the spleen and LN, with similar trends noted in cellularity of CD11b$^+$Gr1$^+$ myeloid population in Mx1-Raptor cKO mice (Figure 4.8A&B, Figure 4.9C&D). Analysing the CD11b$^+$Gr1$^-$ immature myeloid population, there was a significant increase in percentage of this population in the BM and spleen (data not shown). A significant decrease in NK cells percentage was observed in the BM and spleen, with a significant decrease in cellularity of NK cells in the thymus (Figure 4.8A&B, Figure 4.9E&F). Analysing T lineage cells in the thymus, a significant decrease in the percentage and cellularity of CD4$^+$CD8$^+$ DP thymocytes was seen, together with a significant increase in percentage of CD4$^+$CD8$^-$ DN thymocytes, however the CD4$^+$CD8$^-$ population cell number remained largely unchanged (Figure 4.8A&B, Figure 4.9G&H) in Mx1-Raptor cKO mice compared to controls. There was also an increase in percentage of CD8$^+$ T cells with no change in CD4$^+$ T cell lineage with Mx1-Raptor cKO compared to controls (data not shown). These data suggest a significant role of mTORC1 in B cell development and a role in myeloid and T cell lineages in vivo.

The Mx1-cre model excises Raptor in all haemopoietic tissues, enabling analysis of Raptor-deficiency in various haemopoietic organs and cell lineages, generating results that were consistent with previously published data (282). However, by generating Raptor-deficiency specifically in B cells in the CD19-cre model, we wanted to assess the extent of this deficiency in B cells and whether the KO affected the ratio and composition of other haemopoietic lineages. Analysing the CD19-cre$^{+/+}$-Raptor KO mice initially, there was a significant
decrease in percentage and cellularity of CD19+ B cell lineages in the BM and LN, with a further significant decrease in the percentage of CD19+ B cells in the spleen and blood compared to CD19-Raptor controls (Figure 4.8C&D, Figure 4.10A&B). However, as we solely assessed CD19+ B cells, it is important to note that there still exist early B cells, just not B cells with CD19 as a marker. The percentage of NK cells in the spleen of CD19-cre+/Raptor KO mice increased significantly with no other changes in other haemopoietic lineages compared to controls (Figure 4.8C&D, Figure 4.10C-H). Assessment of CD19-cre+/Raptor KO mice revealed a significant reduction in B cell lineage percentage and cellularity in BM, spleen and LN together with reduction in percentage in the blood compared to both CD19-cre+/Raptor KO and control mice as expected (Figure 4.8C-E, Figure 4.10A&B). There was also a significant increase in the percentage of mature myeloid cells in the spleen coupled with an increase in NK cell lineage population in the BM and spleen in CD19-cre+/Raptor KO mice (Figure 4.8C-E, Figure 4.10C&E). Moreover, a significant decrease in the cellularity of CD11b+Gr1+ myeloid cells and NK cells was observed with no changes in T cell lineage in CD19-cre+/Raptor KO mice compared to CD19-cre+/Raptor KO mice (Figure 4.10D,F-H). These data suggest that CD19-cre+/Raptor KO mice do indeed have a decline in B cell lineage across haemopoietic organs compared to controls with a compensatory increase in the percentage of NK cells. However, changes in B cell percentage/cellularity is expected in CD19-cre+/Raptor KO mice due to the placement of the cre recombinase gene within the first coding exon of CD19 antigen gene thereby blocking the expression of CD19 altogether (283). Thus, CD19-cre+/Raptorfl/fl mice were considered the KO mice, while CD19-cre+/Raptor KO mice were disregarded for further analyses of early and late B cell phenotyping due to the lack of CD19 antigen expression.

In order to further assess the nature of B cell subsets affected by Raptor-deficiency, late B cell subsets were analysed in the spleen and LN of control, Mx1-Raptor cKO and CD19-cre+/Raptor KO mice. There was a significant decrease in the percentage of T2, MZP, MZ and fol2 cells in the spleen along with decreasing trends in the percentage of T2, MZ and fol2 cells in the LN of Mx1-Raptor cKO mice compared to controls (Figure 4.11A&B, Figure 4.12). However, these changes were not mirrored by changes in cellularity of late B
cell subsets in the spleen or LN likely due to the increase in splenic organ cellularity with \textit{Mx1-Raptor} cKO.

Analysis of the splenic late B cell populations in \textit{CD19-cre}^{+/−};\textit{Raptor} KO mice revealed a similar phenotype to \textit{Mx1-Raptor} cKO mice, with a significant decrease in percentage of T2, MZP, MZ and fol2 late B cell populations in the spleen compared to controls (Figure 4.11C&D, Figure 4.13A&C). Additionally, there was a significant decrease in percentage of fol1 and fol2 cells in the LN together with a decrease in cellularity of T2 population in the spleen and fol2 population in the LN in \textit{CD19-cre}^{+/−};\textit{Raptor} KO mice compared to controls (Figure 4.13B,G&H).

The role of mTORC1 on B cell viability was assessed by analysing apoptotic markers (Annexin V/7AAD) in BM cells. Induced \textit{Raptor}-deficiency in adult \textit{Mx1-Raptor} cKO mice led to a significant decrease in percentage and cellularity of viable B cells (CD19^+AnnV^7AAD^-) and increased apoptotic cells (CD19^+AnnV^7AAD^+), with a significant decrease in the percentage of early apoptotic B cells (CD19^+AnnV^7AAD^+ in the BM compared to controls (Figure 4.14A&B, Figure 4.15A&B). While there was an increase in apoptosis in B cells with \textit{Raptor}-deficiency, there were only trends towards an increase in apoptotic cells in all haemopoietic cells, with a significant decrease in percentage of early apoptotic cells and an increase in 7AAD^- cells in the BM in \textit{Mx1-Raptor} cKO mice (Figure 4.15C&D). As there was an increase in apoptosis in B cells with \textit{Raptor}-deficiency in adult mice, the \textit{CD19-cre} model was assessed to determine whether a similar trend was observed. Indeed, there were trends of an increase in the percentage of apoptosis, with a decrease in viability in B cells in \textit{CD19-cre}^{+/−};\textit{Raptor} KO BM compared to controls, with no difference in all cells (Figure 4.14C&D, Figure 4.15E-H). These data suggest that \textit{Raptor}-deficiency in B cells causes death by apoptosis without affecting other haemopoietic lineages.

4.2.3 mTORC2 plays a role in later stages of development.

To assess the role of mTORC2 in haemopoiesis, \textit{Vav-cre Rictor^{fl/fl}}, \textit{Mx1-cre Rictor^{fl/fl}} and \textit{CD19-cre Rictor^{fl/fl}} KO models were generated and analysed to determine whether the role of mTORC2 differed when removed at the HSC stage vs. in all haemopoietic lineages of adult mice. Moreover, to specifically assess
the role of mTORC2 in B cells, the CD19-cre Rictor^{fl/fl} model was used. As with Raptor-KO models, it was vital to first determine the optimal timepoints (for the Vav-cre Rictor^{fl/fl}) and frequency of inoculations of poly(I:C) (Mx1-cre Rictor^{fl/fl}) for the mouse models.

To determine the optimal timepoint for phenotypic changes in haemopoietic lineages upon Rictor-deficiency at the HSC stage, Vav-cre Rictor^{fl/fl} (Vav-Rictor control) mice and Vav-cre Rictor^{fl/fl} (Vav-Rictor KO) mice were analysed at E18 (data not shown), 2, 8, and 24 wk of age. A significant decrease in splenic weight was seen at all ages (Figure 4.16B). Additionally, splenic cellularity was reduced at 2 and 8 wk of age, along with a decreasing trend in LN cellularity at all ages (Figure 4.16C).

B cell cellularity was significantly reduced in the spleen at 8 wk with similar trends in the percentage and cellularity over different ages in the spleen of Vav-Rictor KO mice (Figure 4.16D&E). Due to the known role of mTORC2 in T cell development (284), surface markers of haemopoietic lineages were analysed to assess the effect of Rictor-deficiency at the HSC stage over different age groups. A significant decrease in the percentage of CD4^+CD8^+ DP thymocytes cells was seen with a concomitant increase in CD4^−CD8^− DN T cells in the thymus at 8 and 24 wk of age in Vav-Rictor KO mice compared to controls. Furthermore, there was a significant decrease in cellularity of CD4^+CD8^+ DP T cells at 8 wk in Vav-Rictor KO mice compared to controls (Figure 4.17A&B). NK cell lineage cellularity significantly decreased in the spleen at 8 wk in Vav-Rictor KO mice compared to control due to the significant decrease in splenic cellularity in Vav-Rictor KO mice (Figure 4.16B, Figure 4.17E&F). No other changes in other haemopoietic lineages (including myeloid lineage) were observed in mice over weeks (Figure 4.17C&D), which led us to conclude that Vav-Rictor KO mice at 8 wk time was the optimal timepoint to view phenotypic changes in the Vav-Rictor KO model.

Mx1-cre Rictor^{fl/fl} (Mx1-Rictor cKO) mice assessed 5 wk post 4 inoculations of poly(I:C) had a more pronounced phenotype by the cKO compared to mice assessed 3 wk post 4 poly(I:C) inoculations (data not shown). Rictor-deficiency at the HSC stage, in adult mice and in B cells specifically led to a significant decrease in spleen weight together with a significant or decreasing trend in
spleen organ cellularity compared to controls (Figure 4.16A, Figure 4.18A-B). Furthermore, there was a significant decrease in thymic and LN cellularity in Mx1-Rictor cKO mice with similar trends of the same in Vav-Rictor KO mice compared to controls (Figure 4.18B). A significant loss in splenic architecture was observed in Vav-Rictor KO mice compared to controls, with an increase in Ki67 staining. No visible changes in pS6S235/S236 staining was seen with loss in splenic architecture in mice with Rictor-deficiency at the HSC stage. On the contrary, Mx1-Rictor cKO mice did not lead to a complete loss in splenic architecture and showed an increase in Ki67 and pS6S235/S236 staining within the GCs suggesting increased proliferation/cell cycling in these regions of the spleen compared to controls. Additionally, unlike in Vav-Rictor KO mice, Mx1-Rictor cKO spleens also had an increased MZ area as compared to controls (Figure 4.18C&D) alluding to accumulation of MZ B cell population. Successful KO of Rictor at the HSC stage and in adult mice was confirmed by a significant decrease in RICTOR expression in the spleen with a decreasing trend in the thymus of Vav-Rictor and Mx1-Rictor KO models coupled with a significant decrease in RICTOR expression in the liver in Mx1-Rictor cKO mice compared to controls (Figure 4.19A-C,F). Furthermore, Rictor-deficiency was confirmed by a reduction in Rictor expression in the BM, spleen and thymus in Vav-Rictor KO mice and in the BM, spleen and liver in Mx1-Rictor cKO mice compared to controls (Figure 4.19I&K). This was coupled with a significant decrease in downstream target pAKT S473 in the BM and spleen with a decreasing trend in the thymus of Vav-Rictor KO mice with similar decreasing trends in the BM of Mx1-Rictor cKO mice compared to controls. As expected, RAPTOR expression was unaffected by Rictor-deficiency (Figure 4.19D,E,G,H,J,L). These studies suggest a cleaner KO in the Vav-cre Rictorfl/fl model as compared to the Mx1-cre Rictorfl/fl model.

To assess the extent by which Mx1- and CD19-Rictor KO models differ from the Vav-Rictor KO model, different haemopoietic lineages were assessed in all three models. Mx1-Rictor cKO and Vav-Rictor KO mice exhibited a significant decrease in the CD4+CD8+ DP T cell percentage, together with an increase in percentage of CD4+CD8- DN T cells in the thymus (Figure 4.20, Figure 4.21D-F). There was no change in CD4+ T cells with an increasing trend in CD8+ T cells with Rictor-deficiency in all three models (data not shown). Moreover, there were no
changes in the CD11b⁺Gr1⁺, B or NK populations with Rictor-deficiency at the HSC stage suggesting a vital role of mTORC2 in T cell development (Figure 4.20A&B, Figure 4.21A,G,J). In addition to aberrations in T cell lineage, a significant decrease in percentage of B cell and an increase in NK cell lineage was observed in the LN and spleen respectively with Rictor-deficiency in adult mice (Mx1-Rictor cKO) (Figure 4.20C&D, Figure 4.21B,H,K). CD19-cre⁺/⁻ Rictorfl/fl (CD19-Rictor KO) led to a significant decrease in percentage of B cells in the BM, spleen and blood with an increase in percentage of CD11b⁺Gr1⁺ cells (with no changes in cell number - data not shown) in the spleen and blood compared to CD19-cre⁺/-Rictorfl/fl (CD19-Rictor control) (Figure 4.21C,I). Furthermore, there was a significant increase in percentage of NK cells in the blood, with no changes in T cell lineage in CD19-Rictor KO mice compared to CD19-Rictor controls (Figure 4.21F,L). These data suggest that Rictor-deficiency at the HSC and in adult mice leads to aberrations in mature B, T cell populations. As expected, Rictor-deficiency specifically in B cells leads to significant changes in mature B cells, with increased percentages of myeloid and NK cells lineages likely due to the decrease in B cells. Interestingly, there was no change in the percentage of apoptotic cells in all haemopoietic or in B cells in the BM (Figure 4.22). However, there was a decreasing trend in live cells with an increasing trend in early and late apoptotic haemopoietic cells and B cells in the spleen of Vav- and Mx1-Rictor KO mice (Figure 4.23A-H). Moreover, there was a significant increase in the percentage of apoptotic B cells, together with trends in decrease in percentage of live cells with CD19-Rictor KO (Figure 4.23I,J), suggesting only a subtle role of mTORC2 in apoptosis in B cells and other haemopoietic lineages.

To assess the role of Rictor in B cells, early and late B cells markers were assessed in the BM, spleen, and LN. Unlike with Raptor-deficiency, Rictor-deficiency did not lead to any changes in the percentage or cellularity (data not shown) of early B progenitors including LSK, pre-proB and proB cells in the BM of Vav- and Mx1-Rictor KO mice compared to their respective controls (Figure 4.24, Figure 4.26A&B). However, there was a significant increase in the percentage of pre-proB cells in the BM of CD19-Rictor KO mice, together with a significant decrease in the percentage of proB cells compared to controls, suggesting a block in B cell development at the pre-proB cell stage within the CD19-Rictor KO model specifically (Figure 4.26C). To assess late B cell lineage development, we
focussed on the percentages, not cellularity, of late B cell populations due to the significant decrease in total splenic cellularity thereby decreasing the cellularity of most late B cell populations with Rictor-deficiency at the HSC stage and in adult mice (Figure 4.18B). There was a significant decrease in the percentage of T1 cells in the LN, and a decreasing trend in T3 B cell populations in the spleen of Vav-Rictor and Mx1-Rictor KO mice respectively compared to controls (Figure 4.25, Figure 4.26D&E), along with a significant decrease in T1 and T3 percentages in the spleen and T1 B cells in the LN of CD19-Rictor KO mice compared to controls (Figure 4.26F). As T1 B cells transition to T2 and subsequently fol2 which give rise to MZ cells, looking at mature B cell lineages, it was not surprising to observe a significant decrease in MZP and MZ percentages in spleens of Vav-Rictor KO mice, which is consistent with H&E staining showing a decrease in MZ (Figure 4.26G, Figure 4.16C). Additionally, a decrease in the percentage of fol1 B cell population in the LN with a decreasing trend in the spleen in Mx1-Rictor cKO mice was observed compared to controls. There was also a trend in increase in the MZP and MZ population which was consistent with the H&E staining in the spleens of Mx1-Raptor cKO mice (Figure 4.26H, Figure 4.16D) suggesting an accumulation of MZ B cell population. Lastly, a significant decrease in the MZ percentage was observed in the spleen and LN of CD19-Rictor KO mice suggesting aberrations in late B cell populations, specifically in MZ and fol1 B cells with Rictor-deficiency in vivo (Figure 4.26I). These data suggest an important role of mTORC2 in later stages B cell subtypes.
4.3 Discussion

In order to determine the individual roles of mTORC1 and mTORC2 in normal haemopoiesis, the Vav-cre, Mx1-cre and CD19-cre Raptor and Rictor KO mouse models were used to assess haemopoiesis at various stages - the HSC stage, adult mice and specifically in B cells. However, in order to do so, each model needed to be optimised to obtain the robust phenotypic evidence of changes in haemopoietic cell development upon KO/cKO of mTORC1/mTORC2.

4.3.1 Optimisation

Previous literature comprising the Mx1-cre Raptor\textsuperscript{fl/fl} and Mx1-cre Rictor\textsuperscript{fl/fl} models used differing doses and volume of poly(I:C) to induce a cKO in mice. Kalaitzidis \textit{et al}., induced Mx1-Raptor cKO with 3 poly(I:C) inoculations every other day at 15 mg/kg(91), whereas Guo \textit{et al}., carried out 6-8 poly(I:C) inoculations at 10 mg/kg(263), with no reference to the timepoint these mice were assessed post poly(I:C) inoculation. The Mx1-Rictor cKO has previously been induced by 4 poly(I:C) inoculations at 5 mg/kg and assessed at either 1 or 6 months(92). However, data for 1 month was not shown in the paper suggesting a poorer cKO. In other laboratories Rictor cKO has been induced by 7 poly(I:C) inoculations every other day at 400 µg with no mention of the age of the mice when assessed(115). Due to additional papers suggesting 4 poly(I:C) or fewer inoculations(93) reproduced the desired phenotype, a dose of 4 poly(I:C) at 10 mg/kg was delivered to our mice where the timepoint at which the mice were assessed differed between 3 and 5 wk post 4 poly(I:C) inoculation in the Mx1-Rictor model. Kuhn \textit{et al}., showed that one dose of poly(I:C) is sufficient to induce a 100% KO in the liver suggesting that fewer doses can lead to potent KO(234). We determined that the Mx1-cre induced cKO via poly(I:C) inoculation was optimal 5 wk post 4 rounds of poly(I:C) at 10 mg/kg in both Mx1-cre Raptor\textsuperscript{fl/fl} and Mx1-cre Rictor\textsuperscript{fl/fl} models. Successful excision of Raptor and Rictor in these mouse models was confirmed. Additionally, Mx1-Raptor control mice were compared with WT mice inoculated with 4 poly(I:C) inoculation and assessed 5 wk post to assess any changes between the two models with poly(I:C) inoculation. As both the models did not show any significant difference, Mx1-Raptor control mice were used as reference whilst assessing Mx1-Raptor cKO
mice as it suggested that polyI:C inoculation did not produce any drastic effects in either WT or Mx1-Raptor control model.

Discrepancies in the field existed for the timepoint at which the Vav-cre Rictor<sup>fl/fl</sup> mouse model should be assessed to obtain the best phenotype for the KO. Indeed, Vav-cre Rictor<sup>fl/fl</sup> mice have been assessed at 3-4 wk(285) or at 6-8 wk(116) in previous studies. Therefore, the mice were assessed at 2, 8, and 24 wk of age to determine the optimal timepoint for the best phenotype from the KO. Analysis of the development of B, T, NK and myeloid lineages concluded that mice with Rictor deficiency at the HSC stage have an optimal phenotype from the KO at 8 wk of age.

The CD19-cre models for Raptor and Rictor were analysed between 8-10 wk and 18-24 wk respectively due to the known role of Raptor and Rictor at early and later stages of B cell lineage haemopoiesis respectively(282). CD19-cre<sup>+/-Rictor<sup>fl/fl</sup> mice, having homozygous cre expression, exhibited a severe phenotype with a drastic decrease in mature B cells due to the insertion of cre recombinase gene into the first exon of CD19 antigen gene thereby causing a block in CD19 expression and essentially creating a CD19 KO (283). Moreover, Vav-cre model has been shown to be better at the excision of a gene of interest than CD19-cre models, where cre excision is 75-80% and 95% accurate in the BM and spleen respectively (206). The Mb1-cre model (Mb1 is expressed at the pro-proB cell stage) is a better B cell specific model with a better deletion efficiency than CD19-cre model (208). Additionally, the homozgyous expression of cre has been well known to be associated with non-specific excisions within the genome due to the presence of pseudo-loxP sites within the murine genome leading to toxicity(208). Therefore, a heterozygous expression of cre was used for all the models to limit non-specific excisions and the CD19-cre<sup>+/-Rictor<sup>fl/fl</sup> model was not considered for further B cell lineage analysis.

4.3.2 Validation of KO Targets

Testing the gene and protein expression levels of Rictor and Raptor together with their downstream targets in deficient mouse models revealed a significant downregulation of Raptor in haemopoietic organs in Mx1-Raptor cKO as expected. Less expected was the decrease in Rictor expression in the spleen.
with *Raptor*-deficiency in *Mx1-Raptor* cKO mice. Similarly, there was a significant decrease in RAPTOR and RICTOR expression in haemopoietic organs in *Mx1-Raptor* cKO mice. It is possible that mTORC1 controls the protein synthesis of RICTOR thereby decreasing RICTOR expression altogether. This is supported by the finding that *Rictor* gene expression was not significantly modulated in *Mx1-cre Raptor*fl/fl mice. mTORC1 is known to phosphorylate S6K1 which negatively regulates mTORC2 activity (65). However, as our data presented did not show a reduction in S6 phosphorylation, there could be other possible substrates phosphorylating S6. Five phosphorylation sites have been identified for S6, at S235, S236, S240, S244 and S247, where there is an orderly progression of phosphorylation with S236 as the primary phosphorylation site (286). Interestingly, Pende et al., have shown that although S6K2 is primarily responsible for S6 phosphorylation, there are still lower levels of detection of S235 and S236 phosphorylation, after the KO of S6K1 and S6K2, by MAPKs (287) which could be responsible for the phosphorylation of S6. Nevertheless, it is possible that the upstream S6K, a primary effector of S6, is being modulated by other pathways despite *Raptor* cKO thereby phosphorylating S6. Previous literature suggests that S6K1 is phosphorylated directly by PDK1 at T308 residue (288), and by insulin stimulated MAPKs (289,290) which could be other possible upstream substrates phosphorylating S6K1.

Analysis of p4EBP1T37/T46 in *Raptor*-deficiency in adult mice, showed a slight decrease in phosphorylation. A reason behind the lack of significant decrease of p4EBP1 could be due to the antibody used for western blotting. The signal seen on the Western blot was weak, with no signal on various occasions in tissues of *Raptor*-control mice thereby explaining the lack of significance.

Similarly, *Rictor*-deficiency at the HSC stage (*Vav-Rictor* KO) and in adult mice (*Mx1-Rictor* cKO) showed a significant decrease in Rictor expression at the mRNA and protein levels. It was interesting to observe a significant decrease in Raptor expression at the mRNA level in the BM and thymus of *Vav-Rictor* KO mice. However, there was no difference in RAPTOR expression at the protein level in these mice suggesting mTORC2 does not regulate mTORC1 at the early HSC stage (*Vav-Rictor* KO model). Moreover, *Mx1-Rictor* cKO mice did not show any changes in RAPTOR expression at the protein/mRNA levels. These studies indicate that mTORC1 regulation of mTORC2/RICTOR expression is more potent.
compared to mTORC2 vs. mTORC1 dysregulation. Assessing a downstream substrate of mTORC2, Vav-Rictor KO mice displayed a significant decrease in the downstream AKT$^{5473}$ phosphorylation as compared to Mx1-Rictor cKO mice, which displayed similar, yet non-significant trends in the BM, spleen, and thymus. As mentioned, Vav-cre model is regarded as system with a very high efficiency in deletion of the target(208). The Mx1-cre model on the other hand has shown to have other immunogenic side effects(204) and may not represent a complete KO(234). Previous literature has shown that an inducible model of Rictor-deficiency in adult mice (Rosa-cre ER) results in a significant reduction of AKT$^{5473}$ phosphorylation with increased AKT$^{T308}$ phosphorylation and increased FoxO1 activity(111). This suggests there is an increase in PDK1 activity(291) potentially activating the mTORC1 complex, evident by no change in RAPTOR expression with Rictor deficiency in both Rosa-cre and Mx1-cre models. Nevertheless, the difference observed between the phosphorylation of AKT$^{5473}$ in Mx1-cre vs. Rosa-cre could be model specific. Rosa26 is a promoter which is ubiquitously expressed in all tissues and is expressed at an early stage in ES cells, but its function is not yet known(292). On the other hand, Mx1 promoter is expressed in the nucleus of most tissues including spleen, liver, uterus, kidneys, BM, peripheral blood mononuclear cells (PBMCs)(293) in mice, and in most tissues with lower expression in smooth muscle in humans(199). However, its ubiquitous expression in mice has not been confirmed. This difference in the nature of the promoter expression and function together with the mechanism of cre induction (via tamoxifen vs. poly(I:C)) could account for the potent KO in Rosa-cre vs. Mx1-cre transgenic mice.

4.3.3 Splenic Architecture in KO models

Mx1-Raptor cKO in mice resulted in an increase in splenic weight and cellularity and a decrease in BM cellularity, which has been demonstrated previously, together with a disruption in splenic structure with Raptor cKO 5-7 months post poly(I:C) inoculation(91). The reasons for the aberrations in the spleen are unclear. mTORC1 has shown to play a role in cytoskeletal reorganisation, as rapamycin has shown to inhibit IGF1 activated cytoskeletal structure and cell motility in a RhoA dependent manner in tumour cell lines(294). Therefore, it is a possibility that there is an aberration in the F-actin filaments with mTORC1 deficiency thereby demolishing the structure of the spleen as our data
demonstrate a loss of GC and MZ in the spleen altogether with Raptor cKO. However, literature has also shown that mTORC2 controls actin cytoskeleton in a rapamycin independent manner(295) and is mediated by PKCα(296), thereby suggesting contradictory roles of mTOR complexes in actin organisation. Recently, Rictor has shown to positively regulate BCR signalling as Rictor-deficiency in B cells results in overactivation of ezrin, a protein responsible for connecting actin filaments, leading to the formation of a rigid fence of actin thereby restricting lateral BCR movement on the membrane(297). Indeed, we do see a disruption of splenic morphology and architecture in Vav-Rictor KO mice suggesting that both mTOR complexes play a role in splenic architecture. However, whether this is dependent on actin organisation is unclear. Additionally, the increase in spleen weight with a loss of Raptor has been associated with a compensatory mechanism of the body to increase the population of other cells such as erythrocytic, dendritic (not tested) or macrophages leading to extramedullary haemopoiesis due to the decrease in other lymphoid haemopoietic lineages(91).

Interestingly, we show an increase in Ki67 staining in the red pulp of the spleen in Mx1-Raptor cKO mice. Ki67 is a marker for proliferating cells with expression present in all stages of cell cycling - G1, G2, S phases(298). Therefore, observing an increase in Ki67 expression with Raptor cKO suggests a disruption in cell cycling. Dowling et al., have published an essential role of 4EBPs in regulating cell proliferation and cycling in an mTORC1 dependent manner confirming the observed increase in Ki67 expression in mice with Raptor-deficiency(299). In Vav-Rictor KO mice there was no change in proliferation and cycling. Nevertheless, Mx1-Rictor cKO mice (and not Vav-Rictor KO) showed increased accumulation of Ki67 expression in the GCs of the spleen. This suggests a block in proliferation and cell cycling in adult mice alluding to a specific role of Rictor in later stages of development as opposed to at the HSC stage. Wang et al., demonstrated a decrease in proliferation in adult murine endothelial cells with a decrease in vascular endothelial growth factor (VEGF) with Rictor deficiency(300). Similarly, Rictor-deficiency in B cells affected proliferation with the significant decrease in MZ B cells(111).
4.3.4 mTORC1/2 signalling in apoptosis

As discussed in section 3.3, the increase in spleen weight due to Raptor-deficiency correlates with an increase in the red pulp as seen from the H&E staining, which could suggest an increase in erythrophagocytosis in the spleen (301). Mx1-Raptor cKO in adult mice led to increased apoptotic death of B cells with similar trends in mice with deletion of Raptor in B cells. As Raptor-deficiency did not demonstrate other significant changes (but trends in increase in apoptotic cellularity due to the likely effect of mTORC1 on apoptosis in B cells) in other haemopoietic lineages, it is a possibility that B cells are particularly sensitive to apoptosis in the absence of Raptor. Guo et al., observe an increase in apoptosis in myeloid, erythroid and B cell lineages in the BM coupled with a decrease in the anti-apoptotic protein, MCL-1, with mTOR-deficiency(263). These data could allude to the role of both mTORC1 and mTORC2 in apoptosis as they did not assess the individual roles of mTOR complexes. Additionally, induced deletion of Raptor in adult mice led to an increase in apoptosis of differentiated, but not leukaemic stem cells (LSCs), in a mouse model of AML(100). However, these data focusses on a murine model of AML and not healthy haemopoietic lineages. Our data show that B cells are particularly sensitised to apoptosis with Raptor-deficiency in the BM. The BM does not have many T cell subsets but has an increased population of myeloid cells. It would be interesting to assess other haemopoietic organs such as the spleen or thymus and assess myeloid, and other lymphoid lineages to determine the exact role of mTORC1 in apoptosis within different haemopoietic lineages.

Our data suggest a subtle role of mTORC2 in apoptosis as there exist slight trends illustrating an increase in early and late apoptotic cells in the spleens of Vav-Rictor KO and Mx1-Rictor cKO mice and a significant increase in apoptotic B cells in CD19-Rictor KO mice. In agreement with this, published data demonstrates an important role of Rictor in apoptosis. It has previously been shown that Vav-Rictor KO mice exhibit an increase in the pro-apoptotic target Bim with a decrease in the anti-apoptotic BclXL in mature B cells by impairing the canonical and non-canonical NFκB pathway, thereby demonstrating a balance of apoptosis in mature B cells by mTORC2(111). Furthermore, Brunet et al., demonstrated an important role of AKT in phosphorylating and inhibiting the forkhead TF FKHRL1 (FOXO3), thereby inhibiting apoptosis suggesting a role of
mTORC2 in balancing apoptosis(70). RICTOR (and not RAPTOR) knock down (KD) in MCF-7 cells (human breast cancer cell line) revealed that mTORC2 regulates apoptosis in B cells and epithelial cells in a C-MYC dependent manner whereby RICTOR KD upregulates C-MYC expression and subsequent downregulation of E2F1(113). In contrast, conditional Rictor deletion in CD8+ effector T cells did not affect the rate of apoptosis suggesting a redundant role of mTORC2 in regulating T cell mediated apoptosis(125). This suggests a role of mTORC2 in apoptosis in B cells and in other haemopoietic lineages excluding T cells. Clearly there exist discrepancies between our data and in previous literature as our data does not allude to significant apoptosis in B cells with Rictor-deficiency. Perhaps the trends observed in our data could allude to other lineages not affected by mTORC2 which skew the percentages.

### 4.3.5 Impact of mTORC1/2 deletion on haemopoietic lineage development

#### 4.3.5.1 B cells

To assess the individual roles of mTORC1 and mTORC2 in normal haemopoiesis, haemopoietic lineages were assessed in mice with Raptor and Rictor-deficiency. In agreement with previously published literature (91), Mx1-Raptor cKO mice lacked mature B cells in haemopoietic organs, while Rictor-deficient mice only revealed major phenotypic changes later in development. To determine the exact role of mTORC1 and mTORC2 in B cells, populations of early B cells in the BM and late B cells in the spleen and LN were assessed. There was a significant elevation of LSK cells in the BM of Vav-Raptor KO and Mx1-Raptor cKO mice (chapter 3) suggesting a block in B cell development and B cell lineage commitment with Raptor-deficiency. Iwata et al., have shown a block in B cell development at the preB cell stage along with a lack in peripheral B cells independent of BCLXL in mice with Raptor-deficiency in B cells specifically (Mb1-cre cKO). B cell populations with Raptor-deficiency had decreased glycolysis and oxidative phosphorylation indicating an aberration in metabolism(109). This group used a different KO model, which rendered only B cells deficient of mTORC1 via the Mb1-cre cKO model (Mb1 is expressed at the pre-proB cell stage), which will be the reason for the difference observed in the stage at which B cell development is blocked. Additionally, mTORC1 deficiency, and not
mTORC2, is responsible for a decrease in 18 genes encoding for electron transport chain (ETC) proteins together with a decrease in oxidative phosphorylation(302). While assessing the model with Raptor-deficiency in B cells (CD19-cre+/−:Raptor KO) for early B cell progenitors, we observed an increase in LSK and pre-proB cells with a decrease in proB cells with Raptor-deficiency (data not shown), thereby blocking B cell development at the pre-proB cell stage as opposed to at the LSK stage in mice lacking Raptor at the HSC stage (Vav-cre) or in adult mice (Mx1-cre). This suggests that sufficient Raptor expression is required throughout the early stages of B cell development to support maturation of the B cell lineage. Interestingly, Tze et al., demonstrated that a conditional BCR deletion or inhibition of PI3K resulted in a de-differentiation of mature B cells to having early B cell characteristics(303). Whether mTORC1 inactivation leads to the reversal or depletion of B cells is currently unknown.

Rictor-deficiency in Vav-cre (HSC stage) or Mx1-cre (adult mice) mice did not affect B cell lineage commitment suggesting mTORC2 does not play a role in early B cell lineage commitment. However, previous literature has shown that Mx1-Rictor cKO mice exhibit an increase in proB cells with a decrease in mature B cells 6 months post poly(I:C) with an increase Rag1 expression and an increase in cell cycling as there was a significant increase in B cells in G2/S phase with a decrease in cells in G0 phase which was Foxo1 dependent(92). As our conditional mouse model is assessed 5 wk post poly(I:C) inoculation, it is possible that this phenotype has not become evident after about 1 month and needed to be assessed 6 months post inoculation. Additionally, B cells lacking mSIN1 (a component of mTORC2 which is known modulate activity of mTORC2) led to an increase in Rag and Il7r expression (also causing augmentation in V(D)J activity) via the regulation of Foxo1, which is mediated by Akt(112). Our data show that Rictor-deficiency solely in B cells leads to a significant decrease in B cells with an increase in pre-proB cells alluding to a potent role of mTORC2 in B cell maturation. However, as cre excision is not as efficient in CD19 models (206), a more potent Rictor KO in B cells in the BM, such as the Mb1-cre models, may have shown deregulated mTORC1 and Foxo1 activity (via upstream mTORC2 activity).
Given that B cell development is blocked with mTORC1 deficiency, it was not surprising to see aberrations in late B cell populations. Significant reductions in T2 B cells with reductions in MZP, MZ and fol2 populations in the spleen of Mx1-Raptor cKO mice with similar reductions in T2, fol1 and fol2 B cell subsets in CD19-cre<sup>*</sup>-Raptor KO mice. Interestingly, Rictor-deficiency was also associated with a decrease in T1 and T3 B cells and reductions in MZP, MZ and fol1 B cells. These results were in agreement with previous literature determining the function of late B cell populations. T1 cells transition into T2 cells leading to subsequent fol2 B cells. Fol2 B cells are more primitive, quiescent and less abundant compared to fol1 cells, which form the majority of the recirculating pool. MZP B cells arise from fol2 cells leading to MZ B cells. Fol2 cells also generate fol1 cells (44). Therefore, it is appropriate to observe a significant decrease in T2 and the primitive fol2 cells and a concomitant decrease in MZP and MZ cells in Mx1-Raptor mice due to the fundamental role of mTORC1 in B cell development as discussed previously. Rictor-deficiency is associated with disruption in migration and cell cycling, which explains the observed reduction in T1, T3 cells which give rise to the recirculating fol1 B cell population. There were no significant changes observed in fol2 B cells suggesting that mTORC2 plays a role in the ability of fol2 B cells to further develop into fol1, MZP and MZ cells. Lee et al., demonstrate a block in late B cell populations in mice with Rictor-deficiency at the HSC stage with similar results in adult mice via a decrease in T3 B cells and an increase in T1/T2 ratio together with a decrease in MZ cells. They also observe a modest decrease in follicular cells (111), however they did not distinguish between fol1 and fol2 cells. All these data support our results thereby confirming a role for mTORC2 in late B cell development. Although, there is a decrease in MZ population in Vav-Rictor KO mice, there is a trend in increase in MZ and MZP populations when Rictor-deficiency is induced in adult mice (Mx1-Rictor cKO) seen from H&E staining and from phenotypic analysis by flow cytometry. This suggests an accumulation of MZ cells with induced Rictor-deficiency in adult mice, as there is a decline in fol2 cells.

4.3.5.2 Other haemopoietic lineages

A significant reduction in the mature myeloid (CD11b<sup>+</sup>Gr1<sup>+</sup>) population was observed in the BM and blood but an increase in percentage of mature myeloid cells in the secondary lymphoid organs: spleen and LN, in Mx1-Raptor cKO mice.
As lymphopoiesis takes place in the BM, it is possible that there was an accumulation of CD11b⁺ myeloid cells (as seen in the BM) blocking the maturation into CD11b⁺Gr1⁺ myeloid cells with Raptor-deficiency in adult mice. Therefore, there was an increase in the remaining CD11b⁺Gr1⁺ myeloid cells in the secondary lymphoid organs. Additionally, secondary lymphoid organs would have a reduced population of B and T cells thereby increasing the percentage of myeloid cells. It would be interesting to analyse this population at later timepoint (6 months) post poly(I:C) inoculation and to determine whether there is a decrease in mature myeloid population with induced Raptor-deficiency in adult mice. Indeed, mTOR-deficiency leads to a block in myeloid development in vivo and in vitro via the reduction of M-CSF(102) receptor CD115 and the overactivation of STAT5 leading to the downregulation of IRF8(101). Rictor KO in myeloid cells has been shown to result in a bias towards an M1, and not M2, population and increased their sensitivity to apoptotic stimuli(304) and promoted pro-inflammatory M1 genes in response to TLR ligands in a FOXO1/3 dependent manner(106), suggesting a role of mTORC2 in myeloid viability and inflammatory responses. Our data was not focussed on the role of mTORC2 in myeloid lineages. However, assessing the viability of this lineage in the three different models would give us a better insight on the cycling and underlying mechanisms behind this characteristic caused due to mTORC2 abrogation.

Raptor-deficiency also affected NK cell populations and T cell lineages. The earliest thymocytes within the thymus lacking CD4 and CD8 expression and are termed as double negative (DN) thymocytes. About 95% of DN cells give rise to αβ-T cells via successful rearrangement of αβ-TCR via a process known as beta-selection. It is during this proliferative period of selection that T cells either die of apoptosis or express both CD4 and CD8 to become DP. These cells subsequently down-regulate a co-receptor to fully differentiate into either CD4⁺ or CD8⁺ T cells(305). We demonstrate a decrease in CD4⁺CD8⁺ DP thymocytes with a concomitant increase in CD8⁺ and CD4⁺CD8⁻ DN thymocytes with Raptor-deficiency. Although reduced, there is a generation of DP T cells suggesting a role of mTORC1 in the proliferation of naïve cells, which is consistent with previously published data(306). In agreement with our data, rapamycin (mTORC1 inhibitor) treatment of mice with lymphocytic choriomeningitis virus (LCMV) has shown to increase the quantity and quality of CD8+ T cells(306) demonstrating a
role of mTORC1 in the proliferation with redundant roles in T cell development. Nevertheless, there remain discrepancies in the field as Pollizzi et al., have shown a potent role of mTORC1 in effector cells as RHEB mediated deletion of mTORC1 in CD8+ T cells did not differentiate into effector cells, but retained ability to differentiate into memory T cells, but were dysfunctional due to metabolic defects(120). **Rictor**-deficiency in the Vav- and Mx1-cre mouse models strongly affected T cell development with a decrease in CD4+CD8+ DP T cells together with an increase in the CD4+CD8+ DN T cell populations with a modest increase in NK cell population in the spleen of adult mice with **Rictor**-deficiency. mTORC2 has been shown to regulate T cell development as Mx1-**Rictor** cKO partially blocks T cell development at the DN3 (CD3+CD44+CD25+) stage(115) and involves NFκB and FOXO1 pathways(116). Mice with mTOR-deficiency exhibit a block in Th1, Th2, and Th17 cells due to abrogation in the STAT signalling and differentiate towards T-regulatory (T-reg) cells which is independent of mTORC1 suggesting an important role of mTORC2 in T-reg development(307). Additionally, **Rictor** deficiency in T cells causes a block in Th1 and Th2 CD4+ T cell development which is rescued by AKT (via increased expression of Tbet TF) and PKC-θ (via reverting Gata3 expression)(123). Conditional deletion of **Rictor** in CD8+ T cells demonstrates an increased ability of CD8+ T cells to commit to memory precursor effector cells (MPECs) together with more potent recall responses and CD8+ T cells also exhibited a reduction in short-lived effector cell (SLECs) commitment in a Foxo1 dependent manner(125) suggesting mTORC2 regulates effector cell commitment. These published papers suggest a vital role of mTORC2 in T cell development. As the CD19-cre model should only effect CD19+ B cells, is was reassuring to see the majority of effects on B cells with **Raptor** and **Rictor**-deficiency. Nevertheless, there were slight increases in NK and myeloid lineages in the spleen and blood of transgenic mice lacking **Raptor** and **Rictor**, which could be attributed to the significant decrease in B cell lineage in these mice.

Taken together, upon successful deletion of **Raptor** and **Rictor**, our data show an important role of mTORC1 predominantly in B and T cell development. mTORC1 inactivation blocks B cell development at the LSK or the pre-proB cell stage (depending on the individual models used). Additionally, we demonstrate that mTORC2 is not vital for early B cell development but plays a role in late B cells.
by blocking fol2 development into MZ and fol1 cells. mTORC2 also plays an important role in T cell development. Therefore, we demonstrate that although there is a cross-talk between both the complexes, mTORC1 and mTORC2 have unique roles during haemopoiesis.
4.4 Figures

**Figure 4.1**: Optimization of the Mx1-cre Raptor cKO model.
Mx1-cre<sup>-</sup> (cre-, Mx1-Raptor control) and Mx1-cre<sup>+</sup>Raptor<sup>cre/+</sup> (cre+, Mx1-Raptor cKO) mice were inoculated with either 3 or 5 doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=4) or 10 (n=3) wk or 5 wk post inoculations respectively. Spleen weight (mg) (A) and cellularity (log<sub>10</sub>) (B) of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and assessed at either 3, 5, 8 or 10 wk post inoculation. BM (C), LN (D), and thymus (E) cellularity (log<sub>10</sub>) of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and assessed at either 3, 5, 8 or 10 wk post inoculation. Spleen weight (mg) (F) and cellularity (log<sub>10</sub>) of BM, spleen, thymus and LN (G) of Mx1-Raptor control (n=3) and Mx1-Raptor cKO (n=3) mice inoculated with 5 poly(I:C) doses and assessed 5 wk post inoculation. Data are expressed as mean±SEM (p<sub>**</sub>≤0.01, p<sub>***</sub>≤0.001).
Figure 4.2: Optimization of the Mx1-cre Raptor cKO model assessing stem and early B cell progenitors in vivo.

Mx1-Raptor control (cre-) and Mx1-Raptor cKO (cre+) mice were inoculated with either 3 or 5 doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=2) or 10 (n=3) wk or 5 wk post inoculation respectively. Bar graphs demonstrating the percentage (A) and cellularity (log_{10}) (B) of LSK (lin-sca-1^+CD117^+) cells in the BM along with percentage (C) and cellularity (log_{10}) (D) of pre-proB cells (lin-B220^-CD19^+) in the BM and spleen of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and assessed at either 3, 5, 8 or 10 wk post inoculation. Percentage (E) and cellularity (log_{10}) (F) of LSK cells in the BM (n=3) along with percentage (G) and cellularity (log_{10}) (H) of pre-proB cells in the BM (n=1) and spleen of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 5 poly(I:C) doses and assessed 5 wk post inoculation. Data are expressed as mean±SEM (p ≤0.05, p ≤0.001, p ≤0.0001, p ≤0.00001).
Figure 4.3: Optimization of the *Mx1*-cre *Raptor* cKO model assessing B cell lineages *in vivo*. *Mx1*-Raptor control (cre-) and *Mx1*-Raptor cKO (cre+) mice were inoculated with either 3 or 5 doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=2) or 10 (n=3) wk or 5 wk (n=3) post inoculation respectively. Percentage of B cell lineage (CD19+CD11b-) in the BM, spleen, thymus, LN and blood of *Mx1*-Raptor control and *Mx1*-Raptor cKO mice inoculated with 3 doses of poly(I:C) and analyzed at either 3, 5, 8 or 10 wk post inoculation (A) or with 5 doses of poly(I:C) and assessed 5 wk post inoculation (B). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 4.4: Optimization of the Mx1-cre Raptor cKO model assessing late B cell lineages in vivo.

Mx1-Raptor control (cre-) and Mx1-Raptor cKO (cre+) mice were inoculated with either 3 doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=2) or 10 (n=3) wk post inoculation or with 5 doses (n=3) of poly(I:C) and assessed 5 wk post inoculation. Bar graphs demonstrating the percentage of T1 (CD19+CD23-IgM-IgD-IgM-AA4.1+), T2 (CD19+CD23+CD21 CD1d+IgD+IgM-AA4.1+), T3 (CD19+CD23+CD21 CD1d+IgD+IgM AA4.1+) and MZP (CD19+CD23+CD21 CD1d+) and MZ (CD19+CD23+IgM+CD21+) B cells (A), and percentage of fol1 (CD19+CD23+CD21 CD1d+IgD+IgM-AA4.1+) and fol2 (CD19+CD23+CD21 CD1d+IgD+IgM-AA4.1+) B cells (B) in the spleen of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and assessed at either 3, 5, 8 or 10 wk post inoculation. Percentage of T1, T2, T3, and MZP B cells (C), and percentage of MZ, fol1 and fol2 B cells (D) in the spleen of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 5 doses of poly(I:C) and assessed 5 wk post inoculation. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001). T – transitional 1 B cells, MZP – marginal zone B cells, fol – follicular B cells.
Figure 4.5: Control experiment showing no difference between WT mice and mice expressing cre on alleles.

Comparison of spleen weight (mg) (A) and total organ counts (BM, spleen, and thymus) in logarithmic axis (B) between wild type (Wt) (n=8) mice and cre (n=9, Mx1-Raptor control) mice assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculation. Bar graphs demonstrating the percentage (C) and cellularity (log$_{10}$) (D) of B cells in the BM, spleen, and thymus of Wt (n=8) and cre (n=6) mice assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculation. Percentage (E) and cellularity (log$_{10}$) (F) of CD4$^+$CD8$^+$ DP and CD4$^+$CD8$^-$ DN T cells in the thymus of wild type (Wt) and cre mice assessed 5 wk post 4 poly(I:C) inoculation. Percentage (G) and cellularity (log$_{10}$) (H) of CD11b$^+$Gr1$^+$ mature myeloid cells in the BM, spleen and thymus of wild type (Wt) (n=8) and cre (n=6) mice assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculation. Data are expressed as mean±SEM.
Figure 4.6: Characterization of lymphoid organs in Raptor KO models.
A. Spleen weights (mg) of Mx1-Raptor control (cre-) or Mx1-Raptor cKO (cre+) mice inoculated with 3 (n=5), 4 (n=6) or 5 (n=3) doses of 10 mg/kg poly(I:C) were assessed 5 wk post-inoculation to induce the cKO. B. Total organ counts (log_{10}; BM, spleen, thymus and LN) of Mx1-Raptor control or Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation. C. Histology slides showing haematoxylin and eosin (H&E) staining (top row) and Ki67 staining (bottom row) of spleen section of Mx1-Raptor control or Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation. Spleen weights (D) and organ cellularity (log_{10}) (E) of CD19-cre- Raptor^fl/fl^ (cre-, CD19-Raptor control, n=5), CD19-cre+ Raptor^fl/fl^ (cre+, CD19-cre+ Raptor KO, n=7) or CD19-cre++ Raptor^fl/fl^ (cre++, CD19-cre++ Raptor KO, n=6) mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). GC – germinal centre, MZ – marginal zone.
Figure 4.7: Confirmation of Raptor cKO at the protein, gene and at the substrate level for mTOR pathway members in Mx1-Raptor cKO mice.
Representative western blot showing protein expression of RAPTOR and RICTOR, and downstream mTOR proteins: t4EBP1, pS6\textsuperscript{S235/S236}, tS6, pAKT\textsuperscript{S473}, tAKT and loading controls βACTIN and GAPDH in the BM, spleen, thymus and liver from Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation (A). Densitometry of protein expression of RAPTOR/tAKT (n=5 Mx1-Raptor control, n=7 Mx1-Raptor cKO) (B) and RICTOR/tAKT (n=4) in the spleen and thymus Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation (C). MFI ratios of p4EBP1\textsuperscript{T37/T46}/isotype control (n=3) (D) and pAKT\textsuperscript{S473}/isotype control (n=5) (E) in the BM, spleen and thymus of Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation. Gene expression of Raptor (F) and Rictor (G) in the BM (n=4), spleen (n=5) and liver (n=4) of Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation. Data is shown relative to Mx1-Raptor controls with Tbp as the reference gene. Data are expressed as mean±SEM (p ≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.8: Gating strategy of haemopoietic lineages in Mx1-cre and CD19-cre Raptor mouse models.

Representative flow cytometry plots demonstrating the proportion of B cells (CD19<sup>+</sup>CD11b<sup>-</sup>) in the BM, CD4<sup>+</sup> (CD19<sup>-</sup>CD4<sup>+</sup>CD8<sup>-</sup>), CD8<sup>+</sup> (CD19<sup>-</sup>CD8<sup>+</sup>CD4<sup>-</sup>), CD4<sup>-</sup>CD8<sup>+</sup> (CD19<sup>-</sup>CD4<sup>-</sup>CD8<sup>+</sup>) T cells in the thymus, mature myeloid cells (CD19<sup>-</sup>CD11b<sup>+</sup>Gr1<sup>+</sup>) in the BM, and NK cells (CD19<sup>-</sup>CD4<sup>-</sup>NK1.1<sup>+</sup>) in the spleen in Mx1-Raptor control (A) Mx1-Raptor cKO 5 wk post 4 poly(I:C) inoculation (B), CD19-Raptor control (C) CD19-cre<sup>+</sup> Raptor KO (D), and CD19-cre<sup>+</sup> Raptor KO (E) mice. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. RCN – relative cell number.
Figure 4.9: Raptor cKO in adult mice leads to significant aberrations in haemopoietic lineages in vivo.

Bar graphs showing the percentage of B cells (A), CD11b+Gr1+ mature myeloid cells (C), NK cells (E) in the BM, spleen, LN, thymus and blood and cellularity of B cells (B), CD11b+Gr1+ mature myeloid cells (D), NK cells (F) in the BM, spleen, LN and thymus of Mx1-Raptor control (n=6) and Mx1-Raptor cKO (n=3) mice 5 wk post 4 poly(I:C) inoculation. Percentage (G) and cellularity (H) of CD4+CD8+ DP and CD4+CD8- DN thymocytes in the thymus of Mx1-Raptor control (n=6) and Mx1-Raptor cKO (n=3) mice 5 wk post 4 poly(I:C) inoculation. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 4.10: Raptor-deficiency in B cells leads to a decline in B cell lineage in vivo.
Bar graphs showing the percentage of CD19+ B cells (A), CD11b+Gr1+ mature myeloid cells (C), NK cells (E) in the BM, spleen, LN, thymus and blood and cellularity of CD19+ B cells (B), CD11b+Gr1+ mature myeloid cells (D), NK cells (F) in the BM, spleen, LN and thymus of CD19-Raptor control, CD19-cre+/Raptor KO, and CD19-cre+/Raptor KO mice. Percentage (G) and cellularity (H) of CD4+CD8+ and CD4+CD8- T cells in the thymus in CD19-Raptor control (n=5), CD19-cre+/Raptor KO (n=7), and CD19-cre+/Raptor KO (n=6) mice. Data are expressed as mean±SEM (p ≤0.05, p ≤0.001, p ≤0.0001, p ≤0.00001).
Figure 4.11: Gating strategy of late B cell lineages in Mx1-cre and CD19-cre Raptor models. Representative flow cytometry plots showing the proportion of late B cells comprising transitional 1 (T1) cells (CD19+CD21intCD23IgMhi); T2 (CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMhi); T3 (CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMlo); marginal zone precursor (MZP): (CD19+CD21hiCD23+CD1dhi); marginal zone (MZ) (CD19+CD21hiCD23IgMhi); Fol1 (CD19+AA4.1+CD21loCD23+CD1dintIgDhiIgMlo) Fol2 (CD19+AA4.1+CD21loCD23+CD1dintIgDhiIgMhi) in the spleen in Mx1-Raptor control (A), Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (B), CD19-Raptor control (C) and CD19-cre/+ Raptor KO (D) mice. Plots are live and size (FSC-A/SSC-A) gated. RCN – relative cell number.
Figure 4.12: Raptor-deficiency in adult mice leads to aberrations in late B cells in vivo. Bar graphs showing the percentage (A) and cellularity (log_{10}) (B) of T1, T2 and T3 B cells, and percentage (C) and cellularity (log_{10}) (D) of MZP, MZ, Fol1, and Fol2 cells in the spleen in Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation. Percentage (E) and cellularity (log_{10}) (F) of T1, T2 and T3 B cells, along with percentage (G) and cellularity (log_{10}) (H) of MZP, MZ, Fol1, and Fol2 cells in the LN of Mx1-Raptor control (n=6) and Mx1-Raptor cKO (n=3) mice 5 wk post 4 poly(I:C) inoculation. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001).
Figure 4.13: Raptor-deficiency in B cells leads to aberrations in late B cells in vivo.
Bar graphs showing the percentage (A) and cellularity (log_{10}) (B) of T1, T2 and T3 B cells, and percentage (C) and cellularity (log_{10}) (D) of MZP, MZ, Fol1, and Fol2 cells in the spleen of CD19-Raptor control and CD19-cre^{+/-}Raptor KO mice. Percentage (E) and cellularity (log_{10}) (F) of T1, T2 and T3 B cells, and percentage (G) and cellularity (log_{10}) (H) of MZP, MZ, Fol1, and Fol2 cells in the LN in CD19-Raptor control (n=5) and CD19-cre^{+/-}Raptor KO (n=7) mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 4.14: Gating strategy for determining live, early apoptosing and apoptotic cells in Mx1-cre and CD19-cre Raptor models.
Representative flow cytometry plots showing B cells (CD19+), and the proportion of live B cells (CD19+AnnV−7AAD−), early apoptosing B cells (CD19+AnnV−7AAD+) and apoptotic B cells (CD19+AnnV−7AAD+) in BM of Mx1-Raptor control (A) Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (B), CD19-Raptor control (C) CD19-cre−/−Raptor KO (D) mice. Plots are live and size (FSC-A/SSC-A) gated as shown. RCN – Relative cell number.
Figure 4.15: Raptor-deficiency in adult mice leads to increased apoptosis in B cells in vivo.

Bar graphs demonstrate the percentage (A) and cellularity (log_{10}) (B) of CD19⁺ B cells (n=4) along with the percentage (C) and cellularity (log_{10}) (D) of all haemopoietic lineages which are live (AnnV⁻7AAD⁻), early apoptotic (AnnV⁺7AAD⁻), necrotic (AnnV⁺7AAD⁺) or apoptotic cells (Apop; AnnV⁺7AAD⁺) in BM of Mx1-Raptor control (n=6) and Mx1-Raptor cKO (n=3) mice assessed 5 wk post 4 poly(I:C) inoculation. Percentage (E) and cellularity (log_{10}) (F) of CD19⁺ B cells along with the percentage (G) and cellularity (log_{10}) (H) of all haemopoietic cells which are live (AnnV⁻7AAD⁻), early apoptotic (AnnV⁺7AAD⁻), necrotic (AnnV⁺7AAD⁺) or dead by apoptosis (AnnV⁺7AAD⁺) in BM of CD19-Raptor control (n=5) and CD19-cre⁻⁻⁻-Raptor KO (n=7) mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.16: Optimization of the Vav-cre Rictor KO model.

Vav-cre (cre-, Vav-Rictor control) and Vav-cre^{Rictor^{+/-}} (cre+, Vav-Rictor KO) mice were analyzed after 2 (n=3), 8 (n=3), or 24 (n=5) wk to assess the KO at different time points. A. Picture showing differences in spleen size of Vav-Rictor control (left) and Vav-Rictor KO (right) mice 8 wk of age. Spleen weight (mg) (B) and organ cellularity (log_{10}) of BM, spleen, thymus and LN (C) of Vav-Rictor control and Vav-Rictor KO mice assessed after 2, 8, or 24 wk. B cell percentage in the BM, spleen LN and blood (D) and B cell lineage cellularity (log_{10}) in the BM, spleen, thymus and LN (E) of Vav-Rictor control and Vav-Rictor KO mice assessed after 2, 8, or 24 wk. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.17: Optimization of the Vav-cre Rictor KO model age for phenotypic analysis of haemopoietic lineages.

Vav-Rictor control (cre-) and Vav-Rictor KO (cre+) mice were analyzed after 2 (n=3), 8 (n=3), or 24 (n=5) wk to assess the KO at different time-points. Percentage (A) and cellularity (log_{10} (B)) of CD4^+CD8^+ DP and CD4^+CD8^- DN thymocytes in the thymus of Vav-Rictor control and Vav-Rictor KO mice analyzed at 2, 8, or 24 wk of age. Percentage (C) and cellularity (log_{10} (D)) of CD11b^+Gr1^+ mature myeloid cells in the BM, spleen, blood and LN as indicated of Vav-Rictor control and Vav-Rictor KO mice analyzed aged 2, 8, or 24 wk. Percentage (E) and cellularity (log_{10} (F)) of NK cells in the BM, spleen and blood as indicated of Vav-Rictor control and Vav-Rictor KO mice analyzed aged 2, 8, or 24 wk. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.18: Characterization of Rictor KO models.

Spleen weight (mg) (A) and total organ counts (log10) (BM, spleen, thymus and LN) (B) of Vav-Rictor control and Vav-Rictor KO mice at 8 wk (n=3); Mx1-Rictor control and Mx1-Rictor KO mice assessed 5 wk post 4 poly(I:C) inoculation (n=5); and CD19-Rictor control and CD19-Rictor KO mice (n=6) ≥18 wk of age. Histology slides showing H&E staining (top row), Ki67 staining (middle row), and pS6\textsuperscript{S235/S236} (bottom row) in spleens of Vav-Rictor control and Vav-Rictor KO mice at 8 wk of age (C) and of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (D). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.19: Confirming Rictor cKO by assessing protein and gene expression of mTOR pathway members.

Representative western blot showing protein expression of mTOR pathway proteins: RICTOR, RAPTOR, pAKT\textsuperscript{S473}, tAKT, pS6\textsuperscript{S235/S236}, tS6, βACTIN and GAPDH in the BM, spleen, thymus and liver of Vav-Rictor control and Vav-Rictor KO mice 8 wk of age (A) and of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (B). Densitometry showing protein expression (log fold change) of RICTOR/βACTIN in the spleen and thymus (C), RAPTOR/βACTIN in the spleen, thymus and liver (D), and of pAKT\textsuperscript{S473}/tAKT in the BM, spleen, thymus (E) of Vav-Rictor control and Vav-Rictor KO mice 8 wk of age (n=3), and densitometry showing protein expression (log fold change) of RICTOR/βACTIN in the spleen (n=5), thymus (n=3) and liver (n=4) (F), of RAPTOR/βACTIN in the spleen (n=5), thymus (n=3) and liver (n=4) (G), and of pAKT\textsuperscript{S473}/tAKT in the BM (n=4), spleen (n=5), thymus (n=2) (H) of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation. Gene expression (log fold change) of Rictor (I) and Raptor (J) in the BM, spleen and thymus of Vav-Rictor control and Vav-Rictor KO mice 8 wk (n=3) of age, along with gene expression (log fold change) of Rictor (K) and Raptor (L) in the BM (n=8), spleen (n=6) and liver (n=5) of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.20: Gating strategy of haemopoietic lineages in Vav-cre and Mx1-cre Rictor models. Representative flow cytometry plots demonstrating the proportion of B cells (CD19+CD11b−) in the spleen, CD4+ (CD19−CD11b−), CD8+ (CD19−CD11b−CD4+), CD4+CD8+ (CD19−CD11b−CD4+CD8+) T cells in the thymus, mature myeloid cells (CD19−CD11b+Gr1+) in the BM, and NK cells (CD19−CD4−NK1.1+) in the spleen in Vav-Rictor control (A) Vav-Rictor KO aged 8 wk (B), Mx1-Rictor control (C), and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (D). Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. RCN – relative cell number.
Figure 4.21: Rictor-deficiency leads to B and T cell aberrations in vivo.
Bar graphs showing the percentage of B cells in the BM, spleen, LN, and blood of Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=3) (A), Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (B), and CD19-Rictor control and CD19-Rictor KO mice (n=6) (C). Percentage of CD4^+CD8^- DP and CD4^+CD8^- DN T cells in the thymus of Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=3) (D), Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (E), and CD19-Rictor control and CD19-Rictor KO mice (n=6) (F). Percentage of CD11b^-Gr1^- mature myeloid cells in the BM, spleen and blood of Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=3) (G), Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (H), and CD19-Rictor control and CD19-Rictor KO mice (n=6) (I). Percentage of NK cells in the BM, spleen and blood of Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=3) (J), Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (K), and CD19-Rictor control and CD19-Rictor KO mice (n=6) (L). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 4.22: Gating strategy for determination of cell viability in Vav-cre and Mx1-cre Rictor models.

Representative flow cytometry plots showing the proportion of live (AnnV+7AAD−), early apoptosing (AnnV−7AAD−) and apoptotic (AnnV−7AAD+) cells in BM of Vav-Rictor control (A) Vav-Rictor KO mice aged 8 wk (B), Mx1-Rictor control (C) and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (D). Plots are live and size (FSC-A/SSC-A) gated as shown.
Figure 4.23: *Rictor-deficiency does not cause apoptosis in vivo.*
Bar graphs showing the percentage of CD19⁺ B cells in the BM (A) and spleen (B), and percentage of all cells in the BM (C) and spleen (D) which are live, early apoptotic (AnnV⁺), necrotic (7AAD⁺) or dead by apoptosis (Apop) in BM of Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=5). Percentage of CD19⁺ B cells in the BM (E) and spleen (F), and percentage of all cells in the BM (G) and spleen (H) which are live, early apoptotic (AnnV⁺), necrotic (7AAD⁺) or dead by apoptosis in BM of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=5). Bar graphs demonstrating the percentage of CD19⁺ B cells in the BM (I) and spleen (J) which are live, early apoptotic (AnnV⁺), necrotic (7AAD⁺) or dead by apoptosis in BM of CD19-Rictor control and CD19-Rictor KO mice (n=6). Data are expressed as mean±SEM (p *≤0.05).
Figure 4.24: Gating strategy of early B cell lineages in Vav-cre and Mx1-cre Rictor models. Representative flow cytometry plots showing the proportion of proB cells (Lineage B220+CD19+), pre-proB cells (Lineage B220+CD19), LSK cells (Lineage B220 CD19 Sca-1hiCD117hi), and sca-1loCD117hi (Lineage B220 CD19 Sca-1loCD117hi) cells in the BM of Vav-Rictor control (A) and Vav-Rictor KO mice of 8 wk (B), Mx1-Rictor control (C) and Mx1-Rictor cKO 5 wk post 4 poly(I:C) inoculation (D). Lineage peak is shown in red and lineage negative subset was gated based on the unstained population (blue peak). Plots are live and size (FSC-A/SSC-A) gated as shown. RCN – relative cell number.
Figure 4.25: Gating strategy of late B cell lineages in Vav-cre and Mx1-cre Rictor models. Representative flow cytometry plots demonstrating the proportion of late B cells which comprise transitional 1 (T1) cells (CD19-CD21\textsuperscript{int}CD23\textsuperscript{int}IgM\textsuperscript{hi}); T2 (CD19\textsuperscript{-}AA4.1\textsuperscript{+}CD21\textsuperscript{int}CD23\textsuperscript{-}CD1d\textsuperscript{int}IgD\textsuperscript{hi}IgM\textsuperscript{hi}); T3 (CD19\textsuperscript{-}AA4.1\textsuperscript{+}CD21\textsuperscript{int}CD23\textsuperscript{-}CD1d\textsuperscript{-}IgD\textsuperscript{hi}IgM\textsuperscript{lo}); marginal zone precursor (MZP): (CD19\textsuperscript{-}CD21\textsuperscript{hi}CD23-CD1d\textsuperscript{-}); marginal zone (MZ) (CD19\textsuperscript{-}CD21\textsuperscript{hi}CD23\textsuperscript{-}IgM\textsuperscript{hi}); Foli1 (CD19\textsuperscript{-}AA4.1\textsuperscript{+}CD21\textsuperscript{lo}CD23\textsuperscript{-}CD1d\textsuperscript{-}IgD\textsuperscript{hi}IgM\textsuperscript{lo}) Foli2 (CD19\textsuperscript{-}AA4.1\textsuperscript{+}CD21\textsuperscript{lo}CD23\textsuperscript{-}CD1d\textsuperscript{-}IgD\textsuperscript{hi}IgM\textsuperscript{lo}) in the spleen of Vav-Rictor control (A) and Vav-Rictor KO mice of 8 wks (B), Mx1-Rictor control (C) and Mx1-Rictor cKO 5 wks post 4 poly(I:C) inoculation (D). Plots are live and size (FSC-A/SSC-A) gated as shown.
Figure 4.26: *Rictor*-deficiency at the HSC stage, in adult mice, and in B cells leads to aberrations in late B cells *in vivo.*

Bar graphs showing the percentage of LSK, pre-proB and proB cells in the BM of Vav-*Rictor* control and Vav-*Rictor* KO mice aged 8 wk (n=5) (A), Mx1-*Rictor* control and Mx1-*Rictor* cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (B), and CD19-*Rictor* control and CD19-*Rictor* KO mice (n=6) (C). Percentage of T1, T2 and T3 B cells in the spleen and LN of Vav-*Rictor* control and Vav-*Rictor* KO mice aged 8 wk (n=5) (D), Mx1-*Rictor* control and Mx1-*Rictor* cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (E), and CD19-*Rictor* control and CD19-*Rictor* KO mice (n=6) (F). Percentage of MZP, MZ, Fol1, and Fol2 cells in the spleen and LN of Vav-*Rictor* control and Vav-*Rictor* KO mice aged 8 wk (n=5) (G), Mx1-*Rictor* control and Mx1-*Rictor* cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (H), and CD19-*Rictor* control and CD19-*Rictor* KO mice (n=6) (I). Data are expressed as mean±SEM (p *≤*0.05, p **≤*0.001, p ***≤0.0001, p ****≤0.00001).
Chapter 5

Role of mTORC1 and mTORC2 in CLL
5 Role of mTORC1 and mTORC2 in CLL

5.1 Introduction

This chapter focuses on the role of mTORC1 and mTORC2 in leukaemia initiation and/or maintenance. As the Vav-cre<sup>\text{Raptor}\text{flo}flo</sup> model is lethal at the perinatal stage, we did not use this model. As such, two mTORC1 KO models - <sup>Mx1</sup>-cre<sup>Raptor\text{flo}flo</sup> (<sup>Mx1</sup>-Raptor) and <sup>CD19</sup>-cre<sup>Raptor\text{flo}flo</sup> (<sup>CD19</sup>-Raptor) were used. To assess the role of mTORC2 in leukaemia initiation/development, the <sup>CD19</sup>-cre<sup>Rictor\text{flo}flo</sup> (<sup>CD19</sup>-Rictor), Vav-cre<sup>Rictor\text{flo}flo</sup> (Vav-Rictor) and <sup>Mx1</sup>-cre<sup>Rictor\text{flo}flo</sup> (<sup>Mx1</sup>-Rictor) mice models were used. Our lab has previously generated a murine CLL-like disease by retrovirally transducing lymphocyte-progenitors obtained from FLs of wildtype mice with a GFP-tagged kinase dead PKCα (PKCαKR) (229). We utilised a similar technique to generate a murine CLL-like disease from the BM of Raptor and Rictor KO mouse models to assess the role of mTORC1 and mTORC2 respectively in CLL initiation and/or development <em>in vitro</em> and <em>in vivo</em>. 
5.2 Results

5.2.1 Ablation of mTORC1 blocks CLL initiation *in vitro*.

In order to assess the role of mTORC1 in CLL initiation/development *in vitro*, the *Mx1-Raptor* mouse model was used. To generate a CLL-like disease with *Raptor* cKO, mice were inoculated with either 3 or 4 rounds of poly(I:C) as indicated, and BM from either *Mx1-Raptor* control (cre<sup>−/−</sup>) or *Mx1-Raptor* cKO (cre<sup>+/−</sup>) mice was dissected. Purified CD117<sup>+</sup> lymphoid progenitors from the BM were then retrovirally transduced with either GFP<sup>+</sup>-MIEV (for generation into B cells as a control) or GFP<sup>+</sup>-PKCαKR, to induce a murine CLL-like disease, in both *Mx1-Raptor* control or *Mx1-Raptor* cKO models, upon co-culture with OP9 cells (229,231).

*Mx1-Raptor* cKO MIEV and PKCαKR co-cultures (derived from mice dissected 3 wk post 3 poly(I:C) inoculation) failed to generate a CD19<sup>+</sup>GFP<sup>+</sup> population compared to *Mx1-Raptor* controls over D7, 11, 14 and 18 *in vitro* (Figure 5.1). Data demonstrated the inability of the PKCαKR construct to rescue the B cell lineage commitment block caused by *Raptor*-deficiency. Additionally, BM derived from *Mx1-Raptor* cKO mice with 4 poly(I:C) inoculation and dissected 5 wk post treatment, and then retrovirally transduced with MIEV or PKCαKR constructs showed a significant decrease in cellularity of GFP<sup>+</sup>CD19<sup>+</sup> MIEV cells over D3 and D7, coupled with a decrease in percentage of GFP<sup>+</sup>CD19<sup>+</sup> cells at D7, 11, and 14 as compared to *Mx1-Raptor* control MIEV cells (Figure 5.1A,B, Figure 5.2A,C). Similarly, *Mx1-Raptor* cKO PKCαKR cells had a significant decrease in cellularity of GFP<sup>+</sup>CD19<sup>+</sup> cells at D3 and D11 with a significant decrease in the percentage of GFP<sup>+</sup>CD19<sup>+</sup> PKCαKR cells over all culture days compared to *Mx1-Raptor* control PKCαKR cells (Figure 5.1C,D, Figure 5.2B,D). A significant increase in the percentage of GFP<sup>+</sup>CD11b<sup>+</sup> population in *Mx1-Raptor* cKO MIEV cells at D14 and in *Mx1-Raptor* cKO PKCαKR cells at D11 and D14 was observed compared to *Mx1-Raptor* control MIEV and PKCαKR cells (Figure 5.2E,F). These data suggest a lack in B cell lineage commitment with *Raptor*-deficiency regardless of the viral construct. In addition, there is an increase in GFP<sup>+</sup>CD11b<sup>+</sup> population over time suggesting a block in B cell differentiation compared to *Mx1-Raptor* control cells and block in CLL-like development with *Raptor*-deficiency compared to controls.
To further assess the role of mTORC1 in CLL cells, the CD19-Raptor KO model was used as it specifically excises Raptor in B-cells, as described previously (Section 1.7.1.3). Unlike, Mx1-Raptor cKO PKCaKR cells, CD19-Raptor KO PKCaKR cells developed a CLL-like phenotype. CD19-Raptor control and KO MIEV and PKCaKR cells were cultured until D18 to mimic later stages of disease development, then cell proliferation, viability and migration assays were carried out. No changes were observed in MIEV cells derived from CD19-cre’ or CD19-cre’– Raptor mice, but there was an increase in the cell trace violet (CTV) ratios comparing to D0, which was significant in D1/D0 ratio of CD19-Raptor KO PKCaKR cells compared to CD19-Raptor control PKCaKR cells (Figure 5.3A-C). This suggests a decrease in proliferation in PKCaKR cells with Raptor-deficiency as compared to controls. CD19-Raptor KO PKCaKR cells displayed a significant decrease in the percentage of early (AnnV–) and late apoptosis (AnnV7AAD+) with a significant increase in percentage of live cells (AnnV7AAD–) compared to CD19-Raptor control PKCaKR cells (Figure 5.3D,E) suggesting Raptor-deficiency reduces apoptosis in CLL-like cells. To assess whether the CD19-Raptor KO PKCaKR cells migrate to the same extent as controls, a migration assay was performed where the cells were serum-starved for 2 hr and then allowed to migrate towards SDF-1 in transwell plates. There was a significant decrease in the cellularity and percentage of PKCaKR migrating cells in the absence of Raptor, with ~50% decrease in migration in CD19-Raptor KO PKCaKR cells compared to CD19-Raptor control PKCaKR cells (Figure 5.3F,G). Lastly, Raptor-deficient CLL-like cells displayed a trend in increase in G0/G1 phase with a decreasing trend in the G2 phase compared to CD19-Raptor control PKCaKR cells (Figure 5.3H), further suggesting a block in proliferation with Raptor-deficiency.

As inducing Raptor-deficiency in all haemopoietic populations (Mx1-Raptor cKO model) leads to a block in B cell lineage commitment and a lack in CLL-like disease initiation, we assessed the role of mTORC1 in CLL maintenance. Therefore, GFP+PKCaKR cells were generated from BM of Mx1-Raptor control and cKO mice in the absence of poly(I:C) inoculation. There was no significant difference between the percentage of GFP+CD19+ cells generated from Mx1-Raptor cKO MIEV compared to control and Mx1-Raptor cKO PKCaKR cells compared to their respective control (Figure 5.4A,B). Mx1-Raptor control and cKO (no poly(I:C)) PKCaKR cells were cultured in vitro until D10 to mimic disease...
development. To assess role of Raptor in disease maintenance, these cells were treated with 200 units (U) IFNβ for 24 hr, stimulating a TLR3 response and cre expression, to induce cKO in vitro. PCR analysis showed successful excision of Raptor in Mx1-Raptor cKO PKCaKR cells compared to controls (Figure 5.4C). Moreover, there was a decrease in the protein expression of RAPTOR in Mx1-Raptor cKO MIEV and PKCaKR cells compared to Mx1-Raptor controls with IFNβ treatment suggesting successful KO in vitro (Figure 5.4D,E). In addition, there were trends in decrease in pS6^{5235/5236} expression with no changes in RICTOR and pAKT^{S473} expression in Mx1-Raptor cKO PKCaKR cells treated with IFNβ compared to controls (Figure 5.4D,G,H) suggesting mTORC1 downstream targets were reduced upon Raptor excision with no effect on mTORC2 signalling.

To assess the effect of Raptor-deficiency in CLL maintenance in vitro, Mx1-Raptor cKO PKCaKR CLL-like cells treated with IFNβ were assessed for proliferation and cell cycling. There was a significant decrease in the cellularity, with a similar trend in the percentage, of GFP^CD19^ population in the cocultures of Mx1-Raptor cKO PKCaKR cells treated with 50U IFNβ for 3 days and 200U for 24 hr, compared to Mx1-Raptor controls (Figure 5.5A,B). As 200U IFNβ treatment for 24 hr was more robust compared to other treatment arms, 200U IFNβ treatment was carried out on all future experiments. Interestingly, there was also a significant decrease in the cellularity of GFP^CD19^ Mx1-Raptor cKO PKCaKR cells receiving no IFNβ treatment (pink bars) (Figure 5.5A) compared to untreated Mx1-Raptor control PKCaKR cells (light blue bars). While this effect was significant, it did not occur to the same extent as with higher IFNβ treatments. Indeed, a significant decrease in the GFP^CD19^ cellularity was observed in Mx1-Raptor cKO PKCaKR cells with IFNβ treatment compared to untreated cells, with no reductions in cell populations in Mx1-Raptor control PKCaKR cells with or without IFNβ treatment (Figure 5.5C). IFNβ treatment of Mx1-Raptor cKO PKCaKR cells slightly increased G_0 phase, with a decreasing trend in S/G_2 phase compared to the untreated Mx1-Raptor cKO PKCaKR cells and Mx1-Raptor control PKCaKR cells treated and untreated with IFNβ (Figure 5.5D). Moreover, there is a significant increase in the CTV MFI of D2 in IFNβ treated Mx1-Raptor cKO PKCaKR cells compared to treated controls suggesting a block in proliferation due to an increase in CTV MFI (Figure 5.5E,F). These data suggest a similar role for Raptor in disease maintenance as in disease initiation,
whereby there is a block in proliferation with induced \textit{Raptor}-deficiency after mimicking disease development \textit{in vitro}.

5.2.2 mTORC2 plays a role in CLL-like phenotype maintenance at later stages \textit{in vitro}.

To determine the role of mTORC2 in CLL initiation/development, the \textit{Vav-Rictor}, \textit{Mx1-Rictor} and \textit{CD19-Rictor} mouse models were used. BM was derived from \textit{Vav-}, \textit{Mx1-} (dissected 5 wk post 4 poly(I:C) inoculation), and \textit{CD19-Rictor} control or KO mice, and retrovirally transduced with either GFP$^+$-MIEV or GFP$^+$-PKCaKR constructs to induce a CLL-like phenotype. Unlike \textit{Raptor}-deficient cells, PKCaKR cells derived from all the \textit{Rictor} KO models developed a CLL-like phenotype \textit{in vitro}. There was little difference in the cellularity of GFP$^+$CD19$^+$ population earlier in the co-cultures, with a slight decrease in cellularity of GFP$^+$CD19$^+$ population at D28 in \textit{Vav-}, and \textit{CD19-Rictor} KO MIEV and PKCaKR cells compared to their respective controls (Figure 5.6A-C,E,F,H). There was a trend in increase in the cellularity of GFP$^+$CD19$^+$ population of \textit{Mx1-Rictor} cKO MIEV cells with decreasing trends in \textit{Mx1-Rictor} cKO PKCaKR cells at D21 (Figure 5.6D,G). These data suggest \textit{Rictor} is not fundamental for CLL-like disease initiation but may play a role in disease maintenance. Similarly, there was no difference in the percentage of GFP$^+$CD19$^+$ population, but a decreasing trend in the percentage of GFP$^+$CD19$^+$ population was observed at D21 and later days in \textit{Vav-}, \textit{Mx1-} and \textit{CD19- Rictor} KO MIEV and PKCaKR cells, compared to their respective controls (Figure 5.7A-F). This suggests there may be a role of \textit{Rictor} in CLL-like disease maintenance, similar to that played in late B cell maintenance (Chapter 4). Additionally, no changes were observed in GFP$^+$CD11b$^+$ population in \textit{Vav-}, \textit{Mx1-}, or \textit{CD19-Rictor} KO MIEV and PKCaKR cells compared to their respective controls suggesting mTORC2 does not play a role in B cell lineage commitment, further reiterating the redundant role of mTORC2 in CLL-like phenotype initiation \textit{in vitro} (Figure 5.7G-L).

As there was a decreasing trend in GFP$^+$CD19$^+$ cellularity and percentage in later stages of both MIEV and PKCaKR co-cultures with \textit{Rictor}-deficiency, \textit{Vav-} and \textit{Mx1-Rictor} cKO and control PKCaKR cells at D21 were further assessed. Successful KO, confirmed by a significant decrease in \textit{Rictor} expression, was associated with an increasing trend in \textit{Ccnd1} expression and no changes in
Cdkn1a and Cdkn1b in Vav-Rictor KO PKCaKR cells compared to Vav-Rictor control PKCaKR cells, with no changes in Ccnd1, Cdkn1a and Cdkn1b expression in Vav-Rictor KO MIEV cells compared to Vav-Rictor control MIEV cells (Figure 5.8A). A similar trend was seen in Mx1-Rictor cKO PKCaKR cells (4 poly(I:C) inoculation), with a strong trend in increase in Ccnd1, Cdkn1a and Cdkn1b expression in Vav-Rictor KO MIEV cells compared to Vav-Rictor control MIEV cells (Figure 5.8B) alluding to a potential role of mTORC2 in regulating cell cycling in CLL-maintenance in vitro. At the protein level, there was a significant decrease in Rictor expression with a slight decrease in pAKT5473 expression in Mx1-Rictor cKO PKCaKR cells compared to Mx1-Rictor control PKCaKR cells at D21 of culture (Figure 5.8C-E). This confirmed a lack of Rictor at the later co-culture stages mimicking CLL-disease, suggesting that the Mx1-Rictor cKO model is not ‘leaky’. To further assess the role of mTORC2 in CLL, migration, proliferation and cell cycle assays were carried out. An increasing trend in the cellularity and percentage of migrating cells towards SDF-1 was observed at D15 of Vav-Rictor KO PKCaKR cells (Figure 5.9A,B), which was significant at D21 of Vav-Rictor KO PKCaKR cells compared to controls (Figure 5.9C,D), alluding to a role at later stages of disease development. Nevertheless, there were no changes in the MFI ratios of CTV values in Vav-Rictor KO PKCaKR cells at D14 or at D21 compared to controls suggesting no changes in proliferation (Figure 5.9E,F). However, at both D14 and D21 of culture, there was an increasing trend in the percentage of Mx1-Rictor cKO (4 poly(I:C) inoculation) PKCaKR cells in S phase with a decreasing trend of cells in G0/G1 phase compared to Mx1-Rictor control PKCaKR cells (Figure 5.9G,H) suggesting a potential increase in cell cycling in PKCaKR cells with Rictor-deficiency.

5.2.3 mTORC1 affects CLL maintenance in vivo.

As mTORC1 plays a fundamental role in disease initiation and maintenance in vitro, the role of mTORC1 in disease maintenance was assessed in vivo. Immunocompromised NSG mice were transplanted with 5x10^5 Mx1-Raptor control or cKO (no poly(I:C) inoculation) PKCaKR cells co-cultured till D7-10. Upon disease development, classified as ≥ 10% GFP^+ CD19^+ CLL-like disease assessed by weekly tail bleeds, half the cohort of mice were inoculated with poly(I:C) to induce Raptor cKO in the CLL-like cells transplanted into NSG mice. Screening for CLL-like disease in weekly blood samples of NSG mice showed a drastic
reduction, from ≥89.3% in an untreated mouse and other two mice transplanted with \textit{Mx1-Raptor} control PKCaKR cells with or without poly(I:C) treatment to 3.45% in GFP‘CD19‘ CLL-like disease in a mouse transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells and poly(I:C) treated (Figure 5.10A-D). Although there were no changes in splenic weight (Figure 5.11A), there was a decreasing trend in splenic cellularity in mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells with poly(I:C) treatment compared to untreated and \textit{Mx1-Raptor} control with or without poly(I:C) treatment \textit{in vivo} (Figure 5.11B). There was also a decreasing trend in BM cellularity in mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells treated with poly(I:C) compared to mice treated with poly(I:C) and transplanted with \textit{Mx1-Raptor} control PKCaKR cells (Figure 5.11C). Weekly bloods taken from mice to assess disease progression after inducing \textit{Raptor}-deficiency showed a trend in increase in the percentage of GFP‘CD19‘ population in mice transplanted with \textit{Mx1-Raptor} control and cKO PKCaKR cells (no poly(I:C)) (Figure 5.11D). Interestingly, there was a delay in increase in the percentage of GFP‘CD19‘ cells in mice transplanted with \textit{Mx1-Raptor} control PKCaKR cells after treatment with poly(I:C) suggesting that poly(I:C) alters disease progression (Figure 5.11D). Mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells and then treated with poly(I:C) had a decreased percentage of disease load in the blood (GFP‘CD19‘ population) compared to the other arms (Figure 5.11E). Whilst assessing the organs, there was a significant decrease in GFP‘CD19‘ cellularity in the spleen, and a significant decrease in the percentage of GFP‘CD19‘ population in the BM and spleen of poly(I:C) treated mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells compared to those transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells (untreated) and \textit{Mx1-Raptor} control PKCaKR cells respectively (Figure 5.11F,G). No significant difference was noted between the percentage of survival in poly(I:C) treated or untreated mice transplanted with \textit{Mx1-Raptor} control PKCaKR cells (Figure 5.11H) suggesting poly(I:C) inoculation does not increase survival in mice with a CLL-like disease \textit{in vivo}. However, there was a significant increase in survival of poly(I:C) treated mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells compared to untreated mice transplanted with \textit{Mx1-Raptor} cKO or control PKCaKR cells (Figure 5.11I,J), which suggests that \textit{Raptor}-deficiency increases survival in mice with a CLL-like disease \textit{in vivo}. 
Interestingly, there was no significant difference in pAKT\textsuperscript{S473} phosphorylation, but a significant increase in RAPTOR expression, together with a strong trend in increase downstream targets p4EBP1\textsuperscript{T36/T47} expression in poly(I:C) treated mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells compared to \textit{Mx1-Raptor} control PKCaKR cells (Figure 5.12A-D). Additionally, there was a trend in increase in pS6\textsuperscript{S235/S236} expression with a significant decrease in the downstream expression of RICTOR (Figure 5.12E-F). These data suggest a possible re-population of a CLL-like disease clone with increased RAPTOR expression which escaped poly(I:C) dependent \textit{Raptor}-excision. It is important to note here that all the transplanted mice were sacrificed at disease end and not after a single time point, therefore most of the mice transplanted with \textit{Mx1-Raptor} cKO PKCaKR cells + poly(I:C) treated were sacrificed at a later time than the other arms due to a delay in disease (Figure 5.11I,J). We would have expected to see a decrease in RAPTOR if the mice would have been sacrificed at the same time point.

To further assess the role of mTORC1 in leukemogenesis, \textit{CD19-Raptor} control or KO BM cells were transduced with GFP\textsuperscript{+}-PKCaKR and transplanted into NSG mice between D7-10 of culture. There was a decreasing trend of GFP\textsuperscript{+} CD19\textsuperscript{+} CLL-like disease percentage in the bloods of NSG mice transplanted with \textit{CD19-Raptor} KO cells as compared to controls (Figure 5.13) suggesting a non-redundant role of \textit{Raptor} in CD19\textsuperscript{+} cells in disease progression. Although there were no changes in the spleen weight, BM and spleen organ cellularity, there was a clear delay in disease onset, observed by a delay in GFP\textsuperscript{+}CD19\textsuperscript{+} CLL-like cells in the bloods, along with a significant increase in survival of mice transplanted with \textit{CD19-Raptor} KO PKCaKR cells compared to controls (Figure 5.14A-D). As all mice were sacrificed at disease end, most of the mice transplanted with \textit{CD19-Raptor KO} PKCaKR cells survived longer than the controls allowing disease to accumulate eventually compromising the health of the mouse leading to end point. At end point, no change was observed in the cellularity of GFP\textsuperscript{+}CD19\textsuperscript{+} CLL-like cells in the BM and spleen, but there was a significant decrease in percentage of GFP\textsuperscript{+}CD19\textsuperscript{+} CLL-like cells in the BM with a similar trend in the LN of mice transplanted with \textit{CD19-Raptor KO} PKCaKR cells compared to controls (Figure 5.14E,F). Moreover, there were no changes in RAPTOR, pAKT\textsuperscript{S473}, and pS6\textsuperscript{S235/S236} expression in the spleens of mice transplanted with \textit{CD19-Raptor KO} PKCaKR cells compared to controls (Figure 5.14G-J), suggesting a re-population of \textit{Raptor}
in CD19⁺ cells thereby leading to an increase in GFP⁺CD19⁺ cell population in mice treated with CD19-Raptor KO PKCaKR cells over time.

5.2.4 Using mTOR inhibitors and current clinical drugs to combat CLL in vivo.

To compare the effect of mTOR inhibitors and current clinical drugs for CLL in mice transplanted with a CLL-like disease, CD117⁺ lymphocytes purified from BM of B6.SJL mice were retrovirally transduced with GFP⁺-PKCaKR to generate a CLL-like disease and 5x10⁵ cells were transplanted into NSG mice after D7-10 of co-culture. Once the mice had established disease (≥0.4% GFP⁺CD19⁺ CLL-like disease), the mice were treated with either vehicle control (captisol+0.5%methylcellulose), AZD2014 (dual mTOR complex inhibitor), ibrutinib (BTK inhibitor used in clinics), or a combination of AZD2014+ibrutinib (combo). AZD2014 and ibrutinib were administered at 15 mg/kg and 12 mg/kg by OG daily for 2 wk, after which mice were sacrificed and analyzed for disease. A drastic reduction in the percentage of GFP⁺CD19⁺ CLL-like cells was observed in the bloods, from 93.6% in mice treated with vehicle control to 3.68% and 5.92% in mice treated with AZD2014 and ibrutinib respectively (Figure 5.15A-C). Additionally, mice treated with the combo showed a greater decrease in GFP⁺CD19⁺ percentage, from 3.68% in AZD2014 treated mice and 5.92% in ibrutinib treated mice to 0.57% in mice treated with combination (Figure 5.15B-D). These data suggest that mice treated with a combination therapy have a greater reduction in disease load in the blood compared to single agents. There was a clear reduction in the spleen size and a significant reduction in spleen/body weight ratio and spleen cellularity, with no changes in BM cellularity in mice treated with either AZD2014, ibrutinib, or combination compared to vehicle control (Figure 5.16A-C). These findings suggest a reversal of splenomegaly observed in CLL with no changes in BM cellularity with single agents or combination therapy. There was a clear decrease in percentage of GFP⁺CD19⁺ CLL-like disease in mice in weekly tail bleeds post treatment with AZD2014, ibrutinib or combination compared to vehicle controls (Figure 5.16D). Moreover, a significant decrease in cellularity and percentage of the GFP⁺CD19⁺ CLL-like population in the BM, together with a significant decrease in the cellularity and a similar decreasing trend in the percentage of GFP⁺CD19⁺ cells in the spleen were observed in mice treated with AZD2014, ibrutinib or
combination compared to controls (Figure 5.16E-H). GFP∗CD19∗ CLL-like cells were assessed for the expression of CD5∗ marker, which is a subset of CLL cells associated with increased migration as described in the Calissano model (156). A significant decrease in the cellularity of GFP∗CD19∗CD5∗ CLL-like cells was observed in the BM and spleen of mice treated with single agents or with combination compared to controls (Figure 5.16I). These data suggest a potent role of the dual mTOR complex inhibitor, AZD2014, as a promising therapeutic compound for CLL as it has similar results as ibrutinib, a drug currently used as first-line therapy for CLL patients with TP53 mutation/17p deletion. However, combination of ibrutinib and AZD2014 did not have any additive effect with little evidence for synergy.

To assess the ability of mTOR inhibitors to treat advanced CLL-like disease, we performed secondary transplants, where 4x10⁵ cells from the spleen of mice carrying a CLL-like disease (≥95%) was transplanted into NSG or NRG host mice. Once disease was established (≥10% GFP∗CD19∗ CLL-like disease), mice were treated with either rapamycin (administered by ip injection at 4 mg/kg) or AZD2014 (administered by OG at 15 mg/kg) once daily for 3 wk and disease progression was assessed. A reduction in the percentage of GFP∗CD19∗ CLL-like cells in the bloods of mice treated with AZD2014 and rapamycin was seen, from 90.1% to 77.9% and 0.69% respectively compared to vehicle control (Figure 5.17A-C). There was a clear reduction in the spleen size and a strong decreasing trend in spleen/body weight ratio, with no changes in BM and splenic cellularity in mice treated with rapamycin. These findings are coupled with no change in the spleen size and weight, or BM or spleen cellularity in mice treated with AZD2014 compared to vehicle controls, suggesting rapamycin is more potent at decreasing disease load in mice that have undergone secondary transplants (Figure 5.18A-C). In addition, there was a clear decrease in percentage of GFP∗CD19∗ CLL-like disease in the blood post rapamycin treatment, but not with AZD2014 compared to vehicle controls (Figure 5.18D). Moreover, there was a significant decrease in the percentage of GFP∗CD19∗ CLL-like cells in the BM and blood with a similar trend in the spleen and LN, and a decreasing trend in cellularity of GFP∗CD19∗ CLL-like cells in the BM and spleen in mice treated with rapamycin compared to AZD2014 or controls (Figure 5.18E-G). These data indicate a potential decrease in disease load with rapamycin and not with
AZD2014. As expected, no changes in RAPTOR and RICTOR expression was noted in spleens of mice treated with AZD2014 or rapamycin, despite the more potent effect of rapamycin in decreasing disease load, as this was not a KO model (Figure 5.19A-C). No significant changes in pAKT<sup>5473</sup> and pS6<sup>S235/236</sup> levels were noted in drug treated spleens (Figure 5.19A,D,E). Furthermore, spleens of mice treated with AZD2014, and not with rapamycin, had an increasing trend in cyclin genes *Ccnd1, Ccnd2* and *Ccnd3*, with trends in increase in the pro-apoptotic target *Bid* and no changes in *Prkcb* (Figure 5.19F,G), suggesting possible increase in cell cycling with AZD2014 treatment compared to vehicle controls. These data suggest that rapamycin is more potent in targeting a CLL-like disease in secondary transplants of mice than AZD2014, which could have a potential effect on cell cycling of CLL-like disease in vivo.
5.3 Discussion

To assess the role of the mTOR complexes in leukaemia initiation and/or development, cre-loxP models were used for both in vitro and in vivo studies. CLL is characterised by having increased BCR signalling where CLL is driven by antigen-independent autonomous signalling(308). Moreover, it is known that BCR signalling in CLL cells which are anergic internalise and accumulate ligand in exosomes more than in normal B cells. Additionally, ligation of CD79b or IgM has shown independent internalisation in CLL cells but not in healthy B cells. Ibrutinib, a BTK inhibitor has been shown to reduce BCR signalling capacity and induce efficient internalisation(309). Several other inhibitors have been tested to reduce this chronic BCR signalling. Once such drug, Fostamatinib, a partial spleen tyrosine kinase (SYK) inhibitor, although effective in causing CLL-apoptosis, was deemed toxic to certain cell lines and clinical development was discontinued(310). Dasatinib, a tyrosine kinase inhibitor, blocking LYN, BTK and other kinases inhibits BCR signalling and block BCR mediated survival of CLL cells, together with decreasing migration towards SDF-1(311). Although there are very efficient drugs in clinics for CLL, it currently remains incurable and therefore there is a need for curative therapy. The mTOR pathway has previously shown to be upregulated in CLL(312), and here we target this pathway downstream the BCR as a potential therapeutic strategy. We used cre-loxP mouse models to generate a CLL-like disease and assess the role of mTORC1 and mTORC2 in CLL in vitro and in vivo. Our laboratory has previously developed a CLL mouse model by the retroviral transduction of a kinase-dead PKCα (PKCαKR) into lymphocytes isolated from FL of mice(230). We used a similar technique, but we induced a CLL-like disease from the BM of mice enabling us to utilize the KO mouse models. For all the experiments, the BM was purified for CD117+ lymphocytes and retrovirally transduced with either GFP tagged MIEV to assess B cell development, or PKCαKR to induce a CLL-like disease. These cells were cultured in vitro for experiments or were transplanted into NSG host mice after D7-10 of culture to introduce a CLL-like disease in vivo.
5.3.1 Role of mTORC1 and mTORC2 in leukaemia initiation and/or progression \textit{in vitro}

CD117$^+$ lymphocytes retrovirally transduced with GFP$^+$-PKCaKR from the BM of \textit{Mx1-Raptor} cKO mice with 4 poly(I:C) inoculation failed to initiate a CLL-like disease as compared to \textit{Mx1-Raptor} controls \textit{in vitro}. \textit{Mx1-Raptor} control MIEV and PKCaKR cells are driven to a B cell lineage in culture, however, \textit{Mx1-Raptor} cKO MIEV cells failed to commit to a B cell lineage alluding to the role of mTORC1 not only in B cell development (Chapter 4), but also in CLL initiation. Our results highlight that the PKCaKR retroviral construct was unable to rescue the lineage commitment block caused due to \textit{Raptor}-deficiency. The increased percentage of GFP$^+$CD11b$^+$ cells with a concomitant decline in B cell/CLL-like cell population in \textit{Mx1-Raptor} cKO MIEV and PKCaKR cells does not allude to an increase in myeloid population with \textit{Raptor}-deficiency. As there is a block in B cell development, there is increased GFP$^+$CD11b$^+$ population as myeloid lineage development is not completely compromised with \textit{Raptor}-deficiency. Nevertheless, due to the OP9-system\,(231), there is a bias for B-cell development with the addition of Flt3 ligand and IL7 \,(33,313), and a lack of M-CSF, which hinders myeloid lineage development and proliferation. Therefore, there is an initial increase in CD11b$^+$ population and subsequent decline in this population by D7 in \textit{Mx1-Raptor} control MIEV and PKCaKR cells but this trend is compromised with \textit{Raptor} deficiency leading to an increase in percentage of GFP$^+$CD11b$^+$ population.

Whilst assessing the role of mTORC1 in CLL progression, the \textit{CD19-Raptor} KO model was used. Unlike the \textit{Mx1-Raptor} cKO model, there was successful CLL-like disease initiation with \textit{Raptor}-deficiency in CD19$^+$ cells. As CD19 is expressed at the preB cell stage \,(205), retroviral transduction is done at an earlier stage in CD117$^+$ lymphocytes thereby leading to disease initiation. However, the model would KO \textit{Raptor} in CLL-CD19 expressing cells thereby enabling the assessment of the role of \textit{Raptor} in CLL \textit{in vitro}. \textit{CD19-Raptor} KO PKCaKR cells demonstrated a similar block in proliferation and migration with an increasing trend in G0/G1 phase. It was interesting to observe a maintenance of disease till later stages \textit{in vitro} as opposed to a rapid decrease in disease, as \textit{Raptor}-deficiency in B cells leads to a block in B cell development altogether (Chapter 4). One of the reasons for this could be due to the microenvironmental factors due to the co-
Unlike the Mx1-Raptor cKO model, Raptor-deficiency is induced solely in CD19+ cells and not in other haemopoietic lineages in the CD19-Raptor KO model. To induce a CLL-like disease in CD19-Raptor KO model, CD117+ lymphocytes are retrovirally transduced with GFP+-PKCaKR construct. These retrovirally cells are co-cultured with murine derived OP9 stromal cells to aid B-cell/PKCaKR cells generation(314). Additionally, other lymphocytes such as NK cells and a low percentage of macrophages could be present at early stages of culture. Besides the role of OP9 stromal cells in aiding B cell development, it is possible that these other cells release cytokines which aid disease progression till a later stage of disease progression after Raptor KO in B cells. Indeed, chemokines released by BMSCs and NLCs including SDF-1 lead to increased chemotaxis and decreased apoptosis in CLL(315). NLCs also activate the BCR through antigens such as vimentin and calreticulin(316). Although tumour associated macrophages (TAMs) and T cells play critical roles in CLL maintenance, BM cells which are retrovirally transduced do not have a high percentage of T cells. They contain macrophages but not TAMs. With the induction of a CLL-like disease there is a decrease in macrophages. However, it has previously been shown that secretion of CD14 by monocytes has shown to protect CLL by decreasing apoptosis and activating NFκB-mediated signals (317), which could potentially increase the disease progression in CD19-Raptor PKCaKR cells.

It was reassuring to see that BM of Mx1-Raptor cKO mice not treated with poly(I:C) developed a CLL-like disease, confirming that it is indeed Raptor-deficiency causing the block in disease initiation. Optimization of the dosage and time of IFNβ treatment, a TLR receptor agonist used to induce cKO in vitro, was carried out: 200U IFNβ for 24 hr was optimal and was used in all experiments in vitro. However, there was a significant decrease in cellularity in Mx1-Raptor cKO PKCaKR cells (without prior poly(I:C) treatment) without IFNβ treatment compared to Mx1-Raptor controls. This was interesting as no changes were observed in Mx1-Raptor cKO PKCaKR cells treated with 50U IFNβ suggesting this result is not due to cre toxicity(208). However, it suggests an activation of TLR signalling in Mx1-Raptor cKO PKCaKR cells with no prior drug treatment. The reason for this potential TLR activation is not known and requires further assessment. Indeed, it has been demonstrated that there can be spontaneous cre
expression prior to induction of cre expression (203). It is possible that such spontaneous cre expression caused the significant decrease in Mx1-Raptor PKCαKR cellularity with no prior drug treatment.

TLRs are present on innate cells and act a bridge between innate and adaptive immunity. In murine B cells, TLR4 and TLR10 have shown to be prevalently expressed (318). In humans, TLR expression in CLL is similar to that on normal B lymphocytes. However, Dadashian et al., have recently demonstrated an increased cooperation of TLR signalling with BCR signalling leading to downstream NFκB signalling thereby increasing survival of CLL cells residing in LN of patients, which was partially inhibited with ibrutinib treatment (319). However, expression of various TLRs on the PKCαKR mouse model of CLL has not yet been assessed. Therefore, it is possible that there is an increase in stochastic TLR signalling with our murine CLL model leading to cre expression and subsequent Raptor excision. Nevertheless, there was a clear excision of Raptor in Mx1-Raptor cKO (no poly(I:C) treatment) PKCαKR cells with IFNβ treatment which led to a decrease in CLL-disease load with an increasing trend in G0/G1 phase with a decrease in proliferation in vitro. These data suggest Raptor deficiency in B cells and in haemopoietic cells affects CLL progression in a similar manner as its role in CLL initiation.

On the other hand, Rictor-deficiency at the HSC stage, in haemopoietic lineages in adult mice, and solely in CD19+ cells in PKCαKR cells led to a CLL-like disease with a decline in GFP+CD11b+ myeloid cells in vitro suggesting a redundant role of mTORC2 in CLL initiation and lineage commitment. PKCαKR cells with Rictor deficiency displayed an increase in migration, a trend in increased cell cycling (increased percentage of cells in the S phase), with an increasing trend in Ccnd1 expression at later stages of disease progression (D21 of culture) compared to controls alluding to a role of mTORC2 in disease maintenance. A similar trend has been observed in previous studies where there was a decrease in Notch-driven T-acute lymphocytic leukaemia (T-ALL) progression with Rictor deficiency, with an increase in CXCR4 expression causing increased migration and homing in the spleen and not the BM, together with an arrest in proliferation and cell cycling at the G0 phase via FoxO3 activation (123,320). As our data demonstrate an increasing trend in cell cycling and proliferation, this opposing trend could be due to the anti-proliferative role of mTORC2 in T cells as
compared to in B cells. As chronic BCR activation in CLL has been shown to increase RNA translation along with the upregulation of MYC(321), future directions of assessing Rictor-deficiency in CLL should include assessing MYC levels, a downstream target.

5.3.2 Role of mTORC1 and mTORC2 in leukaemia progression in vivo

As Mx1-Raptor cKO PKCaKR cells (with prior poly(I:C) inoculation) failed to develop disease in vitro, NSG mice were transplanted with Mx1-Raptor control or cKO PKCaKR cells (without poly(I:C) inoculation) cultured till D7-10. After disease was well established (≥10% disease), the mice were either left untreated or inoculated with poly(I:C) doses to induce Raptor-deficiency in the transplanted CLL-like disease to assess the role of mTORC1 in CLL progression in vivo. There was a significant decrease in disease percentage in the BM and spleen together with increased survival in diseased mice with Raptor cKO with poly(I:C) inoculation, compared to mice with Mx1-Raptor control PKCaKR cells (with no poly(I:C)) suggesting a decrease in disease maintenance with Raptor-deficiency. However, there was an observed delay in GFP+CD19+ disease progression with mice transplanted with Mx1-Raptor control PKCaKR cells treated with poly(I:C) suggesting a potential role of poly(I:C) in initiating TLR response. TLR in normal B lymphocytes are responsible for identifying virus, bacteria and other agents. Therefore, it is possible that TLR activation delays disease progression. As TLR signalling in CLL has shown to phosphorylate STAT1 and STAT3 and activate NFκB signalling and cause subsequent survival of CLL(319), it is also possible that poly(I:C) inoculation affects normal and leukaemic B cells thereby causing initial delay in CLL progression, but also protecting the murine CLL disease in vivo to an extent. Nevertheless, it was reassuring to see no difference in survival between NSG mice transplanted with Mx1-Raptor control PKCaKR cells with and without poly(I:C) inoculation. Although host mice with Mx1-Raptor cKO PKCaKR cells (with poly(I:C)) had increased survival and decreased disease load, these mice did not have a complete abrogation in disease and eventually the mice succumbed to a CLL-like disease. All mice were sacrificed after their health was compromised due to disease progression, and not after a common time point thereby allowing us to determine the role of mTORC1 in disease maintenance. Analysis of spleens from
Mx1-Raptor cKO PKCαKR cells (with poly(I:C)) at disease end showed a significant increase in RAPTOR expression and an increase in p4EBP1T36/T47, compared to Mx1-Raptor control PKCαKR cells (no poly(I:C)). This suggests ‘escaped deletion’ (208) of Raptor in Mx1-Raptor cKO PKCαKR cells by poly(I:C), leading to a repopulation of disease with Raptor and eventual death of host mice. Interestingly, there was a drastic decrease in RICTOR expression in Mx1-Raptor cKO PKCαKR cells with poly(I:C) inoculation compared to Mx1-Raptor cKO PKCαKR cells alluding to possible regulation of RICTOR by mTORC1. Brown et al., have shown that mTORC2 negatively regulates TLR response as Rictor excision induces a hyperinflammatory response via TLR activation through FoxO1 modulation (71). However, it is not known whether TLR activation modulates Rictor function via FoxO1 modulation thereby affecting RICTOR expression as observed in our results. A similar trend is observed in the Mx1-Raptor control PKCαKR cells with poly(I:C) where there is a significant decrease in RICTOR expression, suggesting TLR mediated modulation of mTORC2. However, as this experiment was performed once, it would be beneficial to perform this again to evaluate this further.

CD19-Raptor control or KO PKCαKR cells were transplanted into NSG mice to address the role of mTORC1 solely in CD19⁺-CLL disease. As the Mx1-Raptor cKO PKCαKR cells with poly(I:C) treatment exhibit a decrease in disease load, we hypothesised a similar result would be seen in the CD19-Raptor KO PKCαKR transplanted mice in vivo. Indeed, we observed a more pronounced increase in survival in mice with CD19-Raptor KO PKCαKR cells compared to CD19-Raptor control PKCαKR cells. Although there was an increase in survival, these mice still died of disease at a later timepoint as seen with an increase in disease load in the blood of NSG mice with CD19-Raptor KO PKCαKR cells after 5 wk. When assessed further, this was due to re-emergence of RAPTOR expression. These data suggest that although Raptor excision can abrogate disease progression, the CD19-cre-loxP model was not very efficient in inducing a 100% knockout in CLL-like cells leading to ‘escaped deletions’ and subsequent re-population of disease. This also reiterates that the CD19-cre KO model is not as efficient as the Vav- and Mb1-cre models, where CD19-cre model has ≥75% KO efficiency compared to Vav- and Mb1-cre with 95% KO efficiency (208), thereby not being the ideal KO model for these experiments.
Previous studies have assessed the role of mTOR in leukaemic settings by inducing PTEN loss which leads to myeloproliferative neoplasms (MPN)(322). This could be a good model for CLL. Kalaitzidis et al., have demonstrated that Pten-loss leads to MPN and inducing Raptor loss after MPN using the cre-loxP system leads to increased survival suggesting a fundamental role of mTORC1 in disease progression(91) as is also seen from our results. Additionally, Rictor deletion using the Mx1-cre system in PTEN loss evoked disease resulted in a disruption in disease maintenance and prevention of HSC exhaustion in adult, but not neonatal mice(93) suggesting a role of mTORC2 in later stages of normal haemopoiesis and in disease, similar to our data.

To determine the therapeutic potential of targeting mTOR complexes pharmacologically in CLL, we transplanted a CLL like disease into mice and then treated mice with clinically relevant inhibitors of the PI3K/mTOR pathway in mice with an established disease to assess leukaemia progression in vivo. Ibrutinib, a BTK inhibitor, has been approved as the current first line therapy for patients with 17p deletion or TP53 mutation (patients displaying a more aggressive form of CLL) after the RESONATE-2 trial (323). AZD2014, the dual mTOR complex inhibitor is currently in phase II clinical trials for gastric carcinoma(324) and shown promise in other cancers such as breast cancer(325). AZD2014, in synergy with ibrutinib has been demonstrated to ablate diffuse large B-cell lymphoma (DLBL) cell lines (ABC subtype)(326) thereby making it an ideal drug for testing in our CLL model. Mice given combination therapy with AZD2014 and ibrutinib had a better overall decrease in disease load in the BM and spleen as compared to the vehicle controls or single agents, suggesting synergy between ibrutinib and AZD2014 in combating CLL(128). Additionally, there was a decrease in CD5’ CLL-like cells with combination and with single agents in the BM and spleen of mice. CLL population with high levels of CD5 expression are classified as the migrating CLL population(156). A recent study has shown a population of CLL cells with high IgM expression residing in the LN as compared to those in the blood suggesting a functional difference between the two subtypes(309). Whether they correlate to the migrating subtype or are different to the Calissano model is unclear. However, our results highlight the importance of combination therapy in targeting different clonal subtypes of the heterogenous disease.
Although combination therapy was more efficient in decreasing disease load, secondary transplants were performed to assess the efficiency between rapamycin (mTORC1 inhibitor) or AZD2014 to assess whether combination therapy of ibrutinib with AZD2014 or rapamycin would yield a better outcome. We hypothesised that AZD2014, inhibiting both mTORC1 and mTORC2 would be a more potent inhibitor than rapamycin alone. However, secondary transplants showed a significant difference between the two agents where AZD2014 was inferior compared to rapamycin in decreasing disease load in vivo. Our results indicate a decreasing trend in splenic cellularity with rapamycin treatment compared to AZD2014 and controls. As there is a clear reduction in spleen size with rapamycin, it was surprising that this did not co-relate with a significant decrease in splenic cellularity. Splenomegaly in CLL is associated with an increase in red pulp (327) thereby increasing splenic cellularity. However, all total counts of the spleen were taken after enrichment of lymphocytes thereby depleting other cell types which could explain the lack of a significant decrease in the splenic cellularity of rapamycin treated mice compared to vehicle controls and those treated with AZD2014. The pharmacokinetics of both the drugs have shown fast absorption with the peak concentration in serum reaching between 0.5-1 hr when both drugs are given orally. Nevertheless, rapamycin yielded best results when the drug was given daily for 2 weeks, whereas AZD2014 inhibited phosphorylation of 4EBP1 by -45% and -41% and phosphorylation of S6K S235/236 by -62% and -37% at 2 and 6 to 8 hr after dose compared to baseline respectively. As rapamycin has a longer half-life compared to AZD2014 (30 hr compared to 3 hr) (328, 329), it would have been interesting to test downstream signalling after one dose (preferably after 2 hr) of AZD2014 and rapamycin to determine the downstream mechanisms. Our laboratory has recently shown that AZD8055 (a drug with the same pharmacophore as AZD2014) is superior to rapamycin at reducing CLL in primary transplants (128) thereby suggesting that the disease is more aggressive as a secondary transplant and potentially more dependent on mTORC1.

Spleens with a CLL-like disease treated with AZD2014 or rapamycin had no changes in RAPTOR or RICTOR expression. However, the phosphorylation of these proteins was not tested making it difficult to comment upon the functionality of the proteins. Nevertheless, there was a trend in decrease in pAKT S473 with both
drugs compared to vehicle controls. It is known that continuous rapamycin treatment leads to mTORC2 inhibition in certain cells (330) suggesting that rapamycin inhibits mTORC2 as seen by the decrease in downstream AKT phosphorylation. Indeed, a phase II trial has shown similar results in patients with refractory renal cancer where patients given AZD2014 treatment had a shorter progression-free survival (PFS) with an increase in disease progression compared to patients given everolimus, a compound derived from rapamycin (331). Assessing the mechanism of action of the two drugs would allow a better understanding about these findings. Rapamycin binds to FKBP12 and this complex allosterically inhibits mTORC1. Rapamycin is known to be a potent immunosuppressant as it hinders T cell activity and proliferation along with inhibiting antibody production (332). As our host mice are immunocompromised, it is unlikely that rapamycin is compromising the microenvironment alluding to rapamycin inhibition of mTORC1 downstream the BCR in a CLL-like disease.

Moreover, we observed a trend in increase in cell cycling genes in the spleens of AZD2014 treated mice whereas those treated with rapamycin do not show similar trends suggesting that the classical cell cycle arrest mechanism was not engaged with rapamycin treatment in decreasing disease load in vivo. Faller et al., have shown that in the murine intestinal cancer model, rapamycin treatment caused a decrease in cancer cell proliferation (not initiation) independent of the classical cell cycle arrest mechanism. They demonstrate a novel mechanism by which mTORC1 regulates translation elongation of malignant cells via the S6K-elongation factor 2 kinase (EF2K)-EF2 axis which, after Raptor-deletion or rapamycin treatment, was reversed (333). It would be of great benefit to assess this S6K mediated translational elongation in our CLL-secondary transplants to determine whether this more aggressive form of disease is increasingly mTORC1 dependent.

Taken together, mTORC1 plays a fundamental role in CLL initiation and progression in vitro and in vivo whereas mTORC2 has roles in CLL maintenance at a later stage in vitro. Although the dual mTOR complex inhibitor, AZD2014 significantly reduces disease load in mice in primary transplants, and is synergistic with ibrutinib in decreasing disease load, AZD2014 is inferior to rapamycin in decreasing disease load in secondary transplants. It will be
interesting to test whether rapamycin can also exhibit synergy with ibrutinib or other drugs in clinics to combat CLL.
5.4 Figures

Figure 5.1 BM from adult mice with Raptor-deficiency does not develop into PKCaKR CLL-like cells in vitro.

Representative flow cytometry plots showing D7 post retroviral transduction of either GFP-tagged MIEV construct of purified CD117⁺ lymphocyte progenitors from the BM of Mx1-Raptor control (A) or cKO (B) mice, or GFP-tagged PKCaKR construct of purified CD117⁺ lymphocyte progenitors from the BM of Mx1-Raptor control (C) or cKO (D) mice dissected 5 wk post 4 poly(I:C) inoculation. Plots were live and size (FSC-A/SSC-A) gated, and doublet cells were excluded and were gated for GFP⁺CD45⁺ before assessing surface expression of CD19⁺ or CD11b⁺ populations. Percentage of GFP⁺CD45⁺CD19⁺ MIEV (n=2) (E) or PKCaKR CLL-like cells (n=2) (F) from Mx1-Raptor control (cre-, blue bars) or cKO (cre+, red bars) mice dissected 3 wk post 3 poly(I:C) inoculation and assessed D7, 11, 14, and 18 post retroviral transduction. Data are expressed as mean±SD.
Figure 5.2 Raptor-deficiency abrogates B cell lineage commitment and leads to the absence of PKCaKR CLL-like cells in vitro.
Cellularity of GFP^+CD19^+ population of Mx1-Raptor control or cKO (4 poly(I:C)) MIEV (A) and Mx1-Raptor control or cKO (4 poly(I:C)) PKCaKR (B) cells over D3 (n=3), 7 (n=6) and 11 (n=6) of culture, together with percentage of GFP^+CD19^+ population of Mx1-Raptor control or cKO (4 poly(I:C)) MIEV (C) and Mx1-Raptor control or cKO (4 poly(I:C)) PKCaKR (D) cells over D3 (n=5), 7 (n=9), 11 (n=8) and 14 (n=8) of culture. Percentage of GFP^+CD11b^+ population of Mx1-Raptor control or cKO (4 poly(I:C)) MIEV (E) and Mx1-Raptor control or cKO (4 poly(I:C)) PKCaKR (F) cells over D3 (n=5), 7 (n=8), 11 (n=10) and 14 (n=6) of culture. Cre+: Raptor-control samples, cre+: Raptor-cKO samples. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 5.3 Raptor-deficiency in CD19+ cells leads to decreased proliferation, migration and cell cycle arrest of PKCaKR CLL-like cells in vitro.

A. Representative plot showing CTV proliferation assay performed every 24 hr for 72 hr on CD19-Raptor control (left) or KO (right) PKCaKR cells at D18 of culture. Bar graphs demonstrating CTV MFI ratios of D1/D0 and D2/D0 of CD19-Raptor control (n=2) and CD19-Raptor KO MIEV (n=2) cells (B) and CD19-Raptor control (n=5) and CD19-Raptor KO PKCaKR cells (n=3) (C).

Representative flow cytometry plots (D), together with percentage (E) of AnnV-7AAD- (Live), AnnV+ (early apoptotic), 7AAD+ (necrotic cells), and AnnV-7AAD+ (late apoptotic) populations of CD19-Raptor control (n=3) and CD19-Raptor KO PKCaKR cells (right) at D18 of culture.

Cellularity (F) and percentage (G) of migration of CD19-Raptor control (n=3) and CD19-Raptor KO (n=3) PKCaKR cells towards SDF-1 after serum starvation. Negative and positive controls represent migration without SDF-1 and 100% migration respectively. H. Percentage of CD19-Raptor control (n=2) and CD19-Raptor KO (n=2) PKCoKR cells at D18 of culture in G0/G1, S, and G2 phases of cell cycling. Cre-: Raptor-control samples, cre+: Raptor-KO samples. Data are expressed as mean±SD/SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 5.4 The generation of an inducible model of Raptor-deficiency in vitro.
Bar graphs showing percentage of CD19+GFP- Mx1-Raptor control or Mx1-Raptor cKO MIEV (A) and Mx1-Raptor control or Mx1-Raptor cKO PKCaKR (B) cells at D7 (n=2), 14 (n=4), and 21 (n=3) with no poly(I:C) inoculation given to mice. C. DNA agarose gel of a PCR reaction showing expression of Raptor in Mx1-Raptor control or Mx1-Raptor cKO (no poly(I:C)) PKCaKR cells treated with or without 200U IFNβ for 24 hr and assessed 72 hr post treatment together with Mx1-Raptor control BM as a reference for Raptor expression. Representative western blot (D) and bar graphs showing expression of RAPTOR/1AKT (E), pS65235/5236/5236 (F), RICTOR/1AKT (G), pAKT5473/1AKT (H) of Mx1-Raptor control or cKO MIEV (n=2) and Mx1-Raptor control or cKO PKCaKR (n=4) cells treated with IFNβ and assessed 72 hr post treatment. Cre-: Raptor-control samples, cre+: Raptor-cKO samples. Data are expressed as mean±SD/SEM (p *≤0.05).
Figure 5.5 CLL-like cells with induced Raptor-deficiency exhibit a block in proliferation in vitro.

Cellularity (n=6) (A) and percentage (n=2) (B) of GFP⁺CD19⁺ Mx1-Raptor control or cKO (no poly(I:C)) PKCaKR cells, either untreated (UT, light blue and pink bars) or treated with 50U IFNβ for D2, D3 or 200U for 24 hr (blue and red bars) and assessed 72 hr post treatment. C. Cellularity (n=6) of Mx1-Raptor control or cKO (no poly(I:C)) PKCaKR cells either untreated or treated with 200U IFNβ for 24 hr and assessed 72 hr post treatment. D. PI staining showing percentage of Mx1-Raptor control and cKO (no poly(I:C)) PKCaKR cells (n=2), either untreated or treated with 200U IFNβ for 24 hr and assessed 72 hr post treatment, in G₀/G₁, S, and G₂ phases of cell cycling. Representative plot (E) and bar graphs (F) showing CTV MFI of D0, D1 and D2 performed every 24 hr for 3 days of Mx1-Raptor control (left) or cKO (no poly(I:C), right) PKCaKR cells (n=6) treated with 200U IFNβ for 24 hr (right) and assessed 72 hr post treatment. Cre⁻: Raptor-control samples, cre⁺: Raptor-cKO samples. Data are expressed as mean±SD/SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 5.6 Rictor-deficiency does not abrogate CLL-initiation in vitro.
Representative graphs showing proportion of GFP+CD19+ cells of Vav-Rictor control (A) and Vav-Rictor KO (B) PKCαKR cells at D21 of culture. Plots were live and size (FSC-A/SSC-A) gated, and doublet cells were excluded and were gated for GFP+CD45+ before assessing surface expression of CD19+ or CD11b+ populations. Cellularity of GFP+CD19+ population of Vav-Rictor control or KO at D7 (n=6), 14 (n=3), 21 (n=5) and 28 (n=2) of culture (C). Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=6), 14 (n=5) and 21 (n=4) of culture (D), and CD19-Rictor control (n=2) or KO (n=2) at D7, 14, 21 and 28 of culture (E) MIEV cells. Cellularity of GFP+CD19+ cells of Vav-Rictor control or KO at D7 (n=5), 14 (n=6), 21 (n=7) and 28 (n=3) of culture (F), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=8), 14 (n=7), and 21 (n=7) of culture (G), and CD19-Rictor control or KO at D7 (n=2), 14 (n=3), 21 (n=3) and 28 (n=3) of culture (H) PKCαKR cells. Cre−: Rictor-control samples, cre+: Rictor-cKO/KO samples. Data are expressed as mean±SD/SEM.
Figure 5.7 CLL-like cells with Rictor-deficiency exhibit a decreasing trend in cell count and percentage at later stages of culture in vitro.

Percentage of GFP⁺CD19⁺ cells of Vav-Rictor control or KO at D7 (n=7), 14 (n=7), and 21 (n=6) of culture (A), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=9), 14 (n=9), 21 (n=5) and 28 (n=3) of culture (B), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture (C) of MIEV cells. Percentage of GFP⁺CD19⁺ cells of Vav-Rictor control (n=7) or KO (n=7) at D7, 14, and 21 of culture (D), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=8), 14 (n=8), 21 (n=6) and 28 (n=2) of culture (E), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture (F) PKCaKR cells. Bar graphs showing percentage of GFP⁺CD11b⁺ cells of Vav-Rictor control (n=6) or KO (n=6) at D7, 14, and 21 of culture (G), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=9), 14 (n=9), 21 (n=5) and 28 (n=3) of culture (H), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture (I) MIEV cells. Percentage of GFP⁺CD11b⁺ cells of Vav-Rictor control (n=6) or KO (n=6) at D7, 14, and 21 of culture (J), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=9), 14 (n=11), 21 (n=7) and 28 (n=5) of culture (K), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture (L) PKCaKR cells. Cre-: Rictor-control samples, cre+: Rictor-cKO/KO samples. Data are expressed as mean±SD/SEM.
Figure 5.8 Rictor-deficiency at the HSC stage and in adult mice plays a role at later stages of CLL in vitro.

Gene expression of Rictor (n=7), Bcl-2 (n=7), Ccnd1 (n=5), Cdkn1a (n=4), Cdkn1b (n=4) in Vav-Rictor KO MIEV (blue) and Vav-Rictor KO PKCαKR (pink) cells (A), along with gene expression of Rictor, Bcl-2 and Ccnd1 in Mx1-Rictor control (blue, n=3) and KO (pink, n=3) PKCαKR cells (B). ΔΔCT calculated by taking Tbp as a reference gene and Vav/Mx1-Rictor control MIEV/PKCαKR samples as reference where all samples were cultured till D21 in vitro. Representative western blot (C) along with bar graphs demonstrating protein expression ratio of RICTOR/GAPDH (D) and pAKT5473/tAKT (E) in Mx1-Rictor control (n=4) and cKO (n=4) PKCαKR cells cultured till D21. Cre+: Rictor-control samples, cre−: Rictor-cKO samples. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 5.9 CLL cells with Rictor-deficiency at the HSC stage exhibit increased migration at later stages of culture.

Cellularity (A) and percentage (B) of migration of Vav-Rictor control (cre-, n=2) and Vav-Rictor KO (cre+, n=2) PKCαKR cells at D15 together with the cellularity (C) and percentage (D) of migration of Vav-Rictor control (n=4) and Vav-Rictor KO (n=4) PKCαKR cells towards SDF-1 after serum starvation when cultured for D21 in vitro. Negative and positive controls represent migration without SDF-1 and 100% migration respectively. Bar graphs of Vav-Rictor control (n=4) and KO PKCαKR cells cultured up to D14 (n=3 Vav-Rictor KO) (E) and D21 (n=2 Vav-Rictor KO) (F) showing CTV MFI ratios of D0/D1 and D2/D0 performed every 24 hr for 3 days. Bar graphs of Mx1-Rictor control (n=4) and cKO (n=5) (4 poly(I:C) inoculation) PKCαKR cells cultured to D14 (G) and D21 in vitro (H) demonstrating percentage of G0/G1, S, and G2 phases of cell cycling. Cre-: Rictor-control samples, cre+: Rictor-cKO samples. Data are expressed as mean±SD/SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 5.10 Raptor-deficiency induced after disease development abrogates CLL-like disease in vivo.

Immunocompromised NSG mice were transplanted with PKCaKR cells and developed disease. Representative flow cytometry plots showing proportion of GFP⁺CD45⁺CD19⁺ CLL-like PKCaKR cells in the blood of NSG mice which were transplanted with 5x10⁵ Mx1-Raptor control PKCaKR cells (A), Mx1-Raptor control PKCaKR cells and given 4 inoculation of poly(I:C) after disease development (B), Mx1-Raptor cKO PKCaKR cells (C) and Mx1-Raptor cKO PKCaKR cells and given 4 inoculation of poly(I:C) after disease development (D). Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. Doublet cells were excluded (FSC-A/FSC-H) and positively selected for CD45 before assessing surface expression of GFP⁺CD19⁺ population.
Figure 5.11 Mice with an established CLL-like disease exhibit a decrease in disease load with induced Raptor-deficiency in vivo.

Data represents transplanted NSG mice with an established CLL-like disease. Spleen weight (mg) (A) and spleen (B) and BM (C) organ cellularity of mice transplanted with either 5x10^5 Mx1-Raptor control PKCaKR cells (light blue bar, n=11), Mx1-Raptor cKO PKCaKR cells (pink bar, n=2), Mx1-Raptor control PKCaKR cells and given 4 inoculation of poly(I:C) after disease development (blue bar, n=3), or Mx1-Raptor cKO PKCaKR cells and given 4 inoculation of poly(I:C) after disease development (red bar, n=5). Percentage of GFP^+CD19^+ CLL-like disease (representative, n=3/arm) in bloods from weekly tail bleeds (D) and from bloods of sacrificed mice (E) which were transplanted with Mx1-Raptor control PKCaKR cells, Mx1-Raptor cKO PKCaKR cells, Mx1-Raptor control PKCaKR cells and given 4 inoculation of poly(I:C), or Mx1-Raptor cKO PKCaKR cells and given 4 inoculation of poly(I:C). Cellularity (F) and percentage (G) of GFP^+CD19^+ cells in BM and spleen of NSG mice transplanted with either Mx1-Raptor control PKCaKR cells (n=8), Mx1-Raptor cKO PKCaKR cells (n=3), Mx1-Raptor control PKCaKR cells + poly(I:C) (n=4) or Mx1-Raptor cKO PKCaKR cells + poly(I:C) (n=5). Kaplan-meier survival graphs comparing the percentage survival between NSG mice transplanted with Mx1-Raptor control PKCaKR cells with (n=4) or without (n=11) poly(I:C) inoculation (H), Mx1-Raptor cKO PKCaKR cells with (n=5) or without (n=7) poly(I:C) inoculation (I), and Mx1-Raptor control (no poly(I:C), n=11) and cKO PKCaKR cells given poly(I:C) (n=7) after disease development (J). Data are expressed as mean±SD/SEM (p ≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001).
Figure 5.12 Mx1-Raptor cKO model is not completely efficient and causes disease relapse due to increased Raptor expression. Representative western blot (A) and densitometry showing protein expression ratios of pAKT<sup>S473</sup>/tAKT (B), RAPTOR/tAKT (C), p4EBP1<sup>T37/T46</sup>/t4EBP1 (D), pS6<sup>S235/S236</sup>/tS6 (E), and RICTOR/tAKT (F) in the spleen taken from host mice transplanted with 5x10<sup>5</sup> Mx1-Raptor control PKCαKR cells (n=3) and Mx1-Raptor cKO PKCαKR cells with 4 inoculation of poly(I:C) after disease development (n=4). Mice were sacrificed once health of the mice has been compromised due to disease. Cre-: Raptor-control, Cre+: Raptor-cKO. Data are expressed as mean±SEM (p ≤0.05).
Figure 5.13 Raptor-deficiency solely in CD19⁺ CLL-like cells does not affect CLL-like disease initiation in vivo.
All NSG mice were transplanted with PKCαKR cells and developed disease. Representative flow cytometry plots showing proportion of GFP⁺CD45⁺CD19⁺ CLL-like PKCαKR cells in the blood of NSG mice transplanted with 5x10⁵ CD19-Raptor control (A) or CD19-Raptor KO (B) PKCαKR cells. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. Doublet cells were excluded (FSC-A/FSC-H) and positively selected for CD45 before assessing surface expression of GFP⁺CD19⁺ population.
Figure 5.14 **Raptor-deficiency solely in CD19⁺ CLL-like cells increases survival in CLL-like disease in vivo.**

All NSG mice were transplanted with PKCαKR cells and developed disease. Spleen weight (mg) (A) and BM and spleen (B) organ cellularity of NSG mice transplanted with 5x10⁵ CD19-Raptor control (n=6) or KO PKCαKR cells (n=6). C. Weekly blood samples were taken and assessed for percentage of GFP⁺CD19⁺ CLL-like disease in mice transplanted with CD19-Raptor control or KO PKCαKR cells. D. Kaplan-meier survival graph comparing the percentage of survival between NSG mice transplanted with CD19-Raptor control (n=4) or KO (n=7) PKCαKR cells. Cellularity of GFP⁺CD19⁺ cells in the BM and spleen (E) and percentage of GFP⁺CD19⁺ cells in BM, spleen, LN and blood (F) of mice transplanted with CD19-Raptor control (n=6) or KO PKCαKR (n=6) cells. Representative western blot (G) and protein expression ratio of RAPTOR/GAPDH (H), pAKT⁵⁴⁷³/AKT (I), and pS6⁵²³⁵/₅²³⁶/S6 (J) in the spleen of mice transplanted with CD19-Raptor control (n=4) or KO PKCαKR cells (n=2). Data are expressed as mean±SD/SEM (p *≤0.05, p **≤0.001).
Figure 5.15 CLL-like disease is reduced with a combination treatment of AZD2014 and ibrutinib in vivo.
NSG mice were transplanted with PKCαKR cells and established disease. Representative flow cytometry plots showing proportion of GFP⁺CD45⁺CD19⁺ CLL-like PKCαKR cells in the blood of mice which were transplanted with $5 \times 10^5$ PKCαKR cells derived from B6.SJL BM and were treated with either the vehicle control (captisol+0.5%methylcellulose) (A), AZD2014 (15 mg/kg) (B), ibrutinib (12 mg/kg) (C) or a combination of AZD2014+ibrutinib (D) once daily for 14 days by oral gavage. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. Doublet cells were excluded (FSC-A/FSC-H) and positively selected for CD45 before assessing surface expression of GFP⁺CD19⁺ population.
Figure 5.16 Combination therapy does not reduce CLL-disease load more efficiently than single agents in vivo.

NSG mice were transplanted with 5x10^5 PKCaKR cells and disease was established prior to commencement of drug therapy. A. Representative picture of spleens from NSG mice with established CLL-like disease and treated with either vehicle control (Veh; captisol+0.5% methylcellulose, n=5), ibrutinib (Ibr, 12 mg/kg n=6), AZD2014 (AZD, 15 mg/kg, n=5) or a combination of AZD2014+ ibrutinib (Com, n=5). B. Ratio of spleen weight/total body weight and cellularity of BM and spleen in mice with established disease and treated with either the Veh (light pink bar), AZD (orange bar), Ibr (turquoise bar) or Com (purple bar). C. Weekly blood samples (representative n=3) were taken and were assessed for percentage of GFP^+CD19^+ CLL-like disease in mice, treated with Veh, AZD, Ibr or Com. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001).
Figure 5.17 Secondary transplants of CLL-like disease are responsive to rapamycin treatment in vivo.
Secondary transplants were carried out with NSG or NRG mice transplanted with PKCαKR cells isolated from the spleen of mice with ≥95% CLL-like disease. Representative flow cytometry plots showing the proportion of GFP+CD45+CD19+ CLL-like PKCαKR cells in the blood of mice treated with either vehicle control (captisol) (A), AZD2014 (15 mg/kg delivered by OG) (B), or rapamycin (4mg/kg, delivered intraperitoneally) (C) given once daily for 3 wk. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. Doublet cells were excluded (FSC-A/FSC-H) and positively selected for CD45 before assessing surface expression of GFP+CD19+ population.
Figure 5.18 Rapamycin is a more potent agent for decreasing CLL-disease load in vivo.
Secondary transplants were carried out with NSG and NRG mice transplanted with PKCaKR cells from the spleen of mice with ≥95% CLL-like disease. A. Picture of spleens from mice with established disease and treated with either vehicle control (Veh; captisol, n=8), rapamycin (Rapa, 4 mg/kg delivered intraperitoneally, n=7) or AZD2014 (AZD, 15 mg/kg, n=9) given once daily for 3 wk. Percentage of spleen/body weight (B) and total cellularity of BM and spleen (C) in mice with a CLL-like disease and treated with either Veh (light pink bar), Rapa (green bar) or AZD (orange bar). D. Weekly blood samples (representative, n=3) were assessed for percentage of GFP⁺CD19⁺ CLL-like disease in Veh, Rapa or AZD treated mice. Cellularity (E) and percentage (F) of GFP⁺CD19⁺ CLL-like cells in the BM and spleen together with the percentage (G) of GFP⁺CD19⁺ CLL-like cells in the LN and blood of mice treated with either Veh, Rapa or AZD. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001).
Secondary transplants were carried out where all NSG and NRG mice were transplanted with PKCαKR cells from the spleen of NSG mice with ≥95% CLL-like disease. Representative western blot (A) and densitometry of protein expression of ratio of RAPTOR/GAPDH (B), RICTOR/GAPDH (C), pAKT\(^{S473}/tAKT\) (D), and pS6\(^{S235/S236}/tS6\) (E) of the spleens of mice treated with either Veh (n=3), Rapa (4 mg/kg delivered intraperitoneally, n=3) or AZD (15 mg/kg delivered by OG, n=2) given once daily for 3 wk. Gene expression (log fold change) of Ccnd1, Ccnd2, Ccnd3 (F) and Bid and Prkcb (G) in the spleen of mice treated with either Veh (n=3), Rapa (n=3) or AZD (n=2). All gene expression data is relative to the vehicle control with Actb as the endogenous reference gene. Data are expressed as mean±SEM (p *≤0.05).
General Discussion and Conclusions

Although much is known about the mTOR signalling pathway and its role in metabolism and diseases such as diabetes, the exact role of the individual complexes, mTORC1 and mTORC2 in normal B cell development and in B cell malignancies was not well known. Therefore, my thesis addressed the individual roles of mTORC1 and mTORC2 in normal haemopoiesis and in CLL initiation/maintenance and the potential for mTOR as a valid therapeutic target in CLL.

Using the well-developed cre-loxP KO systems, KO mouse models were generated for mTORC1 and mTORC2 excising either Raptor or Rictor respectively at different haemopoietic stages giving rise to Vav- (KO at HSC stage), Mx1- (cKO in haemopoietic organs) or CD19-cre (KO in B cells) mouse models. Furthermore, utilising the PKCαKR retroviral construct which enables the generation of a murine CLL-like disease (230), combined analysis of the role of the individual mTOR complexes was carried out during leukaemogenesis in vitro and in vivo.

Generation of mTORC1 KO mouse model confirmed the previous findings that mTORC1-deficiency at the HSC stage is lethal at the perinatal stage due to its fundamental role in regulating erythropoiesis (97). mTORC1-deficiency leads to a block in erythropoiesis at the MEP stage. In agreement with previous literature, the results demonstrate the potent role of mTORC1 in B cell development (109), as deficiency of mTORC1 (in Vav- or Mx1- mice) leads to a block in B cell development at the LSK stage (Chapter 3). While mTORC1 plays a role early in development, mTORC2 plays a subtle opposite yet complementary role to mTORC1 regulation in haemopoiesis giving both the complexes a yin-yang undertone. mTORC2-deficiency leads to aberrations in late B cell populations. Where mTORC1 plays a positive role in erythropoiesis, our results suggest a suppressive role of mTORC2 as Rictor-deficiency leads to an increase in RBC colony capacity. mTORC2 has also shown to play an important role in T cell development, as our results demonstrate a drastic decrease in DP T cells and an increase in DN T cells suggesting a block in T cell development, which is in agreement with previously published data (115)(Chapter 4).

Whilst assessing the role of mTORC1 and mTORC2 in CLL-like disease initiation and/or maintenance, the PKCαKR retroviral construct was used to induce a CLL-
like disease in the BM of the KO models and their respective controls. Our results showed that although mTORC1 and mTORC2 have distinct roles in haemopoiesis and leukaemogenesis, both the complexes regulate CLL and normal haemopoiesis in a similar manner: mTORC1 plays a fundamental role in CLL initiation (due to its role in B cell lineage commitment) in vitro and in vivo, whereas mTORC2 plays a role at later stages of B cell development and leukaemia alluding to a role in B cell and leukaemia maintenance in vitro. Induced Raptor-deficiency in established CLL-like disease led to a decrease in migration, proliferation and trends towards decreased cell cycling in vitro with an abrogation or a delay in disease maintenance in vivo. While the results showing an extension in survival in the PKCαKR CD19-cre mouse model in vivo was interesting, we concluded that the CD19-cre mouse models are not ideal as a KO model due to the reduced efficiency of cre-recombinase excision in this model(208). Therefore, it would be interesting to assess leukaemia maintenance in vivo using other efficient KO models such as Mb1-cre KO model (Chapter 5).

CLL-like disease with Rictor-deficiency led to an increase in migration and trends in increase in cell cycling. Although there were trends showing a decrease in disease load at later stages of disease in vitro, we did not look into this in great detail due to time restrictions of this project. Additionally, the role of mTORC2 in disease maintenance was not assessed in vivo also due to time restrictions. These experiments would be very beneficial in further assessing the exact mechanisms by which mTORC2 plays a role in disease maintenance. These processes allude to a role of mTORC2 in enhancing microenvironmental signals. However, as this cannot be assessed in vivo in NSG mice (highly immunocompromised), it would be of great interest to assess whether mTORC2 maintains CLL by modulating the microenvironment in vitro.

The opposing trends observed in a leukaemic setting between Rictor- and Raptor-deficient PKCαKR cells in vitro was interesting as there are other functions that have been assessed that the mTOR pathway regulates such as B cell development and erythropoiesis which are also differentially regulated by the two complexes where mTORC1 is fundamental for haemopoiesis and mTORC2 either regulates haemopoiesis at a later stage (B cells) or dampens the generation of haemocytes (erythropoiesis) (Chapter 3)(282). These trends
between the two complexes in disease initiation/maintenance, disease migration and trends in cell cycling alludes to the feedback loop in the mTOR pathway between mTORC1 and mTORC2(66) thereby highlighting the importance of both the complexes in the maintenance of both normal haemopoiesis and leukaemogenesis.

Lastly, to test CLL-disease maintenance by using clinically relevant compounds targeting the mTOR signalling pathway, we transplanted NSG mice with the PKCaKR CLL-like disease to induce a CLL-like disease in vivo. Subsequent treatments with AZD2014, ibrutinib, or a combination resulted in a potent reduction of disease maintenance with both ibrutinib and AZD2014 suggesting dual mTOR inhibition could prove a valid therapeutic target for CLL. Moreover, combination therapy on CLL was not additive and did not confer synergy suggesting dual mTOR inhibition to be as potent as combination therapy (Chapter 5).

As mTORC1 has shown to play a fundamental role in disease initiation and maintenance, it was important to address the role of rapamycin in disease maintenance. To test this, secondary transplants were carried out to generate a more aggressive CLL-like disease in host mice which were subsequently treated with either rapamycin or AZD2014, to test whether only mTORC1 inhibition is sufficient for disease attenuation as opposed to using the dual mTOR complex inhibitor AZD2014. Despite the known role of rapamycin in partially inhibiting mTORC1 (partially inhibits 4EBP1 activity, but a potent inhibitor of S6K), rapamycin was superior to AZD2014 in reducing disease load in host mice (Chapter 5). This suggests that an aggressive disease is more mTORC1 dependent, as our previous studies comparing rapamycin and AZD8055 (dual mTOR complex inhibitor with the same pharmacophore as AZD2014) in disease maintenance resulted in a superior effect of AZD8055 in primary transplants(128). This has led us to consider that another target of rapamycin in the mTOR pathway could potentially regulate disease: S6K. Previous research has shown the role of S6K in driving colorectal cancer through the mTOR-S6K-EF2K axis in regulating translational elongation and thus disease maintenance(333). It would be interesting to test the mTORC1-substrate profile
in this aggressive CLL-like disease and compare the sensitivity of rapamycin and AZD2014/AZD8055 on these targets.

Therefore, future directions would be to re-examine the role of mTORC1 in CLL-like disease initiation/maintenance by using an alternative B cell promoter for the cre-LoxP mouse model. Instead of utilising the CD19-Raptor KO model, assessing another promoter which is more efficieint at Raptor deletion such as the Mb1-Raptor KO model would give a clearer insight into the role of mTORC1 in disease progression. Moreover, perfoming secondary transplants of a WT CLL-like disease led to the finding that Rapamycin is more superior than AZD2014 in decreasing disease load in NSG mice suggesting a more aggressive CLL-like disease is mTORC1 dependent. Therefore, re-performing this experiment to assess further downstream mTORC1 targets such as EF2 and EF2K by IHC on spleen and assessing the expression levels of these targets at the protein and message level on the haemopoietic organs (BM and spleen) of these mice would help answer whether translation events are attenuated in this more aggressive CLL-like disease.

Future directions further assessing the role of mTORC2 in CLL would include performing transplants of PKCαKR CLL-like cells transformed from Vav-Rictor KO BM into NSG mice and assessing disease maintenance by evaluating survival and assessing downstream mTOR targets by IHC on the spleens which include pAKT\textsuperscript{S473}, pS6\textsuperscript{S235/S236}. Additionally, at the end of the project, RNA-sequencing of MIEV and PKCαKR cells (transformed from Vav-Rictor control or KO BM) was performed after co-culturing these cells till D21 (mimicking later stages of disease progression). Initial sequencing results showed the intriguing downregulation of Proopiomelanocortin (POMC) in Vav-Rictor KO PKCαKR datasets compared to controls. Therefore, future directions would include further assessing these results by qPCR via assessing various POMC variants in PKCαKR cells, and with dual mTORC inhibition. This could also be assessed in human CLL patient sample cells treated with AZD8055/AZD2014. It has recently been known that POMC is expressed in B lymphocytes\textsuperscript{334}, and therefore would be an interesting experiment to further determine the exact role of mTORC2 in the maintenance of late stages of CLL.
Taken together, we highlight the opposite and complementary roles of mTORC1 and mTORC2 in haemopoiesis and in leukaemogenesis where mTORC1 playing a fundamental developmental role and mTORC2 regulating later stages of B cell lineages and leukaemia. Additionally, we demonstrate a synergistic effect of the dual mTOR inhibitor AZD2014 and ibrutinib in decreasing CLL-like disease in vivo. Lastly, although dual mTOR inhibition has previously shown to be more potent at reducing disease load compared to rapamycin in vivo, our results showed a significant superior role of rapamycin in reducing disease load in a more aggressive form of leukaemia suggesting that the disease becomes more dependent on mTORC1 for the maintenance on disease.
1. de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J. 2000 Jun 1;19(11):2465-74.


52. He X, Dai H, Wang X, Skidmore D, Kurosaki T, Jensen PE. BCAP (B-cell adaptor for phosphoinositide 3-kinase) plays a role in development of Marginal Zone B cells in mice. The Journal of Immunology. 2016 May 1;196:122.9-122.9.


64. Ip CKM, Cheung ANY, Ngan HYS, Wong AST. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011 May;30(21):2420-32.


71. Brown J, Wang H, Suttles J, Graves DT, Martin M. Mammalian Target of Rapamycin Complex 2 (mTORC2) Negatively Regulates Toll-like Receptor 4-


Knight ZA, Schmidt SF, Birsoy K, Tan K, Friedman JM. A critical role for mTORC1 in erythropoiesis and anemia. eLife. 2014 Sep 8;3.


210. Li Y, Choi PS, Casey SC, Felsher DW. Activation of Cre Recombinase Alone Can Induce Complete Tumor Regression. PLOS ONE. 2014 Sep 10;9(9).


272. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002 Jun 15;16(12):1472-87.


277. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBPs: rapamycin-associated protein. PNAS. 1999 Apr 13;96(8):4438-42.


283. Mouse Strain Datasheet - 006785 [Internet]. The Jackson Laboratory. [cited 2019 Feb 27]. Available from: https://www.jax.org/strain/006785


291. Scheid MP, Marignani PA, Woodgett JR. Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B. Molecular and Cellular Biology. 2002 Sep 1;22(17):6247-60.


325. Guichard SM, Curwen J, Bihani T, D’Cruz CM, Yates JWT, Grondine M, et al. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in


Related Publications
